/*
SQLyog Community Edition- MySQL GUI v7.02 
MySQL - 5.1.59-community : Database - gene
*********************************************************************
*/


/*!40101 SET NAMES utf8 */;

/*!40101 SET SQL_MODE=''*/;

/*!40014 SET @OLD_FOREIGN_KEY_CHECKS=@@FOREIGN_KEY_CHECKS, FOREIGN_KEY_CHECKS=0 */;
/*!40101 SET @OLD_SQL_MODE=@@SQL_MODE, SQL_MODE='NO_AUTO_VALUE_ON_ZERO' */;

CREATE DATABASE IF NOT EXISTS/*!32312*/ `gene` /*!40100 DEFAULT CHARACTER SET latin1 */;

USE `gene`;

/*Table structure for table `bf` */

DROP TABLE IF EXISTS `bf`;

CREATE TABLE `bf` (
  `disease` varchar(10000) DEFAULT NULL,
  `miRNA` varchar(10000) DEFAULT NULL,
  `name` varchar(10000) DEFAULT NULL,
  `goid` varchar(10000) DEFAULT NULL,
  `score` varchar(10000) DEFAULT NULL,
  `affiliating genes` varchar(10000) DEFAULT NULL,
  `did` varchar(2000) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

/*Data for the table `bf` */

LOCK TABLES `bf` WRITE;

insert  into `bf`(`disease`,`miRNA`,`name`,`goid`,`score`,`affiliating genes`,`did`) values ('Beckwith-Wiedemann Syndrome','miR-483-5p regulates MeCP2 levels through a human-specific binding site in the MECP2 long 3 UTR.','regulation of gene expression by genetic imprinting','GO:0006349','8.92','CTCF(10664), IGF2(3481), KCNQ1(3784), ZFP57(346171)','OMIM:130650'),('LYSINURIC PROTEIN INTOLERANCE','SLC7A7 Gene : The protein encoded by this gene is the light subunit of a cationic amino acid transporter. This sodium-independent transporter is formed when the light subunit encoded by this gene dimerizes with the heavy subunit transporter protein SLC3A2. This transporter is found in epithelial cell membranes where it transfers cationic and large neutral amino acids from the cell to the extracellular space. Defects in this gene are a cause of lysinuric protein intolerance (LPI).','transport','GO:0006810','9.95','SLC3A1(6519), SLC3A2(6520), SLC7A2(6542), SLC7A5(8140), SLC7A6(9057), SLC7A7(9056),','OMIM:222700'),('LYSINURIC PROTEIN INTOLERANCE','SLC7A7 Gene : The protein encoded by this gene is the light subunit of a cationic amino acid transporter. This sodium-independent transporter is formed when the light subunit encoded by this gene dimerizes with the heavy subunit transporter protein SLC3A2. This transporter is found in epithelial cell membranes where it transfers cationic and large neutral amino acids from the cell to the extracellular space. Defects in this gene are a cause of lysinuric protein intolerance (LPI).','leukocyte migration','GO:0050900','9.77','SLC3A2(6520), SLC7A5(8140), SLC7A6(9057), SLC7A7(9056), SLC7A8(23428),','OMIM:222700'),('LYSINURIC PROTEIN INTOLERANCE','SLC7A7 Gene : The protein encoded by this gene is the light subunit of a cationic amino acid transporter. This sodium-independent transporter is formed when the light subunit encoded by this gene dimerizes with the heavy subunit transporter protein SLC3A2. This transporter is found in epithelial cell membranes where it transfers cationic and large neutral amino acids from the cell to the extracellular space. Defects in this gene are a cause of lysinuric protein intolerance (LPI).','L-amino acid transport','GO:0015807','9.56','SLC7A5(8140), SLC7A6(9057), SLC7A7(9056), SLC7A8(23428)','OMIM:222700'),('LYSINURIC PROTEIN INTOLERANCE','SLC7A7 Gene : The protein encoded by this gene is the light subunit of a cationic amino acid transporter. This sodium-independent transporter is formed when the light subunit encoded by this gene dimerizes with the heavy subunit transporter protein SLC3A2. This transporter is found in epithelial cell membranes where it transfers cationic and large neutral amino acids from the cell to the extracellular space. Defects in this gene are a cause of lysinuric protein intolerance (LPI).','L-alpha-amino acid transmembrane transport','GO:1902475','9.55','SLC3A2(6520), SLC7A5(8140), SLC7A6(9057), SLC7A7(9056), SLC7A8(23428)','OMIM:222700'),('LYSINURIC PROTEIN INTOLERANCE','SLC7A7 Gene : The protein encoded by this gene is the light subunit of a cationic amino acid transporter. This sodium-independent transporter is formed when the light subunit encoded by this gene dimerizes with the heavy subunit transporter protein SLC3A2. This transporter is found in epithelial cell membranes where it transfers cationic and large neutral amino acids from the cell to the extracellular space. Defects in this gene are a cause of lysinuric protein intolerance (LPI).','cellular amino acid biosynthetic process','GO:0008652','9.52','ASL(435), ASS1(445)','OMIM:222700'),('COPROPORPHYRIA, HEREDITARY','miR-217 and miR-377 in combination were found to attenuate HMOX1 protein expression, whereas knockdown of miR-217 and miR-377 up-regulates HMOX1 protein, but exhibits no alteration in HMOX1 mRNA levels, suggesting that the regulation occurs at the translational level','heme biosynthetic process','GO:0006783','9.81','ALAD(210), ALAS1(211), ALAS2(212), CPOX(1371), FECH(2235), HMBS(3145)','OMIM:121300'),('COPROPORPHYRIA, HEREDITARY','miR-217 and miR-377 in combination were found to attenuate HMOX1 protein expression, whereas knockdown of miR-217 and miR-377 up-regulates HMOX1 protein, but exhibits no alteration in HMOX1 mRNA levels, suggesting that the regulation occurs at the translational level','tetrapyrrole biosynthetic process','GO:0033014','9.65','ALAD(210), ALAS1(211), ALAS2(212), HMBS(3145), UROS(7390)','OMIM:121300'),('COPROPORPHYRIA, HEREDITARY','miR-217 and miR-377 in combination were found to attenuate HMOX1 protein expression, whereas knockdown of miR-217 and miR-377 up-regulates HMOX1 protein, but exhibits no alteration in HMOX1 mRNA levels, suggesting that the regulation occurs at the translational level','response to lead ion','GO:0010288','9.58','ALAD(210), CPOX(1371), FECH(2235)','OMIM:121300'),('COPROPORPHYRIA, HEREDITARY','miR-217 and miR-377 in combination were found to attenuate HMOX1 protein expression, whereas knockdown of miR-217 and miR-377 up-regulates HMOX1 protein, but exhibits no alteration in HMOX1 mRNA levels, suggesting that the regulation occurs at the translational level','erythrocyte differentiation','GO:0030218','9.56','ALAS2(212), GATA1(2623)','OMIM:121300'),('COPROPORPHYRIA, HEREDITARY','miR-217 and miR-377 in combination were found to attenuate HMOX1 protein expression, whereas knockdown of miR-217 and miR-377 up-regulates HMOX1 protein, but exhibits no alteration in HMOX1 mRNA levels, suggesting that the regulation occurs at the translational level','protoporphyrinogen IX biosynthetic process','GO:0006782','9.56','ALAD(210), ALAS1(211), ALAS2(212), CPOX(1371) HMBS(3145), PPOX(5498)','OMIM:121300'),('COPROPORPHYRIA, HEREDITARY','miR-217 and miR-377 in combination were found to attenuate HMOX1 protein expression, whereas knockdown of miR-217 and miR-377 up-regulates HMOX1 protein, but exhibits no alteration in HMOX1 mRNA levels, suggesting that the regulation occurs at the translational level','biosynthetic process','GO:0009058','9.55','ALAS1(211), ALAS2(212),','OMIM:121300'),('BAND-LIKE CALCIFICATION WITH SIMPLIFIED GYRATION AND POLYMICROGYRIA',NULL,'regulation of type I interferon-mediated signaling pathway','GO:0060338','8.62','IFNA1(3439), USP18(11274)','OMIM:251290'),('GAUCHER DISEASE, TYPE II','one specific miRNA (miR-127–5p) down-regulated both glucocerebrosidase activity and protein levels by down-regulation of LIMP-2, the receptor involved in proper trafficking of glucocerebrosidase from the endoplasmic reticulum to the lysosome. Two other miRNAs, miR-16–5p and miR-195–5p, were found to up-regulate glucocerebrosidase activity by greater than 40% and to enhance expression and protein levels of the enzyme.','lipid metabolic process','GO:0006629','9.16','GBA(2629), PSAP(5660)','OMIM:230900'),('GAUCHER DISEASE, TYPE II','one specific miRNA (miR-127–5p) down-regulated both glucocerebrosidase activity and protein levels by down-regulation of LIMP-2, the receptor involved in proper trafficking of glucocerebrosidase from the endoplasmic reticulum to the lysosome. Two other miRNAs, miR-16–5p and miR-195–5p, were found to up-regulate glucocerebrosidase activity by greater than 40% and to enhance expression and protein levels of the enzyme.','glycosphingolipid metabolic process','GO:0006687','8.96','GBA(2629), PSAP(5660)','OMIM:230900'),('GAUCHER DISEASE, TYPE II','one specific miRNA (miR-127–5p) down-regulated both glucocerebrosidase activity and protein levels by down-regulation of LIMP-2, the receptor involved in proper trafficking of glucocerebrosidase from the endoplasmic reticulum to the lysosome. Two other miRNAs, miR-16–5p and miR-195–5p, were found to up-regulate glucocerebrosidase activity by greater than 40% and to enhance expression and protein levels of the enzyme.','sphingolipid metabolic process','GO:0006665','8.62','GBA(2629), PSAP(5660)','OMIM:230900'),('Acrodermatitis Enteropathica',NULL,'transport','GO:0006810','9.88','ALB(213), SLC30A2(7780), SLC30A4(7782), SLC39A4(55630), SLC39A5(283375)','OMIM:201100'),('Acrodermatitis Enteropathica',NULL,'ion transport','GO:0006811','9.73','SLC30A2(7780), SLC30A4(7782), SLC39A4(55630), SLC39A5(283375','OMIM:201100'),('Acrodermatitis Enteropathica',NULL,'transmembrane transport','GO:0055085','9.67','SLC30A2(7780), SLC30A4(7782), SLC39A4(55630), SLC39A5(283375','OMIM:201100'),('Acrodermatitis Enteropathica',NULL,'cation transmembrane transport','GO:0098655','9.51','SLC30A2(7780), SLC30A4(7782),','OMIM:201100'),('Acrodermatitis Enteropathica',NULL,'cation transport','GO:0006812','9.49','SLC30A2(7780), SLC30A4(7782),','OMIM:201100'),('GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-POSITIVE,TYPE I',NULL,'response to drug','GO:0042493','9.95','CAT(847), CYBA(1535), CYBB(1536), IFNG(3458), MT-CYB(4519)','OMIM:233700'),('GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-POSITIVE,TYPE I',NULL,'inflammatory response','GO:0006954','9.95','CYBA(1535), CYBB(1536), IL1B(3553), NOX1(27035)','OMIM:233700'),('GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-POSITIVE,TYPE I',NULL,'cellular response to oxidative stress','GO:0034599','9.85','CAT(847), CYBA(1535), CYBB(1536), NCF1(653361), NCF2(4688), NCF4(4689)','OMIM:233700'),('GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-POSITIVE,TYPE I',NULL,'cell redox homeostasis','GO:0045454','9.83','CYBA(1535), CYBB(1536), NCF1(653361), NCF2(4688), NCF4(4689)','OMIM:233700'),('GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-POSITIVE,TYPE I',NULL,'cellular response to mechanical stimulus','GO:0071260','9.8','CYBA(1535), IL1B(3553), RAC1(5879)','OMIM:233700'),('Tyrosinemia, Type I',NULL,'metabolic process','GO:0008152','9.5','ALAD(210), FAH(2184), GSTZ1(2954)','OMIM:276700'),('Tyrosinemia, Type I',NULL,'L-phenylalanine catabolic process','GO:0006559','9.33','FAH(2184), GSTZ1(2954), HPD(3242)','OMIM:276700'),('Tyrosinemia, Type I',NULL,'cellular respiration','GO:0045333','9.26','CYCS(54205), SLC25A13(10165)','OMIM:276700'),('Tyrosinemia, Type I',NULL,'aromatic amino acid family metabolic process','GO:0009072','9.13','FAH(2184), GSTZ1(2954), HPD(3242)','OMIM:276700'),('Tyrosinemia, Type I',NULL,'tyrosine catabolic process','GO:0006572','8.8','FAH(2184), GSTZ1(2954), HPD(3242)','OMIM:276700'),('GRISCELLI SYNDROME, TYPE 2',NULL,'pigmentation','GO:0043473','9.43','MYO5A(4644), RAB27A(5873)','OMIM:607624'),('GRISCELLI SYNDROME, TYPE 2',NULL,'positive regulation of exocytosis','GO:0045921','9.4','RAB27A(5873) UNC13D(201294)','OMIM:607624'),('GRISCELLI SYNDROME, TYPE 2',NULL,'melanosome transport','GO:0032402','9.37','MYO5A(4644), RAB27A(5873)','OMIM:607624'),('GRISCELLI SYNDROME, TYPE 2',NULL,'melanocyte differentiation','GO:0030318','9.32','MYO5A(4644), RAB27A(5873)','OMIM:607624'),('GRISCELLI SYNDROME, TYPE 2',NULL,'natural killer cell degranulation','GO:0043320','9.26','RAB27A(5873) UNC13D(201294)','OMIM:607624'),('GRISCELLI SYNDROME, TYPE 2',NULL,'melanosome localization','GO:0032400','9.16','MYO5A(4644), RAB27A(5873)','OMIM:607624'),('GRISCELLI SYNDROME, TYPE 2',NULL,'exocytosis','GO:0006887','9.02','CCL5(6352), MYO5A(4644), RAB27A(5873), UNC13B(10497), UNC13D(201294)','OMIM:607624'),('PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)',NULL,'protein transport','GO:0015031','9.92','BCAP31(10134), PEX1(5189), PEX13(5194), PEX5(5830), PEX7(5191)','OMIM:614887'),('PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)',NULL,'neuron migration','GO:0001764','9.67','PEX13(5194), PEX5(5830), PEX7(5191)','OMIM:614887'),('PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)',NULL,'fatty acid beta-oxidation','GO:0006635','9.65','ABCD1(215), HSD17B4(3295), PEX2 PEX5(5830), PEX7(5191)','OMIM:614887'),('PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)',NULL,'peroxisome organization','GO:0007031','9.61','ABCD1(215), PEX1(5194), PEX10(5192), PEX12(5193), PEX2(5828), PEX3(8504)','OMIM:614887'),('PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)',NULL,'fatty acid beta-oxidation using acyl-CoA oxidase','GO:0033540','9.51','ABCD1(215), HSD17B4(3295)','OMIM:614887'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'metabolic process','GO:0008152','9.91','AGL(178), GAA(2548), GYS1(2997), GYS2(2998), PFKM(5213), PYGL(5836)','OMIM:232220'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'protein phosphorylation','GO:0006468','9.85','PHKA1(5255), PHKA2(5256), PHKB(5257), PHKG2(5261), PRKAG2(51422)','OMIM:232220'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'carbohydrate metabolic process','GO:0005975','9.81','AGL(178), GAA(2548), GBE1(2632) PHKA1(5255), PHKA2(5256), PHKB(5257),','OMIM:232220'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'neutrophil degranulation','GO:0043312','9.8','AGL(178), GAA(2548), GYG1(2992), PYGL(5836)','OMIM:232220'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'generation of precursor metabolites and energy','GO:0006091','9.8','GBE1 GYS2(2998), PHKA1(5255), PHKA2(5256), PHKB(5257), PHKG2(5261)','OMIM:232220'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'glycogen biosynthetic process','GO:0005978','9.73','AGL(178), GBE1(2632), GYG1(2992), GYS1(2997), GYS2(2998), PHKG2(5261)','OMIM:232220'),('COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4',NULL,'tRNA aminoacylation for protein translation','GO:0006418','9.33','EARS2(124454), FARS2(10667), VARS2(57176)','OMIM:610678'),('COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4',NULL,'mitochondrial translational elongation','GO:0070125','9.32','GFM1 TSFM',NULL),('COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4',NULL,'translational elongation','GO:0006414','9.26','GFM1 TSFM',NULL),('COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4',NULL,'tRNA aminoacylation','GO:0043039','9.13','AARS2 EARS2 FARS2',NULL),('COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4',NULL,'translation','GO:0006412','9.1','AARS2 EARS2 FARS2 GFM1 TSFM VARS2',NULL),(' Coach Syndrome:',NULL,'cell projection organization','GO:0030030','9.37','CC2D2A TMEM67',NULL),(' Coach Syndrome:',NULL,'determination of left/right symmetry','GO:0007368','9.32','CC2D2A RPGRIP1L',NULL),(' Coach Syndrome:',NULL,'camera-type eye development','GO:0043010','9.26','CC2D2A RPGRIP1L',NULL),(' Coach Syndrome:',NULL,'non-motile cilium assembly','GO:1905515','9.16','CC2D2A RPGRIP1L',NULL),(' Coach Syndrome:',NULL,'cilium assembly','GO:0060271','9.13','CC2D2A RPGRIP1L TMEM67',NULL),(' Coach Syndrome:',NULL,'ciliary basal body docking','GO:0097711','8.8','CC2D2A RPGRIP1L TMEM67',NULL),('GAUCHER DISEASE, TYPE IIIC',NULL,'metabolic process','GO:0008152','9.63','ARSA CHIA CHIT1 GBA HEXA PKLR',NULL),('GAUCHER DISEASE, TYPE IIIC',NULL,'negative regulation of inflammatory response','GO:0050728','9.61','ACP5 ADA GBA',NULL),('GAUCHER DISEASE, TYPE IIIC',NULL,'sphingolipid metabolic process','GO:0006665','9.54','GBA PSAP UGCG',NULL),('GAUCHER DISEASE, TYPE IIIC',NULL,'response to pH','GO:0009268','9.46','ARSA GBA',NULL),('GAUCHER DISEASE, TYPE IIIC',NULL,'carbohydrate metabolic process','GO:0005975','9.43','CHIA CHIT1 GBA GBA3 HEXA PKLR',NULL),('MAST CELL DISEASE',NULL,'defense response to virus','GO:0051607','9.73','IFNA1 IFNA2 ISG20',NULL),('MAST CELL DISEASE',NULL,'cytokine-mediated signaling pathway','GO:0019221','9.71','IFNA1 IFNA2 KIT',NULL),('MAST CELL DISEASE',NULL,'defense response','GO:0006952','9.69','IFNA1 IFNA2 MPO',NULL),('MAST CELL DISEASE',NULL,'regulation of type I interferon-mediated signaling pathway','GO:0060338','9.55','IFNA1 IFNA2',NULL),('MAST CELL DISEASE',NULL,'cell-matrix adhesion','GO:0007160','9.54','CD44 CD63 ITGB1',NULL),('MAST CELL DISEASE',NULL,'T cell activation involved in immune response','GO:0002286','9.52','IFNA1 IFNA2',NULL),('MAST CELL DISEASE',NULL,'positive regulation of peptidyl-serine phosphorylation of STAT protein','GO:0033141','9.49','IFNA1 IFNA2',NULL),('CYSTIC FIBROSIS',NULL,'neutrophil degranulation','GO:0043312','9.92','DNAJC5 ELANE FCGR2A S100A8 S100A9',NULL),('CYSTIC FIBROSIS',NULL,'defense response to bacterium','GO:0042742','9.81','DEFB1 ELANE S100A8 S100A9',NULL),('CYSTIC FIBROSIS',NULL,'chemotaxis','GO:0006935','9.78','CXCL8 DEFB1 S100A8 S100A9',NULL),('CYSTIC FIBROSIS',NULL,'chloride transmembrane transport','GO:1902476','9.72','CFTR CLCA1 CLCA4',NULL),('CYSTIC FIBROSIS',NULL,'chloride transport','GO:0006821','9.71','CFTR CLCA1 CLCA4',NULL),('CYSTIC FIBROSIS',NULL,'neutrophil chemotaxis','GO:0030593','9.67','CXCL8 S100A8 S100A9',NULL),('CYSTIC FIBROSIS',NULL,'astrocyte development','GO:0014002','9.57','S100A8 S100A9',NULL),('CYSTIC FIBROSIS',NULL,'acute inflammatory response','GO:0002526','9.56','DEFB1 S100A8',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'heart development','GO:0007507','9.83','NEK8 PKD1 PKD2 TSC2',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'negative regulation of canonical Wnt signaling pathway','GO:0090090','9.79','INVS NPHP3 NPHP4',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'cell cycle arrest','GO:0007050','9.77','PKD1 PKD2 TSC2',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'liver development','GO:0001889','9.72','HNF1B PKD1 PKD2',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'determination of left/right symmetry','GO:0007368','9.71','NEK8 NPHP3 PKD2',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'spinal cord development','GO:0021510','9.62','PKD1 PKD2',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'JAK-STAT cascade',' GO:0007259','9.62','PKD1 PKD2',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'single organismal cell-cell adhesion','GO:0016337','9.62','NPHP1 NPHP4 PKD1 PKHD1',NULL);

UNLOCK TABLES;

/*Table structure for table `category` */

DROP TABLE IF EXISTS `category`;

CREATE TABLE `category` (
  `s.no` varchar(500) DEFAULT NULL,
  `catagory` varchar(500) DEFAULT NULL,
  `count` varchar(500) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

/*Data for the table `category` */

LOCK TABLES `category` WRITE;

insert  into `category`(`s.no`,`catagory`,`count`) values ('1','BONE & MUSCLE DISEASE','7'),('2','LIVER & KIDENEY DISEASE','3'),('3','SKIN DISEASE','5'),('4','BRAIN DISEASE','5'),('5','RESPIRATION DISEASE','1');

UNLOCK TABLES;

/*Table structure for table `cc` */

DROP TABLE IF EXISTS `cc`;

CREATE TABLE `cc` (
  `disease` varchar(8000) DEFAULT NULL,
  `miRNA` varchar(8000) DEFAULT NULL,
  `name` varchar(8000) DEFAULT NULL,
  `goid` varchar(8000) DEFAULT NULL,
  `score` varchar(8000) DEFAULT NULL,
  `affiliating genes` varchar(8000) DEFAULT NULL,
  `did` varchar(2000) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

/*Data for the table `cc` */

LOCK TABLES `cc` WRITE;

insert  into `cc`(`disease`,`miRNA`,`name`,`goid`,`score`,`affiliating genes`,`did`) values ('LYSINURIC PROTEIN INTOLERANCE','SLC7A7 Gene : The protein encoded by this gene is the light subunit of a cationic amino acid transporter. This sodium-independent transporter is formed when the light subunit encoded by this gene dimerizes with the heavy subunit transporter protein SLC3A2. This transporter is found in epithelial cell membranes where it transfers cationic and large neutral amino acids from the cell to the extracellular space. Defects in this gene are a cause of lysinuric protein intolerance (LPI).','plasma membrane','GO:0005886','9.8','SLC3A1(6519),SLC3A2(6520),SLC7A2(6542),SLC7A5(8140),SLC7A6(9057),SLC7A7(9056)','OMIM:222700'),('LYSINURIC PROTEIN INTOLERANCE','SLC7A7 Gene : The protein encoded by this gene is the light subunit of a cationic amino acid transporter. This sodium-independent transporter is formed when the light subunit encoded by this gene dimerizes with the heavy subunit transporter protein SLC3A2. This transporter is found in epithelial cell membranes where it transfers cationic and large neutral amino acids from the cell to the extracellular space. Defects in this gene are a cause of lysinuric protein intolerance (LPI).','extracellular exosome','GO:0070062','9.63','ASL(435),ASS1(445),SLC3A1(6519),SLC3A2(6520),SLC7A5(8140),SLC7A8(23428)','OMIM:222700'),('LYSINURIC PROTEIN INTOLERANCE','SLC7A7 Gene : The protein encoded by this gene is the light subunit of a cationic amino acid transporter. This sodium-independent transporter is formed when the light subunit encoded by this gene dimerizes with the heavy subunit transporter protein SLC3A2. This transporter is found in epithelial cell membranes where it transfers cationic and large neutral amino acids from the cell to the extracellular space. Defects in this gene are a cause of lysinuric protein intolerance (LPI).','basolateral plasma membrane','GO:0016323','9.13','SLC7A6(9057),SLC7A7(9056),SLC7A8(23428)','OMIM:222700'),('LYSINURIC PROTEIN INTOLERANCE','SLC7A7 Gene : The protein encoded by this gene is the light subunit of a cationic amino acid transporter. This sodium-independent transporter is formed when the light subunit encoded by this gene dimerizes with the heavy subunit transporter protein SLC3A2. This transporter is found in epithelial cell membranes where it transfers cationic and large neutral amino acids from the cell to the extracellular space. Defects in this gene are a cause of lysinuric protein intolerance (LPI).','integral component of plasma membrane','GO:0005887','9.1','SLC3A1(6519),SLC7A2(6542),SLC7A5(8140),SLC7A6(9057),SLC7A7(9056),SLC7A8(23428)','OMIM:222700'),('COPROPORPHYRIA, HEREDITARY','miR-217 and miR-377 in combination were found to attenuate HMOX1 protein expression, whereas knockdown of miR-217 and miR-377 up-regulates HMOX1 protein, but exhibits no alteration in HMOX1 mRNA levels, suggesting that the regulation occurs at the translational level','mitochondrial inner membrane','GO:0005743','9.26','ALAS2(212),CPOX(1371),FECH(2235),PPOX(5498)','OMIM:121300'),('COPROPORPHYRIA, HEREDITARY','miR-217 and miR-377 in combination were found to attenuate HMOX1 protein expression, whereas knockdown of miR-217 and miR-377 up-regulates HMOX1 protein, but exhibits no alteration in HMOX1 mRNA levels, suggesting that the regulation occurs at the translational level','mitochondrion','GO:0005739','9.17','ALAS1(211),ALAS2(212),CPOX(1371),FECH(2235),LIG3(3980),PPOX(5498)','OMIM:121300'),('BAND-LIKE CALCIFICATION WITH SIMPLIFIED GYRATION AND POLYMICROGYRIA','','bicellular tight junction','GO:0005923','8.62','JAM3(83700),OCLN(100506658)','OMIM:251290'),('GAUCHER DISEASE, TYPE II','one specific miRNA (miR-127–5p) down-regulated both glucocerebrosidase activity and protein levels by down-regulation of LIMP-2, the receptor involved in proper trafficking of glucocerebrosidase from the endoplasmic reticulum to the lysosome. Two other miRNAs, miR-16–5p and miR-195–5p, were found to up-regulate glucocerebrosidase activity by greater than 40% and to enhance expression and protein levels of the enzyme.','lysosome','GO:0005764','9.16','GBA(2629),PSAP(5660)','OMIM:230900'),('GAUCHER DISEASE, TYPE II','one specific miRNA (miR-127–5p) down-regulated both glucocerebrosidase activity and protein levels by down-regulation of LIMP-2, the receptor involved in proper trafficking of glucocerebrosidase from the endoplasmic reticulum to the lysosome. Two other miRNAs, miR-16–5p and miR-195–5p, were found to up-regulate glucocerebrosidase activity by greater than 40% and to enhance expression and protein levels of the enzyme.','lysosomal membrane','GO:0005765','8.96','GBA(2629),PSAP(5660)','OMIM:230900'),('GAUCHER DISEASE, TYPE II','one specific miRNA (miR-127–5p) down-regulated both glucocerebrosidase activity and protein levels by down-regulation of LIMP-2, the receptor involved in proper trafficking of glucocerebrosidase from the endoplasmic reticulum to the lysosome. Two other miRNAs, miR-16–5p and miR-195–5p, were found to up-regulate glucocerebrosidase activity by greater than 40% and to enhance expression and protein levels of the enzyme.','lysosomal membrane','GO:0005765','8.96','GBA(2629),PSAP(5660)','OMIM:230900'),('Acrodermatitis Enteropathica','','late endosome','GO:0005770','8.62','SLC30A2(7780),SLC30A4(7782)','OMIM:201100'),('GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-POSITIVE,TYPE I',NULL,'extracellular space','GO:0005615','9.76','CAT(847),CLEC11A(6320),CSF2(1437),CSF3(1440),IFNG(3458),IL1B(3553)','OMIM:233700'),('GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-POSITIVE,TYPE I',NULL,'secretory granule','GO:0030141','9.43','CYBA(1535),IL1B(3553),MPO(4353)','OMIM:233700'),('GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-POSITIVE,TYPE I',NULL,'phagolysosome','GO:0032010','9.13','NCF1(653361),NCF2(4688),NCF4(4689)','OMIM:233700'),('GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-POSITIVE,TYPE I',NULL,'NADPH oxidase complex','GO:0043020','9.1','CYBA(1535),CYBB(1536),NCF1(653361),NCF2(4688),NCF4(4689),NOX1(27053)','OMIM:233700'),('Tyrosinemia, Type I',NULL,'cytosol','GO:0005829','9.1 ','AFP(174),ALAD(210),CYCS(54205),FAH(2184),GSTZ1(2954),HPD(3242)','OMIM:276700'),('GRISCELLI SYNDROME, TYPE 2','','lysosome','GO:0005764','9.43','MYO5A(4644),RAB27A(5873),UNC13D(201294)','OMIM:607624'),('GRISCELLI SYNDROME, TYPE 2',NULL,'photoreceptor outer segment','GO:0001750','9.32','MYO5A(4644),RAB27A(5873)','OMIM:607624'),('GRISCELLI SYNDROME, TYPE 2',NULL,'exocytic vesicle','GO:0070382','9.16','RAB27A(5873),UNC13D(201294)','OMIM:607624'),('GRISCELLI SYNDROME, TYPE 2',NULL,'late endosome','GO:0005770','9.13','MYO5A(4644),RAB27A(5873),UNC13D(201294)','OMIM:607624'),('GRISCELLI SYNDROME, TYPE 2',NULL,'Weibel-Palade body','GO:0033093','8.62','RAB27A(5873),UNC13D(201294)','OMIM:607624'),('PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)',NULL,'peroxisome','GO:0005777','9.77','ABCD1(215),CAT(847),HSD17B4(3295),PEX1(5189),PEX10(5192),PEX12(5193)','OMIM:614887'),('PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)',NULL,'peroxisome','GO:0005777','9.77','ABCD1(215),CAT(847),HSD17B4(3295),PEX1(5189),PEX10(5192),PEX12(5193)','OMIM:614887'),('PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)',NULL,'peroxisomal matrix','GO:0005782','9.56','CAT(847),HSD17B4(3295),PEX7(5191),PIPOX(51268)','OMIM:614887'),('PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)',NULL,'peroxisomal membrane','GO:0005778','9.36','ABCD1(215),CAT(847),HSD17B4(3295),PEX1(5189),PEX10(5192),PEX12(5193)','OMIM:614887'),('PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)',NULL,'membrane','GO:0016020','10.17','ABCD1(215),BCAP31(10134),CAT(847),F2R(2149),HSD17B4(3295),PEX1(5189)','OMIM:614887'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'cytosol','GO:0005829','9.77','AGL(178),GBE1(2632),GYG1(2992),GYS1(2997),GYS2(2998),PFKM(5213)','OMIM:232220'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'ficolin-1-rich granule lumen','GO:1904813','9.43','AGL(178),GYG1(2992),PYGL(5836)','OMIM:232220'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'secretory granule lumen','GO:0034774','9.33','AGL(178),GYG1(2992),PYGL(5836)','OMIM:232220'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'inclusion body','GO:0016234','9.32','AGL(178),GYS1(2997)','OMIM:232220'),('COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4',NULL,'mitochondrial matrix','GO:0005759','9.26','EARS2(124454),FARS2(10667),GFM1(85476),TSFM(10102)','OMIM:610678'),('COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4',NULL,'mitochondrion','GO:0005739','9.17','AARS2(57505),AIFM1(9131),EARS2(124454),FARS2(10667),GFM1(85467),TSFM(10102)','OMIM:610678'),('Coach Syndrome:',NULL,'cytoskeleton','GO:0005856','9.62','CC2D2A(57545),INPP5E(56623),RPGRIP1L(23322),TMEM67(91147)','OMIM:216360'),('Coach Syndrome:',NULL,'cell projection','GO:0042995','9.46','CC2D2A(57545),INPP5E(56623),RPGRIP1L(23322),TMEM67(91147)','OMIM:216360'),('Coach Syndrome:',NULL,'axoneme','GO:0005930','9.37','INPP5E(56623),RPGRIP1L(23322)','OMIM:216360'),('Coach Syndrome:',NULL,'MKS complex','GO:0036038','9.26','CC2D2A(57545),TMEM67(91147)','OMIM:216360'),('Coach Syndrome:',NULL,'cilium','GO:0005929','9.26','CC2D2A(57545),INPP5E(56623),RPGRIP1L(23322),TMEM67(91147)','OMIM:216360'),('Coach Syndrome:',NULL,'ciliary transition zone','GO:0035869','8.8','CC2D2A(57545),RPGRIP1L(23322),TMEM67(91147)','OMIM:216360'),('GAUCHER DISEASE, TYPE IIIC',NULL,'extracellular space','GO:0005615','9.7','ADA(100),ARSA(410),CCL18(6362),CHIA(27159),CHIT1(1118),GBA(2629)','OMIM:231005'),('GAUCHER DISEASE, TYPE IIIC',NULL,'lysosomal lumen','GO:0043202','9.35','ARSA(410),GBA(2629),HEXA(3073),PSAP(5660),SCARB2(950)','OMIM:231005'),('GAUCHER DISEASE, TYPE IIIC',NULL,'lysosome','GO:0005764','9.23','ACP5(54),ADA(100),ARSA(410),CHIT1(1118),GBA(2629),HEXA(3073)','OMIM:231005'),('CYSTIC FIBROSIS',NULL,'extracellular space','GO:0005615','9.17','BMP6(654),CD63(967),FGF2(2247),IFNA1(3439),IFNA2(3440),KIT(3815)','OMIM:219700'),('CYSTIC FIBROSIS',NULL,'extracellular space','GO:0005615','9.17','BMP6(654),CD63(967),FGF2(2247),IFNA1(3439),IFNA2(3440),KIT(3815)','OMIM:219700'),('CYSTIC FIBROSIS',NULL,'microvillus','GO:0005902','9.5','CLCA1 (1179),SLC9A3R1(9368),TGFB1(7040)','OMIM:219700'),('CYSTIC FIBROSIS',NULL,'microvillus','GO:0005902','9.5','CLCA1 (1179),SLC9A3R1(9368),TGFB1(7040)','OMIM:219700'),('CYSTIC FIBROSIS',NULL,'microvillus','GO:0005902','9.5','CLCA1 (1179),SLC9A3R1(9368),TGFB1(7040)','OMIM:219700'),('CYSTIC FIBROSIS',NULL,'microvillus','GO:0005902','9.5','CLCA1 (1179),SLC9A3R1(9368),TGFB1(7040)','OMIM:219700'),('CYSTIC FIBROSIS',NULL,'microvillus','GO:0005902','9.5','CLCA1 (1179),SLC9A3R1(9368),TGFB1(7040)','OMIM:219700'),('POLYCYSTIC KIDNEY DISEASE',NULL,'apical plasma membrane','GO:0016324','9.73','CRB2(286204),MUC1(4582),PKHD1(5314),UMOD(7369)','OMIN:173900'),('POLYCYSTIC KIDNEY DISEASE',NULL,'cell-cell junction','GO:0005911','9.67','NPHP1(4867),NPHP4(261734),PKD2(5311)','OMIN:173900'),('POLYCYSTIC KIDNEY DISEASE',NULL,'ciliary basal body','GO:0036064','9.63','NPHP4 PKD2 PKHD1',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'cell projection','GO:0042995','9.61','INVS NEK8 NPHP1 NPHP3 NPHP4 PKD1',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'motile cilium','GO:0031514','9.58','NPHP1 PKD1 PKD2',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'ciliary membrane','GO:0060170','9.54','PKD1(5310),PKD2(5311),UMOD(7369)',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'ciliary base','GO:0097546','9.5','NEK8(284086)NPHP3(27031),NPHP4(261734)',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'non-motile cilium','GO:0097730','9.48','NPHP4(261734),PKD2(5311)',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'ciliary basal body','GO:0036064','9.63','NPHP4(261734),PKD2(5311),PKHD1(5314)',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'cell projection','GO:0042995','9.61','INVS(27130),NEK8(284086), NPHP1(4867),NPHP3(27031),NPHP4(261734),PKD1(5310)',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'motile cilium','GO:0031514','9.58','NPHP1(4867),PKD1(5310),PKD2(5311)',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'ciliary membrane','GO:0060170','9.54','PKD1(5310),PKD2(5311),UMOD(7369)',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'ciliary base','GO:0097546','9.5','NEK8(284086)NPHP3(27031),NPHP4(261734)',NULL),('POLYCYSTIC KIDNEY DISEASE',NULL,'non-motile cilium','GO:0097730','9.48','NPHP4(261734),PKD2(5311)',NULL);

UNLOCK TABLES;

/*Table structure for table `gene` */

DROP TABLE IF EXISTS `gene`;

CREATE TABLE `gene` (
  `genename` varchar(222) DEFAULT NULL,
  `geneid` varchar(222) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

/*Data for the table `gene` */

LOCK TABLES `gene` WRITE;

insert  into `gene`(`genename`,`geneid`) values ('GENE NAME','GENE ID'),('NSD1','64324'),('CDKN1C','1028'),(' H19 ','283120'),('KCNQ1OT1','10984'),(' H19-ICR ','15259599E8'),('CYP7B1 ','9420'),('SNX10','29887'),('ATPAF2 ','91647'),('PC ','5091'),('SLC7A7 ','9056'),('CPOX','1371'),('OCLN ','10506658E8'),('GBA','2629'),('SLC39A4 ','55630'),('LYST ','1130'),('FUCA1','2517'),('ABCD3 ','5825'),('PIGM ','93183'),('SLC22A5','6584'),('FAH ','2184'),('MIF ','4282'),('EIF2AK3','9451'),('COG6 ','57511'),('RAB27A ','5873'),('NCF1 ','653361'),('IDS ','3423'),('IDUA ','3425'),('DLD ','1738'),('SMPD1','6609'),('APOE','348'),('TMEM70 ','54968'),('PEX14 ','5195'),('ITCH','83737'),('SGSH ','6448'),('PSAP ','5660'),('GNPTAB ','79158'),('AGPAT2','10555'),('NPHP3 ','27031'),('YARS2 ','51067'),('PHKG2 ','5261'),('SERPINA1 ','5265'),('GCDH ','2639'),('PIGA ','5277'),('HFE ','3077'),('MRPL3','11222'),('ABCB11 ','8647'),('PRKCD ','5580'),('SH2D1A ','4068'),('CECR1','51816'),('CC2D2A','57545'),(' TMEM67','91147'),(' RPGRIP1L ','23322'),('CYBB ','1536'),('PEX1 ','5189'),('HNF4A','3172'),('ALG13 ','79868'),('PIEZO1','9780'),('ALDH7A1 ','501'),('BOLA3 ','388962'),('GBA ','2629'),('HGSNAT','138050'),('SOX10','6663'),('SLC37A4 ','2542'),('KIT ','3815'),('CFTR','1080'),('NCF2','4688'),('HMOX1 ','3162'),('ITK ','3702'),('CTLA4 ','1493'),('GLB1','2720'),('PRF1 ','5551'),('ABCA1','19'),('GPD1 ','2819'),('SLC25A19','60386'),('PEPD ','5184'),('ABCB4 ','5244'),('MARS ','4141'),('RHBDF2','79651'),('LMNA ','4000'),('NPC1 ','4864'),('C15ORF41','84529'),('SLC30A10 ','55532'),('MMAB','326625'),('PCCA','5095'),(' PCCB ','5096'),('PYGL ','5836'),('ERCC8','1161'),('CYBA','1535'),('HPLH1 ','27259'),('LBR','3930'),('SC5D ','6309'),('ALMS1','7840'),('PHKB ','5257'),('TREX1 ','11277'),('DHFR ','1719'),('GBA','2629'),('MVK','4598'),('IL1RN','3557'),('HSD17B4','3295'),('ALDOB ','229'),('ABCB11 ','8647'),('DGUOK ','1716'),('SKIV2L ','6499'),('NRAS ','4893'),('POLG ','5428'),('POLD1 ','5424'),('G6PC','2538'),('PMM2 ','5373'),('FBP1','2203'),('GFM1 ','85476'),('TCIRG1 ','10312'),('SBDS ','51119'),('GBA ','2629'),('TMEM165 ','55858'),('ASAH1 ','427'),('STEAP3 ','55240'),('IDUA','3425'),('BSCL2','26580'),('ADAMTSL2 ','9719'),('PEX2 ','5828'),('JAM3','83700'),('GNMT ','27232'),('GBA ','2629'),('HBB ','3043'),('NLRP3 ','114548'),('GALE ','2582'),('PSMB8 ','5696'),('ALG1 ','56052'),('MMAA ','166785'),('LPIN2 ','9663'),('PTRF','284119'),('SMPD1 ','6609'),('CASR ','846'),('PNPLA2 ','57104'),('DIS3L2 ','129563'),('HFE2 ','148738'),('HBB ','3043'),(' LCRB ','387281'),('SLC25A20 ','788'),('PHKA2 ','5256'),('GNE ','10020'),('GNS ','2799'),('FAM111A ','63901'),('MEFV ','4210'),('FGA ','2243'),('LYZ ','4069'),(' APOA1','335'),('IFT172 ','26160'),('FASTKD2','22868'),(' TACO1','51204'),(' COX20 ','116228'),('SCO1 ','6341'),(' COX10 ','1352'),('COX14 ','84987'),(' COX6B1 ','1340'),('PET100 ','10131801E8'),(' APOPT1 ','84334'),('LIPA ','3988'),('ASL','435'),('HEXA ','3073'),('ABCC2 ','1244'),('ATP8B1','5205'),('ALG2','85365'),('FBN1','2200'),('DOLK ','22845'),('PEX12 ','5193'),('ARSB','411'),('PRKCSH ','5589'),('SEC63 ','11231'),('CPT1A','1374'),('KTWS','791122'),('ADA ','100'),('LCS1 ','84565'),('CD40LG','959'),('CLDN1 ','9076'),('IFIH1 ','64135'),('COX4I2 ','84701'),('CTSK','1513'),('CPT2 ','1376'),('ACOX1 ','51'),('MAN2B1 ','4125'),('LIG4 ','3981'),('MOGS','7841'),('TNFRSF13B ','23495'),('PDGFRA ','5156'),('CD27 ','939'),('ABHD5 ','51099'),('MUT','4594'),('INPPL1','3636'),('SLC37A4 ','2542'),('SLC17A5 ','26503'),('RMND1 ','55005'),('AUH ','549'),('DPM1 ','8813'),('MPC1 ','51660'),('CIDEC ','63924'),('TNFRSF1A ','7132'),('AKR1D1 ','6718'),('HADHA ','3030'),('THCYTX ','84434'),('IFT122 ','55764'),('TGFB1 ','7040'),('KCNH1 ','3756'),('GUSB ','2990'),('ERCC6 ','2074'),('NAGLU','4669'),('ETFA ','2108'),('ETFB','2109'),(' ETFDH','2110'),('MECP2 ','4204'),('PEX5 ','5830'),('HSD3B7','80270'),('GALT ','2592'),('PEX12 ','5193'),('DCDC2 ','51473'),('NLRP3','114548'),('JAK2','3717'),('NAGA ','4668'),('ZAP70 ','7535'),('FAS ','355'),('FASLG ','356'),('RMRP ','6023'),('CTNS','1497'),('GALNS','2588'),('DCLRE1C','64421'),(' RAG1 ','5896'),(' RAG2 ','5897'),('GPC3 ','2719'),('GLB1 ','2720'),('COG4 ','25839'),('SLC29A3 ','55315'),('PEX6 ','5190'),('KLF1 ','10661'),('CASP10 ','843'),('ATP8B1 ','5205'),('ATP7B ','540'),('SUMF1 ','285362'),('CBS ','875'),('SUMF1','285362'),('RBCK1 ','10616'),('BSCL2 ','26580'),('IDUA ','3425'),('PEX26 ','55670'),('CPT2 ','1376'),('RNASEH2A ','10535'),('TTC37','9652'),('ICOS ','29851'),('PEX3 ','8504'),('IL7R ','3575'),('PTPRC ','5788'),('AGA','175'),('gjhg','6546'),('jhgjhghjghj','6467');

UNLOCK TABLES;

/*Table structure for table `gene1` */

DROP TABLE IF EXISTS `gene1`;

CREATE TABLE `gene1` (
  `s.no` varchar(5000) DEFAULT NULL,
  `diseaseid` varchar(5000) DEFAULT NULL,
  `diseasename` varchar(5000) DEFAULT NULL,
  `associategenes` varchar(10000) DEFAULT NULL,
  `tf&mim` varchar(10000) DEFAULT NULL,
  `molecularbasis` varchar(5000) DEFAULT NULL,
  `cure` varchar(5000) DEFAULT NULL,
  `pic` varchar(5000) DEFAULT NULL,
  `list` varchar(5000) DEFAULT NULL,
  `mirna` varchar(5000) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

/*Data for the table `gene1` */

LOCK TABLES `gene1` WRITE;

insert  into `gene1`(`s.no`,`diseaseid`,`diseasename`,`associategenes`,`tf&mim`,`molecularbasis`,`cure`,`pic`,`list`,`mirna`) values ('1','OMIM:130650','BECKWITH-WIEDEMANN SYNDROME','NSD1 (64324),CDKN1C (1028),H19 (283120),KCNQ1OT1 (10984),H19-ICR (105259599),NAP1L4 (4676),PHLDA2 (7262),IGF2(3481)  ','\"ICR1 A maternally inherited point mutation was identified in ICR1 in both IGF2  & H19  which altered binding of OCT transcription factors\",\"616186\"&\"H19\",\"103280\"&\"KCNQ1OT1\",\"604115\"&\"CDKN1C\",\"600856\"','Caused by mutation in the cyclin-dependent kinase inhibitor 1C gene (CDKN1C, 600856.0001)&Caused by mutation in the nuclear receptor binding SET domain protein 1 (NSD1, 606681.0011)& Caused by mutation in the KCNQ1-overlapping transcript 1 gene (KCNQ1OT1, 604115.0001)&Caused by contiguous gene duplication of imprinted region of 11p15.5&Caused by contiguous gene deletion of imprinted region of 11p15.5 ','1. Patients with Beckwith-Wiedemann syndrome (BWS) may require frequent feedings or diazoxide to treat their hypoglycemia. 2. Infants and children must demonstrate the ability to maintain euglycemia during a fast of age-appropriate duration. The normal duration of fasting for an infant or child depends on body mass and the maturity of counterregulatory responses to hypoglycemia, which include gluconeogenesis, glycogenolysis, and ketogenesis.','Image\\BONE & MUSCLE DISEASE\\1.jpg','BONE & MUSCLE DISEASE',' mir:1300'),('2','OMIM:613812','BILE ACID SYNTHESIS DEFECT,CONGENITAL,3','CYP7B1 (9420)','\"CYP7B1   gene with protein product: Entrez Gene: 9420 C, Ensembl: ENSG00000172817 C Vega: OTTHUMG00000164387 C, UCSC: uc003xvj.3 D, Protein Resource : O75881 D\",\"603711\"&\"Cholesterol degradation to bile acids in the liver can be initiated by either cholesterol 7a-hydroxylase (CYP7A1) of the classic (neutral) pathway, or by mitochondrial sterol 27-hydroxylase (CYP27A1) of the alternative (or acidic) pathway.\" ',NULL,'Diagnosis is based on serum hepatic enzyme and bilirubin profile, and analysis of urine, serum and bile using liquid secondary ionization mass spectrometry (LSIMS) and gas chromatography - mass spectrometry (GC-MS).','Image\\LIVER & KIDENEY DISEASE\\2.jpg','LIVER & KIDENEY DISEASE','mir:613812'),('3','OMIM:615085,259700,259710,611490    ','OSTEOPETROSIS,AUTOSOMAL RECESSIVE 8','SNX10 (29887)','\"SNX10\",\"614780\"',NULL,'Patients may require blood transfusions, treatment for infections and management of their developmental and visual problems. Bone marrow transplant can alleviate many features of the disease but needs to be performed early to minimise optic nerve encroachment.','Image\\BONE & MUSCLE DISEASE\\3.jpg','BONE & MUSCLE DISEASE','mir:611490 '),('4','OMIM:604273','MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY,NUCLEAR TYPE 1; MC5DN1','ATPAF2 (91647),DNAH8 (1769)','\"ATPAF2,ATP12 Homolog,ATP12p,LP3663,MC5DN1\",\"608918\"',' Caused by mutation in the transmembrane protein 70 gene (TMEM70, 612418.0001) - Caused by mutation in the ATP synthase F1 complex assembly factor-2 gene (ATPAF2, 608918.0001)',NULL,'Image\\OTHERS\\4.jpg','OTHERS',' mir:604273'),('5','OMIM:266150','PYRUVATE CARBOXYLASE DEFICIENCY','PC (5091)','\"PC\",\"608786\"',NULL,'Treatments in patients with pyruvate carboxylase deficiency (PCD) are aimed at stimulating the pyruvate dehydrogenase complex (PDC) and providing alternative fuels. Correction of the biochemical abnormality can reverse some symptoms, but central nervous system damage progresses regardless of treatment.&The PDC can provide an alternative pathway for pyruvate metabolism PDC activity can be optimized by cofactor supplementation with thiamine and lipoic acid and administration of dichloroacetate. Increased pyruvate metabolism through this pathway can help reduce the pyruvate and lactate levels.&Biotin supplementation is given to help optimize the residual enzyme activity but is usually of little use.&Citrate supplementation reduces the acidosis and provides the needed substrate in the citric acid cycle.&Aspartic acid supplementation allows the urea cycle to proceed and reduces the ammonia level.&One patient reportedly was successfully treated with a continuous nocturnal gastric drip feeding of uncooked cornstarch.','Image\\BONE & MUSCLE DISEASE\\5.jpg','BONE & MUSCLE DISEASE','mir:266150'),('6','OMIM:222700','LYSINURIC PROTEIN INTOLERANCE','SLC7A7 (9056)','\"SLC7A7\",\"603593\"','Caused by mutation in the solute carrier family 7 (cationic amino acid transporter, y+ system), member 7 gene (SLC7A7, 603593.0001)','Treatment revolves around protein-restricted diet and supplement of lysine, ornithine, and citrulline. The complication of pulmonary alveolar proteinosis has been reported to be successfully treated by whole lung lavage','Image\\LIVER & KIDENEY DISEASE\\6.jpg','LIVER & KIDENEY DISEASE','mir:222700'),('7','OMIM:121300','COPROPORPHYRIA,HEREDITARY','CPOX (1371),HMBS (3145),PPOX (5498),ALAD (210),FECH (2235),UROD (7389),UROS (7390),PCBD1 (5092),SPOCK1 (6695)   ','\"CPOX - Harderoporphyria\",\"612732\"&\"CPOX - Coproporphyria\",\"612732\"','Caused by mutation in the coproporphyrinogen oxidase gene (CPO, 612732.0001)','The goals in managing an acute attack of porphyria are to decrease heme synthesis and to reduce the production of porphyrin precursors.&High oral doses of glucose (400 g/d) can inhibit heme synthesis and are useful for the treatment of mild attacks. Intravenous glucose solutions (eg, 5% or 10% dextrose in water) can be used in patients who cannot eat, but may aggravate hyponatremia.&Nausea and vomiting - Prochloperazine, promazine, or ondansetron&Severe agitation and anxiety - Chlorpromazine','Image\\SKIN DISEASE\\7.jpg','SKIN DISEASE','mir:12130'),('8','OMIM:251290','BAND-LIKE CALCIFICATION WITH SIMPLIFIED GYRATION AND POLYMICROGYRIA','OCLN (100506658),USP18 (11274),JAM3 (83700),COL4A1 (1282),DKC1 (1736),IFNA1 (3439)  ','\"OCLN\",\"602876\"','Caused by mutation in the occludin gene (OCLN, 602876.0001)',NULL,'Image\\BRAIN DISEASE\\8.jpg','BRAIN DISEASE','mir:251290'),('9','OMIM:230900','GAUCHER DISEASE,TYPE II','GBA (2629),PSAP (5660)','\"GBA\",\"606463\"',NULL,'Treating Gaucher disease minimizes symptoms and permanent damage to your body. There are two types of Gaucher disease treatments currently available: enzyme replacement therapy (ERT) and substrate reduction therapy (SRT).','Image\\BRAIN DISEASE\\9.jpg','BRAIN DISEASE','mir:230900'),('10','OMIM:201100','ACRODERMATITIS ENTEROPATHICA,ZINC-DEFICIENCY TYPE','SLC39A4 (55630),SLC39A4 (55630),SLC30A4 (7782),ALB (213),PLIN2 (123),OTC (5009),SLC30A2 (7780),SLC39A5 (283375)   ','\"SLC39A4\",\"607059\"',NULL,'Warm compresses to remove the scale crust, followed by application of white petrolatum to eroded skin lesions, may enhance reepithelialization when used concurrently with zinc replacement.&Warm compresses and petrolatum applied 3 times a day to areas of weeping or crusted dermatitis may enhance re-epithelialization when used concurrently with zinc replacement.','Image\\SKIN DISEASE\\10.jpg','SKIN DISEASE','mir:20100'),('11','OMIM:233700','GRANULOMATOUS DISEASE,CHRONIC,AUTOSOMAL RECESSIVE,CYTOCHROME B-POSITIVE,TYPE I','NCF1 (653361),NCF4 (4689),CYBB (1536),CYBA (1535),NCF2 (4688),NCF1 (653361),IFNG (3458),MT-CYB (4519),MPO (4353)   ','\"NCF1\",\"608512\"&\"CYBB\",\"300481\"',NULL,'Patients with superficial or deep infections (vs those with obstructing granulomas) should receive aggressive antibiotics; the initial route is parenteral. Treatment usually requires antibiotic coverage for several weeks and should be associated with clear physical signs of resolution and systemic improvement (eg, decreased WBC count and decreased erythrocyte sedimentation rate if elevated at presentation).&Ciprofloxacin with or without additional drug for staphylococcal infection is a common first choice in patients with chronic granulomatous disease. If no response is noted within the first 24-48 hours, coverage should be broadened to include additional antistaphylococcal agents (including coverage for methicillin-resistant Staphylococcus aureus), gram-negative possibilities, and Nocardia species.','Image\\BONE & MUSCLE DISEASE\\11.jpg','BONE & MUSCLE DISEASE','mir:233700'),('12','OMIM:276700','TYROSINEMIA,TYPE I','FAH (2184),GSTZ1 (2954),HPD (3242),ALAD (210),AFP (174),CYCS (54205)        ','\"FAH\",\"613871\"','Caused by mutation in the fumarylacetoacetase gene (FAH, 613871.0001)','There is currently no cure for tyrosinemia type 1. Individuals with this condition need to be on a special diet restricted in two amino acids, tyrosine and phenylalanine, throughout life. Affected individuals may also be treated with a medication called nitisinone. Early diagnosis and prompt treatment are essential for an improved prognosis. ','Image\\SKIN DISEASE\\12.jpg','SKIN DISEASE','mir:276700'),('13','OMIM:607624','GRISCELLI SYNDROME,TYPE 2','RAB27A (5873),UNC13D (201294),MLPH (79083),MYO5A (4644),CCL5 (6352),AGFG1 (3267)      ','\"RAB27A\",\"603868\"',' Caused by mutations in the Ras-associated protein RAB27A gene (RAB27A, 603868.0001)','Medical treatment of patients with Griscelli syndrome is difficult. The only real treatment for the hemophagocytic lymphohistiocytosis syndromes of which Griscelli syndrome is a part is stem cell transplantation. For patients with defects in RAB27A, antibiotics and antiviral agents are used with mixed effects. Similarly, medications may not control the neurologic symptoms of the disease.','Image\\SKIN DISEASE\\13.jpg','SKIN DISEASE','mir:607624'),('14','OMIM:614887','PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)','PEX14 (5195),HSD17B4 (3295),PEX1 (5189),PEX3 (8504),PEX7 (5191),PEX2 (5828),PEX1 (5189)     ','\"PEX14\",\"601791\"',NULL,'The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition.cholic acid (Brand name: Cholbam) - Manufactured by Asklepion Pharmaceuticals, LLC&FDA-approved indication: Treatment of bile acid synthesis disorders due to single enzyme defects and as adjunctive treatment of peroxisomal disorders including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from d','Image\\BONE & MUSCLE DISEASE\\14.jpg','BONE & MUSCLE DISEASE','mir:614887'),('17','OMIM:610678','COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4','TUFM (7284)','\"TUFM\",\"602389\"','caused by defects in the mitochondrial oxidative phosphorylationdue to protein mistranslation, leading to a failure to assemble adequate amounts of three oxidative phosphorylationcomplexes.','No Treatment / medicine available','Image\\BONE & MUSCLE DISEASE\\17.jpg','BONE & MUSCLE DISEASE','mir:610678'),('18','OMIM:216360','COACH SYNDROME','CC2D2A (57545),TMEM67 (91147),RPGRIP1L (23322),INPP5E (56623)  ','\"CC2D2A\",\"612013\"&\"TMEM67\",\"609884\"&\"RPGRIP1L\",\"610937\"','Caused by mutation in the transmembrane protein 67 gene (TMEM67, 609884.0013)&Caused by mutation in the coiled-coil and C2 domains-containing protein 2A gene (CC2D2A, 612013.0006)&Caused by mutation in the RPGRIP1-like gene (RPGRIP1L, 610937.0011)','The main clinical problem for patients with COACH syndrome is progressive portal hypertension and liver failure. Treatment aims to reduce symptoms and prevent complications.','Image\\BRAIN DISEASE\\18.jpg','BRAIN DISEASE','mir:216360'),('19','OMIM:231005','GAUCHER DISEASE,TYPE IIIC','GBA (2629)','\"GBA\",\"606463\"','Caused by mutation in the acid beta-glucosidase gene (GBA, 606463.0006)','The treatment for patients with GD type 3 exhibiting clinically significant non neurological manifestations is enzyme substitution therapy (imiglucerase with marketing authorization (MA) since 1997). It appears to slow progression of the neurological symptoms and is effective against the systemic manifestations.','Image\\BONE & MUSCLE DISEASE\\19.JPG','BONE & MUSCLE DISEASE','mir:231005'),('20','OMIM:232220','GLYCOGEN STORAGE DISEASE IB','SLC37A4 (2542)','\"SLC37A4\",\"602671\"','Caused by mutation in the glucose-6-phosphate transporter 1 gene (G6PT1, 602671.0001)','Treatment varies depending on the type of GSD. For types of GSD that involve the liver, treatment is aimed at keeping the right level of glucose in the blood. This is often enough to maintain the cells fuel needs and prevent long-term complications associated with poorly controlled GSD. Treatment consists of taking regular doses of uncooked cornstarch and/or nutrition supplements. Cornstarch is a complex carbohydrate that is difficult for the body to digest; therefore it maintains normal blood sugar levels  normal while preventing excess glycogen storage in the liver.','Image\\LIVER & KIDENEY DISEASE\\20.jpg','LIVER & KIDENEY DISEASE','mir:232220'),('21','OMIM:154800','MAST CELL DISEASE','KIT (3815),IFNA2 (3440),MITF (4286),MPO (4353),ITGB1 (3688),SYT1 (6857),CD44 (960),BMP6 (654)       ','\"KIT\",\"164920\"','Mastocytosis is a disorder that can occur in both children and adults. It is caused by the presence of too many mast cells in your body.','kin and bone marrow biopsies, 1. Measurement of mast cell mediators in blood and urine,2.Blood count, 3.Liver function studies, 4.Genetic tests, Antihistamines are commonly used. Cromolyn sodium, ketotifen and leukotriene-modifying agents are additional medications which may provide benefit. Epinephrine may be required to treat episodes of low blood pressure.','Image\\SKIN DISEASE\\21.jpg','SKIN DISEASE','mir:154800'),('22','OMIM:219700','CYSTIC FIBROSIS','CFTR (1080),TGFB1 (7040),FCGR2A (2212),DNASE1 (1773),S100A8 (6279),SLC9A3R1 (9368),CLCA1 (1179),DEFB1 (1672),CLCA4 (22802)     ','\"FCGR2A\",\"146790\"&\"CFTR\",\"602421\"&\"TGFB1\",\"190180\"','Caused by mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR, 602421.0001)','There is no cure for cystic fibrosis, but treatment can ease symptoms and reduce complications.&Antibiotics to treat and prevent lung infections&Anti-inflammatory medications to lessen swelling in the airways in your lungs&Mucus-thinning drugs to help you cough up the mucus, which can improve lung function&Inhaled medications called bronchodilators that can help keep your airways open by relaxing the muscles around your bronchial tubes&Oral pancreatic enzymes to help your digestive tract absorb nutrients','Image\\RESPIRATION DISEASE\\22.jpeg','RESPIRATION DISEASE','mir:219700'),('23','OMIN:173900','POLYCYSTIC KIDNEY DISEASE','UMOD (7369),PKD1 (5310),HNF1B (6928),TSC2 (7249),NPHP1 (4867),INVS (27130),MUC1 (4582),NPHP4 (261734) ','\"PKD1\",\"601313\"','Caused by different genetic flaws: Autosomal dominant polycystic kidney disease (ADPKD) and Autosomal recessive polycystic kidney disease (ARPKD).','Some of the treatment options may include: 1.pain medication, except Ibuprofen, which is not recommended as it may worsen kidney disease, 2.blood pressure medication, 3.antibiotics to treat UTIs, 4.a low sodium diet, 5.diuretics to help remove excess fluid from the body, 6.surgery to drain cysts and help relieve discomfort',NULL,NULL,'mir:173900'),('24','OMIM:253300','Spinal Muscular Atrophy-1 (SMA1)','SMN1 (6606),IGHMBP2 (3508),NAIP (4671),SMN2 (6607),SCO2 (9997),SYP (6855),COX14 (84987),VRK1 (7443),FKTN (2218),ZPR1 (8882)  ',NULL,NULL,'Acetylcholine & abobotulinumtoxinA & Botulinum Toxins & Botulinum Toxins, Type A & Cholinergic Agents',NULL,NULL,'mir:253300'),('25','OMIM:253301','Spinal Muscular Atrophy-2','SMN1 (6606),SMN2 (6607),NAIP (4671),NCAM1 (4684)',NULL,NULL,'Hydroxyurea & 4-Aminopyridine & Riluzole & Nucleic Acid Synthesis Inhibitors & Neuroprotective Agents',NULL,NULL,'mir:253301'),('26','OMIM:253302','Spinal Muscular Atrophy-4 ','SMN1 (6606),SMN2 (6607) ,COL6A1 (1291),MSTN (2660),VAPB (9217),PLEKHG5 (57449), FST (10468)',NULL,NULL,NULL,NULL,NULL,'mir:253302'),('15','OMIM:611721','COMBINED SAPOSIN DEFICIENCY','PEX14 (5195), HSD17B4,  COMBINED SAPOSIN DEFICIENCY','\"PEX14\",\"601791\"','The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition.','The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition.',NULL,NULL,NULL),('16','OMIM:613027','GLYCOGEN STORAGE DISEASE IXC','PHKG2 (5261),  \r\nGYS2, GYG1,  \r\nPYGL, PHKA2,  \r\nGBE1,  \r\nPYGM, G6PC','\"PHKG2\",\"172471\"','In some cases, diet therapy is helpful. Meticulous adherence to a dietary regimen may reduce liver size, prevent hypoglycemia, allow for reduction in symptoms, and allow for growth and development.','In some cases, diet therapy is helpful. Meticulous adherence to a dietary regimen may reduce liver size, prevent hypoglycemia, allow for reduction in symptoms, and allow for growth and development.',NULL,NULL,NULL);

UNLOCK TABLES;

/*Table structure for table `gened` */

DROP TABLE IF EXISTS `gened`;

CREATE TABLE `gened` (
  `id` varchar(222) DEFAULT NULL,
  `name` varchar(2222) DEFAULT NULL,
  `geneid` varchar(2222) DEFAULT NULL,
  `ie` varchar(2222) DEFAULT NULL,
  `sympt` varchar(22222) DEFAULT NULL,
  `prec` varchar(2222) DEFAULT NULL,
  `ppi` varchar(1000) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

/*Data for the table `gened` */

LOCK TABLES `gened` WRITE;

insert  into `gened`(`id`,`name`,`geneid`,`ie`,`sympt`,`prec`,`ppi`) values ('OMIM:130650','BECKWITH-WIEDEMANN SYNDROME','NSD1 (64324), CDKN1C (1028), H19 (283120), KCNQ1OT1 (10984), H19-ICR (105259599),SLC39A4 (55630),APOE (348)','Intrinsic','BWS is caused by various epigenetic and/or genetic alterations that dysregulate imprinted genes on chromosome 11p15.5. Molecular subgroups are associated with different recurrence risks and different clinical findings (e.g. tumor risks).Low blood sugar (hypoglycemia)','Tumor surveillance should be initiated if BWS is suspected/diagnosed and in a clinically unaffected monozygotic twin of a patient, but should not be guided by genotype/phenotype correlations at this time. Screening for hypoglycemia should be undertaken in the neonatal period if there are suggestive or diagnostic prenatal findings, and even for clinically unaffected newborns at increased risk based on family history.','55'),('OMIM:613812','BILE ACID SYNTHESIS DEFECT, CONGENITAL, 3','CYP7B1 (9420)','extrinsic','Stunted or abnormal growth.\nDiarrhea.\nLoss of liver functStunted or abnormal growth.\nDiarrhea.\nLoss of liver f','We are in the process of getting a bile acid, called cholic acid','75'),('OMIM:615085','OSTEOPETROSIS, AUTOSOMAL RECESSIVE 8','SNX10 (29887),IDS (3423),ITCH (83737),GNPTAB (79158),PIEZO1 (9780),CTLA4 (1493),ABCA1 (19),SLC25A19 (60386).PHKB (5257),PSMB8 (5696),PEX26 (55670)','Intrinsic','disease (CGD). It is also used to slow down the progression of severe, malignant osteopetrosis (SMO). Interferon gamma ...','At present, there is no effective medical treatment for osteopetrosis. Management is supportive and aims at providing multidisciplinary surveillance and symptomatic treatment.','58'),('OMIM:604273','ATPASE DEFICIENCY, NUCLEAR-ENCODED','ATPAF2 (91647),FUCA1 (2517),CYBB (1536),GNS (2799)','extrinsic','cryptorchidism,hypospadias,microcephaly,low-set ears','Treatment of simple aldosterone deficiency should be first ','56'),('OMIM:266150','PYRUVATE CARBOXYLASE DEFICIENCY','PC (5091),HNF4A (3172),HMOX1 (3162),GNS (2799)','extrinsic','abdominal pain, vomiting, tiredness and muscle weakness. Children with this type of PC deficiency usually die in infancy or early childhood, but some survive to adulthood.','The aim of treatment is to provide alternative energy sources and to correct acute metabolic acidosis. Other management and treatment options depend on the type of PC deficiency. Current symptomatic and supportive treatments are generally ineffective.','66'),('OMIM:222700','LYSINURIC PROTEIN INTOLERANCE','SLC7A7 (9056),PIEZO1 (9780),IDUA (3425),GNS (2799)','',' psychotic episodes,osteoporosis,cutis laxa ','Treatment revolves around protein-restricted diet and supplement of lysine, ornithine, and citrulline. The complication of pulmonary alveolar proteinosis has been reported to be successfully treated by whole lung lavage.','74'),('OMIM:121300','COPROPORPHYRIA, HEREDITARY','CPOX (1371),PCCB (5096),BSCL2 (26580).','extrinsic','Management includes the suppression of triggering factors, relief from pain (opiates), vomiting and anxiety, and the prevention of attacks (by avoiding triggering factors, particularly drugs).','When an acute attack is confirmed, urgent treatment with an injection of human hemin and/or perfusion of carbohydrates is required.','64'),('OMIM:251290','BAND-LIKE CALCIFICATION WITH SIMPLIFIED GYRATION AND POLYMICROGYRIA','OCLN (100506658),ABCA1 (19),IDUA (3425)','Intrinsic','Treatment is symptomatic only.','Treatment is symptomatic only.','59'),('OMIM:230900','GAUCHER DISEASE, TYPE II','GBA (2629),IDUA (3425),HNF4A (3172)','intrinsic','The treatment does not seem to have an effect on neurological manifestations and is therefore not indicated for patients with GD type 2.','The treatment does not seem to have an effect on neurological manifestations and is therefore not indicated for patients with GD type 2.','69'),('OMIM:201100','ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE','SLC39A4 (55630)','extrinsic','for child welling and tenderness in the abdomen and lymph nodes,jaundice','Antihistamines,hepatitis B','78'),('OMIM:214500','CHEDIAK-HIGASHI SYNDROME','LYST (1130),IDUA (3425),CPT2 (1376),PEX26 (55670)','extrinsic',' vision problems such as reduced sharpness; rapid, involuntary eye movements (nystagmus);  increased sensitivity to light (photophobia),Chediak-Higashi syndrome have problems with blood clotting (coagulation) that lead to easy bruising and abnormal bleeding.','Allogeneic transplantation from an HLA-matched sibling or from an unrelated donor or cord blood transplantation.','55'),('OMIM:230000','FUCOSIDOSIS','FUCA1 (2517),KCNQ1OT1 (10984),PCCB (5096),PHKB (5257),CPT2 (1376)','Intrinsic','include impaired growth; abnormal bone development (dysostosis multiplex); seizures; abnormal muscle stiffness (spasticity); clusters of enlarged blood vessels forming small, dark red spots on the skin (angiokeratomas); distinctive facial features.','no cure to stop','65'),('OMIM:616278','BILE ACID SYNTHESIS DEFECT, CONGENITAL, 5','ABCD3 (5825),HNF4A (3172),BOLA3 (388962),IDUA (3425),CPT2 (1376)','Intrinsic',' absorb fat, fat-soluble vitamins, malabsorption,blood clotting problems,rickets. ','Cholic acid replacement therapy,restoring vitamins A, D, E, and K.','74'),('OMIM:610293','GLYCOSYLPHOSPHATIDYLINOSITOL DEFICIENCY','PIGM (93183),AGPAT2 (10555),PIEZO1 (9780),HGSNAT (138050)','Intrinsic','Portal vein thrombasis,portal hypertension,Seizures. ',' sodium phenylbutyrate, a histone deacetylase inhibitor, resulted in significant clinical improvement and remission of seizures','71'),('OMIM:212140','CARNITINE DEFICIENCY, SYSTEMIC PRIMARY','SLC22A5 (6584),SLC39A4 (55630),BSCL2 (26580),LIPA (3988).','extrinsic','severe brain dysfunction,severe brain dysfunction (encephalopathy), a weakened and enlarged heart (cardiomyopathy), confusion, vomiting, muscle weakness, and low blood sugar (hypoglycemia)','riboflavin, glycine, or biotin.','73'),('OMIM:276700','TYROSINEMIA, TYPE I','FAH (2184),KCNQ1OT1 (10984),SLC30A10 (55532),CPT2 (1376)','Intrinsic','fever, diarrhea, vomiting, an abnormally enlarged liver (hepatomegaly), andyellowing of the skin and the whites of the eyes','nitisinone','72'),('OMIM:604302','SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS','MIF (4282),SLC39A4 (55630),APOE (348)','extrinsic','high fevers, rheumatic rash, enlargement of the liver and spleen, enlargement of the lymph nodes, and anemia.','celebrex,vollaren,ibuprofen,naproxen','62'),('OMIM:226980','EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH EARLY-ONSET DIABETES MELLITUS','EIF2AK3 (9451),IDUA (3425)','extrinsic','joint pain,knees, early-onset arthritis, and a waddling walk,multiple epiphyseal dysplasia','Medical Therapy,Surgical Therapy,Knee,tibial tubercle, hypoplasia of the femoral condyle, and subluxation of the patella. ','63'),('OMIM:614576','CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIL','COG6 (57511),IDS (3423),LIPA (3988)','Intrinsic','low levels of blood sugar (hypoglycemia),scarring (fibrosis) of the liver, failure to thrive, and cyclic vomiting','Orthopedic issues in adults,Routine therapies,IV hydration and physical therapy','64'),('OMIM:607624','GRISCELLI SYNDROME, TYPE 2','RAB27A (5873),SLC30A10 (55532),FASTKD2 (22868), TACO1 (51204), COX20 (116228), SCO1 (6341), COX10 (1352), COX14 (84987), COX6B1 (1340), PET100 (100131801), APOPT1 (84334)','Intrinsic',' caused by a mutation in RAB27A,pyogenic infection, enlargement of the liver and spleen, a low blood neutrophil level, low blood platelet level, and immunodeficiency.','stem cell transplantation,','69'),('OMIM:233700','GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-POSITIVE,TYPE I','NCF1 (653361),HGSNAT (138050),MMAB (326625)','intrinsic','Bone damage and infections,Chronic infections in the nose','Antibiotics,interferon-gamma,Surgery','66'),('OMIM:309900','MUCOPOLYSACCHARIDOSIS TYPE II','IDS (3423),ITCH (83737)','extrinsic','Hunter syndrome such as abdominal hernias, ear infections, runny noses, and colds.','Bone marrow transplantation (BMT),enzyme replacement therapy (ERT), iduronate sulfatase (IDS)','61'),('OMIM:607015','HURLER-SCHEIE SYNDROME','IDUA (3425),GPD1 (2819)','extrinsic',' the brain, heart, joints, skeleton respiratory tract and liver, as well as vision and hearing. ','Bone Marrow Transpalntation(BMT),Umbilical Cord Blood Transpalntation(UCBT)','79'),('OMIM:246900','DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY','DLD (1738),ITCH (83737)','extrinsic','hyperventilation, vomiting, and abdominal pain, occasionally resulting in death','branched-chain alpha-keto acid dehydrogenase (BCKD), pyruvate dehydrogenase (PDH), and alpha (?)-ketoglutarate dehydrogenase (?KGDH).','68'),('OMIM:607616','NIEMANN-PICK DISEASE, TYPE B','SMPD1 (6609),EIF2AK3 (9451)','Intrinsic','Difficulty moving limbs,Enlarged spleen.Enlarged liver,Seizures\n','hematopoietic progenitor cell (HPC) transplantation.','79'),('OMIM:269600','SEA-BLUE HISTIOCYTE DISEASE','APOE (348),GNPTAB (79158),TMEM67 (91147)','Intrinsic','Abnormality of coagulation,Mediastinal lymphadenopathy, Subcutaneous hemorrhage.  ','diagnosis, management, and genetic counseling of patients','59'),('OMIM:614052','MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 2','TMEM70 (54968),PIEZO1 (9780),BOLA3 (388962),CYBA (1535),HSD17B4 (3295)','extrinsic','characterized by early neonatal onset of hypotonia, hypetrophic cardiomyopathy and apneic spells within hours after birth accompanied by lactic acidosis, hyperammonemia and 3-methylglutaconic aciduria.','The management of mitochondrial disease is largely supportive and may include early diagnosis and treatment of diabetes mellitus, cardiac pacing, ptosis correction, intraocular lens replacement for cataracts, and cochlear implantation for sensorineural hearing loss','54'),('OMIM:614887','PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)','PEX14 (5195),ITK (3702),MMAB (326625)','Intrinsic','Feeding and nutrition,Hearing,Vision,liver','hearing impairment,Cataract removal,adequate calorie intake,Supplementation of vitamin K.','51'),('OMIM:613385','AUTOIMMUNE DISEASE, MULTISYSTEM, WITH FACIAL DYSMORPHISM','ITCH (83737),MMAB (326625)','extrinsic','joints are affected, blood is affected','hormone replacement therapy,blood transfusions,anti-inflammatory medication','52'),('OMIM:252900','MUCOPOLYSACCHARIDOSIS TYPE IIIA','SGSH (6448),CDKN1C (1028),C15ORF41 (84529),CYBA (1535)','Intrinsic','Dense calvaria,Diarrhea,Growth abnormality,Asymmetric septal hypertrophy','no cure or standard treatment for people','53'),('OMIM:611721','COMBINED SAPOSIN DEFICIENCY','PSAP (5660),OCLN (100506658),CYBB (1536),HMOX1 (3162)','extrinsic','bnormality of eye movement, muscular hypotonia, dystonia,splenomegaly','selenium,Combined Saposin Deficiency','69'),('OMIM:252500','MUCOLIPIDOSIS II ALPHA/BETA','GNPTAB (79158),RAB27A (5873),TREX1 (11277)','Intrinsic','Hoarse voice,hearing loss,diarrhea,itch,rash,pain,nausea,headache','accupunture,Aerobic exercise,Antibiotic,Angioplasty,Aromatherapy,Blood Pressure Medications','67'),('OMIM:608594','LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 1','AGPAT2 (10555),SLC39A4 (55630),EIF2AK3 (9451)','extrinsic','hearing loss, limited mental ability, epilepsy, or muscle weakness','calories,good nutrition,insulin,hormone replacement therapy','55'),('OMIM:208540','RENAL-HEPATIC-PANCREATIC DYSPLASIA','NPHP3 (27031),CDKN1C (1028),ITK (3702),C15ORF41 (84529),DHFR (1719),GNS (2799)','Intrinsic','Brain cyst,Hydrocephalus,Abnormal Kidney development,Abnormal Liver Development,Abnormal Pancreatic Development,Liver fibrosis,Cystic Kidneys.','Pediatric Neurosurgery,Neuromusuculous kidney medicine,vascular surgery,Neuropathology.','66'),('OMIM:613561','MYOPATHY, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA 2','YARS2 (51067),OCLN (100506658),CTLA4 (1493)','extrinsic','Absence of sensory complaints or paresthesias; however, deep tendon reflexes (DTRs) may be diminished/absent in hypokalemic paralysis.Symmetric proximal muscle weakness,Malaise, fatigue,Dark-colored urine (suggests myoglobinuria) and/or fever.Absence of sensory complaints or paresthesias; however, deep tendon reflexes (DTRs) may be diminished/absent in hypokalemic paralysis.','to avoid situations that tax the muscles and promote muscle pain and weakness, like strenuous exercise.','57'),('OMIM:613027','GLYCOGEN STORAGE DISEASE IXC','PHKG2 (5261),PC (5091),ITCH (83737),MMAB (326625),BSCL2 (26580)','Intrinsic','Liver phosphorylase, kinase deficiency,Reduced muscle tone,enlarged liver,liver dysfunction','no cure ','50'),('OMIM:613490','ALPHA-1-ANTITRYPSIN DEFICIENCY','SERPINA1 (5265),CDKN1C (1028),ALMS1 (7840)','extrinsic','Shortness of breath,Cough,Wheezing,Chest infections','lung transplantation,Rehabiltation,','59'),('OMIM:231670','GLUTARIC ACIDEMIA I','GCDH (2639),PC (5091)','Intrinsic','poor feeding or loss of appetite,lack of energy,abnormal movements,abnormal movements,irritability,breathing difficulties.',' amino acids lysine, hydroxylysine, and tryptophan,“glutaryl-CoA dehydrogenase','51'),('OMIM:300868','MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2','PIGA (5277),EIF2AK3 (9451)','Intrinsic','absence of sensory complaints or paresthesias; however, deep tendon reflexes (DTRs) may be diminished/absent in hypokalemic paralysis.Symmetric proximal muscle weakness,Malaise, fatigue,Dark-colored urine (suggests myoglobinuria) and/or fever.Absence of s','low muscle tone (hypotonia)at birth, myoclonic seizures','75'),('OMIM:235200','HEMOCHROMATOSIS','HFE (3077),IDS (3423),C15ORF41 (84529)','extrinsic','joint pain,fatigue, general weakness, weight loss, and stomach pain',' diabetes or cirrhosis (scarring of the liver)','65'),('OMIM:614582','COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 9','MRPL3 (11222),IDUA (3425),YARS2 (51067)','Intrinsic','Abdominal ascites\nAbdominal ascites\nKidney tubulopathy,reduced muscle tone,abdominal ascites','spinal muscular atrophy,muscular distrophy,carcinoide syndrome','56'),('OMIM:601847','CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 2','ABCB11 (8647),C15ORF41 (84529)','extrinsic','cholestasis, jaundice, and failure to thrive.','familial intrahepatic cholestasis;enterohepatic recirculation ','76'),('OMIM:615559','AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE III','PRKCD (5580),EIF2AK3 (9451),ADAMTSL2 (9719)','Intrinsic','nephrotic syndrome,autoimmune thrombocytopenia,hepatomegaly, lymphadenopathy.','Phramacological therapy,Stem cell Transplantation,diet and  activity','66'),('OMIM:308240','LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1','SH2D1A (4068),IDS (3423),CYBA (1535),ADAMTSL2 (9719)','Intrinsic','asymptomatic,fulminating or fatal infectious mononucleosis,liver failure,B-cell lymphomas,aplastic anemia, hypogammaglobulinemia.','Hematopoietic stem cell transplantation','80'),('OMIM:615688','POLYARTERITIS NODOSA, CHILDHOOD-ONSET','CECR1 (51816),PC (5091),GNPTAB (79158),HNF4A (3172)','extrinsic','sudden weight loss,a decreased appetite,abdominal pain,excessive fatigue,muscle and joint aches,fever','corticosteroids,immune suppressants,antiviral medications','70'),('OMIM:216360','COACH SYNDROME','CC2D2A (57545), TMEM67 (91147), RPGRIP1L (23322),C15ORF41 (84529)','Intrinsic','mental retardation, liver problems (fibrosis), and difficulty with movement ( ataxia ),abnormality of the eye (called a coloboma) or abnormal eye movements (such as nystagmus ).','ADHD,stroke','71'),('OMIM:306400','GRANULOMATOUS DISEASE, CHRONIC, X-LINKED','CYBB (1536),OCLN (100506658),YARS2 (51067),TMEM67 (91147)','extrinsic','Pneumonia,bacterial or fungal infections,wounds, ','Hematopoietic stem cell transplantation,Bone marrow transplantation,Noninfectious granulomas .','55'),('OMIM:214100','PEROXISOME BIOGENESIS DISORDER 1A (ZELLWEGER)','PEX1 (5189),NCF1 (653361),PHKG2 (5261)','Intrinsic','muscle weakness,hearing abnormality,central hypotonia,respiratory tract infection.','adequate calories, hearing aids, cataract removal in infancy, glasses, vitamin supplementation, primary bile acid therapy, antiepileptic drugs, and possibly monitoring for hyperoxaluria','66'),('OMIM:616026','FANCONI RENOTUBULAR SYNDROME 4 WITH MATURITY-ONSET DIABETES OF THEYOUNG','HNF4A (3172),KCNQ1OT1 (10984),FUCA1 (2517),RHBDF2 (79651),MMAB (326625)','Intrinsic','Passing increased amount of urine,Pain in the bones,Weakness.','Dehydration,Metabolic Acidosis','59'),('OMIM:300884','CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IS','ALG13 (79868),FUCA1 (2517),MIF (4282)','Intrinsic',' low levels of blood sugar (hypoglycemia), scarring (fibrosis) of the liver, failure to thrive, and cyclic vomiting.','Mannose Supplementation','69'),('OMIM:194380','DEHYDRATED HEREDITARY STOMATOCYTOSIS WITH OR WITHOUT PSEUDOHYPERKALEMIAAND/OR PERINATAL EDEMA','PIEZO1 (9780),RAB27A (5873)','extrinsic','jaundice,pallor,cholelithiasis,hepatomegaly','Folic acid supplementation,Iron depletion,Splenectomy.','51'),('OMIM:266100','EPILEPSY, PYRIDOXINE-DEPENDENT','ALDH7A1 (501),HMOX1 (3162),ADAMTSL2 (9719)','extrinsic','body temperature (hypothermia), poor muscle tone (dystonia) soon after birth','pyridoxine,intractable neonatal seizures','61'),('OMIM:614299','MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 2','BOLA3 (388962),RHBDF2 (79651),PCCA (5095','Intrinsic','Decreased activity of mitochondrial respiratory chain,Failure to thrive,Abnormality of mitochondrial metabolism',' diabetes mellitus, cardiac pacing, ptosis correction, intraocular lens replacement for cataracts, and cochlear implantation for sensorineural hearing loss','71'),('OMIM:231005','GAUCHER DISEASE, TYPE IIIC','GBA (2629),CDKN1C (1028),ADAMTSL2 (9719)','extrinsic','Easy bruising,Nosebleeds,Fatigue,Enlarged spleen or liver, which makes your belly look swollen','Enzyme replacement therapy (ERT),Glucosylceramide synthase','52'),('OMIM:252930','MUCOPOLYSACCHARIDOSIS TYPE IIIC','HGSNAT (138050),MRPL3 (11222),CYBA (1535)','intrinsic','Asymmetric septal hypertrophy,Coarse facial features,Dense calvariaDolichocephaly,Dysostosis multiplex.',' bone marrow transplantation (BMT) and enzyme replacement therapy (ERT),HSCT (hematopoietic stem cell transplantation)','72'),('OMIM:611721','COMBINED SAPOSIN DEFICIENCY','PSAP (5660),OCLN (100506658),CYBB (1536),HMOX1 (3162)','extrinsic','bnormality of eye movement, muscular hypotonia, dystonia,splenomegaly','selenium,Combined Saposin Deficiency','69'),('OMIM:252500','MUCOLIPIDOSIS II ALPHA/BETA','GNPTAB (79158),RAB27A (5873),TREX1 (11277)','Intrinsic','Hoarse voice,hearing loss,diarrhea,itch,rash,pain,nausea,headache','accupunture,Aerobic exercise,Antibiotic,Angioplasty,Aromatherapy,Blood Pressure Medications','67'),('OMIM:608594','LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 1','AGPAT2 (10555),SLC39A4 (55630),EIF2AK3 (9451)','extrinsic','hearing loss, limited mental ability, epilepsy, or muscle weakness','calories,good nutrition,insulin,hormone replacement therapy','55'),('OMIM:208540','RENAL-HEPATIC-PANCREATIC DYSPLASIA','NPHP3 (27031),CDKN1C (1028),ITK (3702),C15ORF41 (84529),DHFR (1719),GNS (2799)','Intrinsic','Brain cyst,Hydrocephalus,Abnormal Kidney development,Abnormal Liver Development,Abnormal Pancreatic Development,Liver fibrosis,Cystic Kidneys.','Pediatric Neurosurgery,Neuromusuculous kidney medicine,vascular surgery,Neuropathology.','66'),('OMIM:613561','MYOPATHY, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA 2','YARS2 (51067),OCLN (100506658),CTLA4 (1493)','extrinsic','Absence of sensory complaints or paresthesias; however, deep tendon reflexes (DTRs) may be diminished/absent in hypokalemic paralysis.Symmetric proximal muscle weakness,Malaise, fatigue,Dark-colored urine (suggests myoglobinuria) and/or fever.Absence of sensory complaints or paresthesias; however, deep tendon reflexes (DTRs) may be diminished/absent in hypokalemic paralysis.','to avoid situations that tax the muscles and promote muscle pain and weakness, like strenuous exercise.','57'),('OMIM:613027','GLYCOGEN STORAGE DISEASE IXC','PHKG2 (5261),PC (5091),ITCH (83737),MMAB (326625),BSCL2 (26580)','Intrinsic','Liver phosphorylase, kinase deficiency,Reduced muscle tone,enlarged liver,liver dysfunction','no cure ','50'),('OMIM:613490','ALPHA-1-ANTITRYPSIN DEFICIENCY','SERPINA1 (5265),CDKN1C (1028),ALMS1 (7840)','extrinsic','Shortness of breath,Cough,Wheezing,Chest infections','lung transplantation,Rehabiltation,','59'),('OMIM:231670','GLUTARIC ACIDEMIA I','GCDH (2639),PC (5091)','Intrinsic','poor feeding or loss of appetite,lack of energy,abnormal movements,abnormal movements,irritability,breathing difficulties.',' amino acids lysine, hydroxylysine, and tryptophan,“glutaryl-CoA dehydrogenase','51'),('OMIM:300868','MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2','PIGA (5277),EIF2AK3 (9451)','Intrinsic','absence of sensory complaints or paresthesias; however, deep tendon reflexes (DTRs) may be diminished/absent in hypokalemic paralysis.Symmetric proximal muscle weakness,Malaise, fatigue,Dark-colored urine (suggests myoglobinuria) and/or fever.Absence of s','low muscle tone (hypotonia)at birth, myoclonic seizures','75'),('OMIM:235200','HEMOCHROMATOSIS','HFE (3077),IDS (3423),C15ORF41 (84529)','extrinsic','joint pain,fatigue, general weakness, weight loss, and stomach pain',' diabetes or cirrhosis (scarring of the liver)','65'),('OMIM:614582','COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 9','MRPL3 (11222),IDUA (3425),YARS2 (51067)','Intrinsic','Abdominal ascites\nAbdominal ascites\nKidney tubulopathy,reduced muscle tone,abdominal ascites','spinal muscular atrophy,muscular distrophy,carcinoide syndrome','56'),('OMIM:601847','CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 2','ABCB11 (8647),C15ORF41 (84529)','extrinsic','cholestasis, jaundice, and failure to thrive.','familial intrahepatic cholestasis;enterohepatic recirculation ','76'),('OMIM:615559','AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE III','PRKCD (5580),EIF2AK3 (9451),ADAMTSL2 (9719)','Intrinsic','nephrotic syndrome,autoimmune thrombocytopenia,hepatomegaly, lymphadenopathy.','Phramacological therapy,Stem cell Transplantation,diet and  activity','66'),('OMIM:308240','LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1','SH2D1A (4068),IDS (3423),CYBA (1535),ADAMTSL2 (9719)','Intrinsic','asymptomatic,fulminating or fatal infectious mononucleosis,liver failure,B-cell lymphomas,aplastic anemia, hypogammaglobulinemia.','Hematopoietic stem cell transplantation','80'),('OMIM:615688','POLYARTERITIS NODOSA, CHILDHOOD-ONSET','CECR1 (51816),PC (5091),GNPTAB (79158),HNF4A (3172)','extrinsic','sudden weight loss,a decreased appetite,abdominal pain,excessive fatigue,muscle and joint aches,fever','corticosteroids,immune suppressants,antiviral medications','70'),('OMIM:216360','COACH SYNDROME','CC2D2A (57545), TMEM67 (91147), RPGRIP1L (23322),C15ORF41 (84529)','Intrinsic','mental retardation, liver problems (fibrosis), and difficulty with movement ( ataxia ),abnormality of the eye (called a coloboma) or abnormal eye movements (such as nystagmus ).','ADHD,stroke','71'),('OMIM:306400','GRANULOMATOUS DISEASE, CHRONIC, X-LINKED','CYBB (1536),OCLN (100506658),YARS2 (51067),TMEM67 (91147)','extrinsic','Pneumonia,bacterial or fungal infections,wounds, ','Hematopoietic stem cell transplantation,Bone marrow transplantation,Noninfectious granulomas .','55'),('OMIM:214100','PEROXISOME BIOGENESIS DISORDER 1A (ZELLWEGER)','PEX1 (5189),NCF1 (653361),PHKG2 (5261)','Intrinsic','muscle weakness,hearing abnormality,central hypotonia,respiratory tract infection.','adequate calories, hearing aids, cataract removal in infancy, glasses, vitamin supplementation, primary bile acid therapy, antiepileptic drugs, and possibly monitoring for hyperoxaluria','66'),('OMIM:616026','FANCONI RENOTUBULAR SYNDROME 4 WITH MATURITY-ONSET DIABETES OF THEYOUNG','HNF4A (3172),KCNQ1OT1 (10984),FUCA1 (2517),RHBDF2 (79651),MMAB (326625)','Intrinsic','Passing increased amount of urine,Pain in the bones,Weakness.','Dehydration,Metabolic Acidosis','59'),('OMIM:300884','CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IS','ALG13 (79868),FUCA1 (2517),MIF (4282)','Intrinsic',' low levels of blood sugar (hypoglycemia), scarring (fibrosis) of the liver, failure to thrive, and cyclic vomiting.','Mannose Supplementation','69'),('OMIM:194380','DEHYDRATED HEREDITARY STOMATOCYTOSIS WITH OR WITHOUT PSEUDOHYPERKALEMIAAND/OR PERINATAL EDEMA','PIEZO1 (9780),RAB27A (5873)','extrinsic','jaundice,pallor,cholelithiasis,hepatomegaly','Folic acid supplementation,Iron depletion,Splenectomy.','51'),('OMIM:266100','EPILEPSY, PYRIDOXINE-DEPENDENT','ALDH7A1 (501),HMOX1 (3162),ADAMTSL2 (9719)','extrinsic','body temperature (hypothermia), poor muscle tone (dystonia) soon after birth','pyridoxine,intractable neonatal seizures','61'),('OMIM:614299','MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 2','BOLA3 (388962),RHBDF2 (79651),PCCA (5095','Intrinsic','Decreased activity of mitochondrial respiratory chain,Failure to thrive,Abnormality of mitochondrial metabolism',' diabetes mellitus, cardiac pacing, ptosis correction, intraocular lens replacement for cataracts, and cochlear implantation for sensorineural hearing loss','71'),('OMIM:231005','GAUCHER DISEASE, TYPE IIIC','GBA (2629),CDKN1C (1028),ADAMTSL2 (9719)','extrinsic','Easy bruising,Nosebleeds,Fatigue,Enlarged spleen or liver, which makes your belly look swollen','Enzyme replacement therapy (ERT),Glucosylceramide synthase','52'),('OMIM:252930','MUCOPOLYSACCHARIDOSIS TYPE IIIC','HGSNAT (138050),MRPL3 (11222),CYBA (1535)','intrinsic','Asymmetric septal hypertrophy,Coarse facial features,Dense calvariaDolichocephaly,Dysostosis multiplex.',' bone marrow transplantation (BMT) and enzyme replacement therapy (ERT),HSCT (hematopoietic stem cell transplantation)','72'),('OMIM:154800','MAST CELL DISEASE','KIT (3815),ITCH (83737),LCRB (387281)','intrinsic',' pruritus,flushing, nausea, vomiting, diarrhoea, abdominal pain, vascular instability and anaphylaxis. Also, complications may arise when mast cells accumulate in the skin, gastrointestinal tract, bone marrow, liver, spleen, and lymph nodes.','Cromolyn sodium, ketotifen and leukotriene-modifying agents are additional medications which may provide benefit. Epinephrine may be required to treat episodes of low blood pressure. More aggressive forms of Systemic Mastocytosis may require interferon, immune modulators or chemotherapeutic agents.','65'),('OMIM:219700','CYSTIC FIBROSIS','CFTR (1080),CYBB (1536),GPD1 (2819)','extrinsic','Coughing up thick mucus,Wheezing or shortness of breath,Growths, called polyps, in the nose,Bulky, oily, or foul-smelling stool,','nebulised aztreonam and dry powder versions of colistin and tobramycin for inhalation; dry powder inhaled mannitol','75'),('OMIM:233710','GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-POSITIVE,TYPE II','NCF2 (4688),IDUA (3425),SOX10 (6663),DHFR (1719)','Intrinsic','pneumonia,abscesses of the skin, tissues, and organs,suppurative arthritis,osteomyelitis,superficial skin infections such as cellulitis or impetigo','Management of chronic granulomatous disease revolves around two goals: 1) diagnose the disease early so that antibiotic prophylaxis can be given to keep an infection from occurring, and 2) educate the patient about his or her condition so that prompt treatment can be given if an infection occurs','63'),('OMIM:614034','HEME OXYGENASE 1 DEFICIENCY','HMOX1 (3162),IDUA (3425),PEX1 (5189),ADAMTSL2 (9719)','Intrinsic','proteinuria,hematuria,growth delay,hemolytic anemia,hepatomegaly.','TGF-?1 Treatment of Primary Proximal Tubular Epithelial Cell Cultures','53'),('OMIM:613011','LYMPHOPROLIFERATIVE SYNDROME 1','ITK (3702),CDKN1C (1028),MRPL3 (11222),PEX1 (5189)','extrinsic',' high numbers of white blood cells called lymphocytes accumulate in the lymph nodes, liver, and spleen, which can lead to enlargement of these organs. ALPS can cause numerous autoimmune problems such as anemia (low count of red blood cells), thrombocytopenia (low count of platelets), and neutropenia (low count of neutrophils, the most common type of white blood cell in humans).','to justify the risks and mortality associated with allogeneic bone marrow transplantation,stem cell transplantation has been successful in ALPS patients and can be considered a treatment option for those with severe, recalcitrant disease and a matched donor.','67'),('OMIM:616100','AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE V','CTLA4 (1493),IDS (3423),PNPLA2 (57104)','Intrinsic',' high numbers of white blood cells called lymphocytes accumulate in the lymph nodes, liver, and spleen, which can lead to enlargement of these organs. ALPS can cause numerous autoimmune problems such as anemia (low count of red blood cells), thrombocytopenia (low count of platelets), and neutropenia (low count of neutrophils, the most common type of white blood cell in humans).','to justify the risks and mortality associated with allogeneic bone marrow transplantation,stem cell transplantation has been successful in ALPS patients and can be considered a treatment option for those with severe, recalcitrant disease and a matched donor.','80'),('OMIM:230500','GM1-GANGLIOSIDOSIS, TYPE I','GLB1 (2720),GNPTAB (79158),PNPLA2 (57104)','extrinsic','Differential diagnosis includes mucopolysaccharidoses, sphingolipidoses and oligosaccharidoses',' no effective medical treatment is available for the underlying disorder in patients with G M1 gangliosidosis. Bone marrow transplantation was successful in an individual with infantile/juvenile GM1 gangliosidosis; however, no long-term benefit was reported. [20] Presymptomatic cord-blood hematopoietic stem-cell transplantation has been advocated by some as a possible treatment because of success in other lysosomal storage disorders.','57'),('OMIM:603553','HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 2','PRF1 (5551),NCF1 (653361),HFE (3077),FASTKD2 (22868), TACO1 (51204), COX20 (116228), SCO1 (6341), COX10 (1352), COX14 (84987), COX6B1 (1340), PET100 (100131801), APOPT1 (84334)','Intrinsic','Low or absent NK (natural killer) cell function,Prolonged fever.Blood cell abnormalities,Enlarged spleen.Increased triglycerides (fat) or decreased fibrinogen (protein necessary for clotting) in the blood.Increased ferritin (protein that stores iron) in the blood.','While optimal treatment of HLH is still being debated, current treatment regimes usually involve high dose corticosteroids, etoposide and cyclosporin. Intravenousimmunoglobulin is also used. Methotrexate and vincristine have also been used. Other medications include cytokine targeted therapy.','56'),('OMIM:205400','TANGIER DISEASE','ABCA1 (19),GNPTAB (79158),FAM111A (63901)','extrinsic','the liver, spleen and lymph nodes may become enlarged. Brain dysfunction, loss of tendon reflexes and coronary artery disease may also occur. In some cases, small solid elevated skin lesions (papules) may also appear','Diagnostic Tests,Drug Therapy,Surgery and Rehabilitation,Genetic Counseling.','68'),('OMIM:614480','HYPERTRIGLYCERIDEMIA, TRANSIENT INFANTILE','GPD1 (2819),IDS (3423),ADAMTSL2 (9719)','Intrinsic','hypertriglyceridemia,hepatic steatosis, hepatic fibrosis','Fibrates,Pharmacologic Therapy,Niacin,Omega acids','73'),('OMIM:607196','MICROCEPHALY, AMISH TYPE','SLC25A19 (60386),SGSH (6448),PHKG2 (5261),CTLA4 (1493)','extrinsic','Balance and coordination problems,Developmental delays (delayed sitting, standing, walking),Trouble swallowing and problems with feeding,\r\nHyperactivity (trouble paying attention or sitting still).','There\'s no cure for microcephaly, but there are treatments to help with development, behavior, and seizures,If your child has mild microcephaly, he\'ll need regular doctor checkups to monitor how he grows and develops.','79'),('OMIM:170100','PROLIDASE DEFICIENCY','PEPD (5184),PC (5091),LYST (1130),BOLA3 (388962),SOX10 (6663)PEX2 (5828),FAM111A (63901).','Intrinsic','Diarrhea, vomiting, and dehydration may also occur, Affected individuals may have enlargement of the spleen (splenomegaly); in some cases, both the spleen and liver are enlarged (hepatosplenomegaly).','Treatment is symptomatic. Care should be provided by a multidisciplinary team in order to monitor and treat skin, lung, and immunologic manifestations. Topical proline plus glycine ointment, steroids, methylprednisolone, blood transfusions, plasmapheresis, and topical growth hormone ointment have all been used to treat ulcers, with varying degrees of improvement reported. Antibiotic prophylaxis may be necessary in some cases. In patients with splenomegaly, contact sports should be avoided.','77'),('OMIM:602347','CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 3','ABCB4 (5244)','extrinsic','Patients usually present in early childhood with cholestasis, jaundice, and failure to thrive.','in treating patients with progressive familial intrahepatic cholestasis with ursodeoxycholic acid (20-30 mg/kg/d), which may be tried as an initial treatment. Other therapies for the symptomatic relief of pruritus include antihistamines, rifampin, and bile acid-binding agents.','67'),('OMIM:615486','INTERSTITIAL LUNG AND LIVER DISEASE','MARS (4141),MEFV (4210)','Intrinsic','Abdominal pain,DiarrheaFatigue,,Loss of appetiteMuscle pain','Several types of ILD, most notably sarcoidosis and hypersensitivity reactions, get better on their own, or they respond to treatment with corticosteroids. Avoidance of toxin or allergen exposures also can be beneficial.','54'),('OMIM:148500','TYLOSIS WITH ESOPHAGEAL CANCER','RHBDF2 (79651),OCLN (100506658),MRPL3 (11222),KIT (3815),GBA (2629)','extrinsic','Abnormality of the intestine,Gastrointestinal hemorrhage,Abnormality of the mediastinum','Affected individuals may have periodic endoscopic and oral cavity evaluations by a gastroentrologist to detect esophageal cancer. For the palmoplantar keratoderma, a dermatologist may recommend oral retinoids such as etretinate, isotretinoin, and acitretin. Topical therapies may include soaking in salt water and then gentle removal of dead tissue (debridement) and 50% propylene glycol in water under plastic dressing overnight weekly','69'),('OMIM:151660','LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2','LMNA (4000),PIGM (93183),APOE (348),AGPAT2 (10555),PCCA (5095),DIS3L2 (129563),MEFV (4210)','Intrinsic',' partial lipodystrophy, severe insulin resistance, fatty liver, acanthosis nigricans, and diabetes','Treatment consists of correcting metabolic abnormalities and managing complications. Monitoring diet (reduced intake of dietary fats and carbohydrates) and maintaining daily physical activity can improve the metabolic complications of lipodystrophy. Insulin sensitizers (mainly metformin) and lipid-lowering drugs (statins, or fibrates in case of major hypertriglyceridemia) can also be helpful. Diabetes may require other non-specific treatments, along with insulin. Treatment with metreleptin has resulted in regression of hepatic steatosis and an improvement in metabolic homeostasis, but is only approved in Japan and for the treatment of generalized forms of lipodystrophies in the US (and through compassionate programs in other countries). Regular cardiac monitoring is recommended. Ethinylestradiol should be avoided in women with FPLD2. Plastic surgery can help some patients.','59'),('OMIM:257220','NIEMANN-PICK DISEASE, TYPE C1','NPC1 (4864),HFE (3077),GBA (2629),APOA1 (335)','extrinsic','cerebellar ataxia (unsteady walking with uncoordinated limb movements), dysarthria (slurred speech), dysphagia (difficulty in swallowing), tremor, epilepsy (both partial and generalized), vertical supranuclear palsy (upgaze palsy, downgaze palsy, saccadic palsy or paralysis','Seizures generally respond at least partially to antiepileptic drugs until a fairly advanced stage of the disease. Cataplexy can usually be controlled by clomipramine, protriptyline, or modafinil. Anticholinergic agents have been reported to improve dystonia and tremor in some patients. Physiotherapy is useful in the management of spasticity and the prevention of contractures. Melatonin may be used to treat insomnia. Patients with a slow disease course may benefit from special schooling for handicapped children. Proper management of infections and of feeding difficulties (gastrostomy) is essential at an advanced stage of the disease.','74'),('OMIM:615631','ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE IB','C15ORF41 (84529),APOA1 (335),FGA (2243), LYZ (4069)','Intrinsic',' CDA is one of many types of anemia, characterized by ineffective erythropoiesis, and resulting from a decrease in the number of red blood cells (RBCs) in the body and a less than normal quantity of hemoglobin in the blood.','Medications, such as iron chelating agents or interferon alpha-2A (only in CDA type I),Selected surgical procedures (removal of the spleen and/or gallbladder), when required','52'),('OMIM:613280','HYPERMANGANESEMIA WITH DYSTONIA, POLYCYTHEMIA, AND CIRRHOSIS','SLC30A10 (55532),NPC1 (4864),APOA1 (335)','Intrinsic','can appear in childhood (early-onset), typically between ages 2 and 15, or in adulthood (adult-onset),Other neurological symptoms in affected children include involuntary trembling (tremor), unusually slow movement (bradykinesia), and slurred speech (dysarthria)','Diagnostic Tests,Drug Therapy,Surgery and Rehabilitation,Genetic Counseling.','60'),('OMIM:251110','METHYLMALONIC ACIDURIA, CBLB TYPE','MMAB (326625),TMEM70 (54968),RHBDF2 (79651)','Intrinsic','Inflammation of the pancreas (pancreatitis),Increased acid in the blood (metabolic acidosis),Feeding difficulties,Breathing difficulties,Intellectual disabilities','Treatment for Methylmalonic Acidemia involves dietary management. Individuals with the disorder should consume low protein, high calorie diets and avoid periods of fasting from food. Some individuals may benefit from carnitine supplementation or B12 injection therapy. Other treatment for Methylmalonic Acidemia may include kidney and liver transplantations.','70'),('OMIM:606054','PROPIONIC ACIDEMIA','PCCA (5095), PCCB (5096),ALG13 (79868)','Intrinsic','The initial symptoms include poor feeding, vomiting, loss of appetite, weak muscle tone (hypotonia), and lack of energy (lethargy).','L-carnitine has shown to be beneficial in Propionic Acidemia as it facilitates removal of toxins from the blood and helps in providing energy to the body. Certain oral antibiotics are also helpful in reducing propionic acid build up in the intestines. Apart from medications supplement like Biotin is also very helpful for children with Propionic Acidemia.','50'),('OMIM:232700','GLYCOGEN STORAGE DISEASE VI','PYGL (5836),SGSH (6448),HMOX1 (3162),CYBA (1535)','Intrinsic','The first sign is usually an enlarged liver (hepatomegaly). Affected individuals may also have low blood sugar (hypoglycemia) or a buildup of lactic acid in the body (lactic acidosis) during prolonged periods without food (fasting','Treatment with cornstarch and a high protein diet is recommended in an effort to achieve normal labs and normal growth. Treatment improves growth velocity and bone density in this condition, and reduces the frequency of hypoglycemia and ketosis. Treatment is individualized in an attempt to maintain glucose concentrations above 70 mg/dL and normalize ketones after an overnight fast.','57'),('OMIM:216400','COCKAYNE SYNDROME, TYPE A','ERCC8 (1161),TMEM70 (54968),HPLH1 (27259)','extrinsic','Abnormal auditory evoked potentials,Abnormality of the hair,Abnormality of visual evoked potentials,Arrhythmia,Atypical scarring of skin.','The condition is diagnosed by the presence of the typical physical characteristics, and the unusually slow growth. Confirmation is by molecular genetic testing. Another technique involves a DNA repair test carried out on special cells called fibroblasts.','67'),('OMIM:233690','GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-NEGATIVE','CYBA (1535),PC (5091)','extrinsic',' inflammation of the lymph glands (suppurative lymphadenitis), skin infections, and pneumonia. Blood studies can show evidence of chronic infection','The orphan drug, Actimmune (interferon gamma-1b), has been approved by the Food and Drug Administration (FDA) for the treatment of chronic granulomatous disease,such as trimethoprim and sulfamethoxazole to protect against bacterial infections, and itraconazole for anti-fungal protection,Corticosteroid drugs,Bone marrow transplants.','63'),('OMIM:267700','HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 1','HPLH1 (27259),SMPD1 (6609)','extrinsic','Enlarged liver and/or spleen,Breathing problems,Kidney abnormalities,Heart problems,Increased risk for certain cancers (leukemia, lymphoma)',' Prior to hematopoietic cell transplanation, affected people are usually treated with chemotherapyand/or immunotherapy to destroy excess immune cells which can lead to life-threatening inflammation','52'),('OMIM:215140','GREENBERG DYSPLASIA','LBR (3930),SMPD1 (6609)','extrinsic','Abnormal bone calcification,Severe hydrops,Poor skull calcification,Red blood cell disorder,Increased maternal blood pressure','The pregnant mother undergoes ultrasound to examine the fetus. A fetus with the medical condition shows hydrops fetalis, short limb dwarfism, polydactyly and chondro-osseous changes.','59'),('OMIM:607330','LATHOSTEROLOSIS','SC5D (6309),PHKG2 (5261),ABCA1 (19)','extrinsic','Liver disease ,Mental retardation, Congenital malformations, Small head, Unusual facial appearance, Extra little toe, Webbed toes, Severe psychomotor delay, Reduced muscle tone, Corneal clouding, Enlarged gums, Enlarged liver, Enlarged spleen, Genital anomalies, Neurological symptoms, Myoclonus, White matter demyelination.,Brain (cerebral) calcification ,Receding forehead, Anteverted nostrils, Small jaw, Prominent upper lip,High arched palate, Cleft palate,Craniofacial defects.','Treatment involves cholesterol supplementation and reduction of 7-hydrocholesterol. Simvastin, a 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitor, has been proven to be beneficial in normalizing the lathosterol level in one patient. Liver transplantation was successful in normalizing liver function and cholesterol levels in a patient who had developed end stage liver disease. Moreover, it appeared to improve neurocognitive functions. Regular opthalmological evalutations and ultrasound monitoring of the liver are recommended.','55'),('OMIM:203800','ALSTROM SYNDROME','ALMS1 (7840),ABCA1 (19)','extrinsic',' vision and hearing abnormalities, and obesity in childhood, insulin resistance, diabetes mellitus, heart disease (dilated cardiomyopathy) and slowly progressive kidney (renal) dysfunction, potentially leading to renal failure.','Diabetes medication,Hearing aids,Heart medications,Thyroid hormone replacement','69'),('OMIM:261750','GLYCOGEN STORAGE DISEASE IXB','PHKB (5257),PRF1 (5551)','Intrinsic','Differential diagnoses include other glycogen storage diseases such as GSD due to liver phosphorylase deficiency (GSD type VI), GSD due to glycogen debranching enzyme deficiency (GSD type III), and GSD due to glucose-6-phosphatase (GSD type I) (see these terms).','Most patients do not require any specific treatment; a few patients may need to use cornstarch snacks','65'),('OMIM:225750','AICARDI-GOUTIERES SYNDROME 1','TREX1 (11277),RAB27A (5873),RHBDF2 (79651)','Intrinsic','Hepatomegaly,Abnormality of extrapyramidal motor function ,Autosomal dominant inheritance,Chronic CSF lymphocytosis,Deep white matter hypodensities','Treatment is symptomatic (management of the feeding problems, psychomotor delay and, if present, epilepsy).','71'),('OMIM:613839','MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY','DHFR (1719),SOX10 (6663),PYGL (5836)','Intrinsic','due to a homozygous DHFR mutation causesmegaloblastic anemia and cerebral folate deficiency leading to severe neurologic disease','Folate Therapy,Cobalamin Therapy,Monitoring Response to Therapy.','69'),('OMIM:231000','GAUCHER DISEASE, TYPE III','GBA (2629),IDS (3423),GPD1 (2819),RHBDF2 (79651)','Intrinsic','Ophthalmoparesis,Increased bone mineral density,Osteolysis,Splenomegaly,Aseptic necrosis.','Enzyme replacement therapy (ERT),Substrate reduction therapy (SRT),Symptom Management and Ongoing Care,Psychological Care.','55'),('OMIM:610377','MEVALONIC ACIDURIA','MVK (4598),SLC22A5 (6584),PCCA (5095','Intrinsic','Failure to thrive,Reduced muscle tone','\nThe disorder normally delays development and results in various dysmorphic features and mental retardation amidst other manifestations. The medical patient may also fail to thrive','72'),('OMIM:612852','OSTEOMYELITIS, STERILE MULTIFOCAL, WITH PERIOSTITIS AND PUSTULOSIS','IL1RN (3557),NCF1 (653361),MRPL3 (11222)','Intrinsic','large fontanelles,microcephaly,dolichocephaly,muscular hypotonia.','Making a diagnosis for a genetic or rare disease can often be challenging. Healthcare professionals typically look at a person’s medical history, symptoms, physical exam, and laboratory test results in order to make a diagnosis','68'),('OMIM:261515','D-BIFUNCTIONAL PROTEIN DEFICIENCY','HSD17B4 (3295),TMEM70 (54968)','Intrinsic',' hypotonia (low muscle tone) and seizures within the first month of life, vision and hearing problems, distinct facial features, and developmental delay.','D-BP can be distinguished from Zellweger Syndrome by normal plasmalogen synthesis. Recent studies in D-BP knockout mice show compensatory upregulation of other peroxisomal enzymes in absence of D-BP such as palmitoyl-CoA oxidase, peroxisomal thiolase, and branched chain acyl-CoA oxidase','53'),('OMIM:229600','FRUCTOSE INTOLERANCE, HEREDITARY','ALDOB (229),SGSH (6448),CFTR (1080)','Intrinsic','Onset of symptoms after starting an infant on food or formula,Poor feeding as a baby,Irritability,Avoidance of fruits and fructose/sucrose-containing foods.','Complete elimination of fructose and sucrose from the diet is an effective treatment for most patients. Treatment of individual complications follows mainstream medical guidelines. For example, some patients can take medication to lower the level of uric acid in their blood and thereby decrease their risk for gout. ','56'),('OMIM:605479','CHOLESTASIS, BENIGN RECURRENT INTRAHEPATIC, 2','ABCB11 (8647),PIGM (93183),ALMS1 (7840)','extrinsic','drug-induced cholestatic disease as well as intrahepatic cholestasis of pregnancy, primary biliary cirrhosis and primary sclerosing cholangitis (see these terms). BRIC can be differentiated from PFIC on the basis of the disease course and liver histology','rifampicin and cholestyramine can be used to reduce pruritus and to induce remission of a cholestatic episode in some patients. Plasmapheresis/MARS (Molecular Adsorbents Recirculation System) has also been shown to be of benefit in some cases. For individuals that are unresponsive to medical therapy, endoscopic nasobiliary drainage is generally effective. Partial external biliary diversion is also used to improve quality of life and prevent disease progression. Liver transplantation may eventually be indicated for patients with frequent and severe episodes.','79'),('OMIM:251880','MITOCHONDRIAL DNA DEPLETION SYNDROME 3 (HEPATOCEREBRAL TYPE)','DGUOK (1716),AGPAT2 (10555),PHKG2 (5261),HMOX1 (3162),GPD1 (2819),FAM111A (63901)','Intrinsic','including hypotonia, hypoglycemia, persistent vomiting, and failure to thrive within the first year of life. Mutations in three genes have been linked to hepatopathic','myopathic, hepatopathic, and/or encephalomyopathic.','61'),('OMIM:614602','TRICHOHEPATOENTERIC SYNDROME 2','SKIV2L (6499),SLC22A5 (6584),MIF (4282),HGSNAT (138050),HMOX1 (3162),MVK (4598)','extrinsic','Insomnia,Depressed mood,Anxious mood,Fatigue,Pain','No specific treatment or cure exists. Affected children usually need total parenteral nutrition through a central venous catheter. Further worsening of liver damage should however be avoided if possible. Diarrhea will likely continue even though food stops passing through the gastrointestinal system. They can subsequently be managed with tube feeding, and some may be weaned from nutritional support during adolescence','54'),('OMIM:614470','RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER','NRAS (4893),FAH (2184),NPHP3 (27031),C15ORF41 (84529)','Intrinsic','The autoimmune phenotype can present in childhood or adulthood and primarily includes autoimmune hemolytic anemia, ITP, and neutropenia. Some patients have a history of recurrentrespiratory tract infections. It is unclear if increased risk for malignancy is part of RALD.','it is a rare geneticdisorder characterized by monocytosis, autoimmune cytopenias,lymphoproliferation, hepatosplenomegaly, and hypergammaglobulinemia.','78'),('OMIM:203700','MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE)','POLG (5428),IDS (3423),SLC25A19 (60386)','Intrinsic','intractable epilepsy,areflexiaof onset. The most common cause of death is pulmonary infection. Only a few patients have survived to late childhood and adolescence.','No specific treatment or cure exists. Affected children usually need total parenteral nutrition through a central venous catheter','62'),('OMIM:615381','MANDIBULAR HYPOPLASIA, DEAFNESS, PROGEROID FEATURES, AND LIPODYSTROPHYSYNDROME','POLD1 (5424),NCF1 (653361),PEPD (5184),MARS (4141)','extrinsic','mandibular hypoplasia (a small lower jaw),','As fat cannot be stored under the skin it is important to have a healthy diet without excess fat.','55'),('OMIM:232200','GLYCOGEN STORAGE DISEASE IA','G6PC (2538),LYST (1130),IDUA (3425),PEPD (5184),NPC1 (4864)','extrinsic','ast-induced hypoglycemia (tremors, seizures, cyanosis, and apnea). Patients present disturbed glucose homeostasis usually characterized by poor tolerance to fasting, significant hepatomegaly (sometimes eight to ten cm below the right costal margin), growth retardation (short stature and delayed puberty), generally improved by an appropriate diet, osteopenia and, in some cases, osteoporosis, round doll-like facial appearance with full cheeks, mild hypotonia, nephromegaly, and platelet dysfunction that may lead to frequent epistaxis. Diarrhea may be encountered. Late complications are hepatic (adenomas with rare but possible transformation into hepatocellular carcinoma) and renal (glomerular hyperfiltration leading to proteinuria and sometimes to renal failure), but also include anemia, sometimes severe, and a risk of hypoglycemic brain damage. Pulmonary hypertension has been reported in few cases.','Pay scrupulous attention to the dental and oral health of patients with glycogen-storage disease type Ib to reduce incidence of infection.','77'),('OMIM:212065','CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IA','PMM2 (5373),KCNQ1OT1 (10984),NPC1 (4864)','extrinsic','MGAT2-CDG is a form of congenital disorders of N-linked glycosylation characterized by facial dysmorphism (large, posteriorly rotated ears with prominent antihelices, convex nasal ridge, open mouth, large and crowded teeth), stereotypic hand movements, seizures, and varying degrees of developmental delay. A bleeding tendency is also observed and this results from diminished platelet aggregation. The disease is caused by loss-of-function mutations in the gene MGAT2 ','It can be treated as orally with mannose  and CDG lli with fucose,and Monitoring of Mannose uptake by Blood assay in recommended.  ','63'),('OMIM:229700','FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY','FBP1 (2203),TMEM70 (54968),CECR1 (51816),HPLH1 (27259)','Intrinsic','Hepatomegaly, Hyperventilation, Hypoglycemia, Irritability.','FBP deficiency management aims at avoiding hypoglycemia and lactic acidosis through frequent feeding, enriched with glucose or maltodextrin, especially in illness associated with fever. Prevention and treatment of metabolic decompensation (with glucose orally or intravenously) is essential. Fasting periods longer than 8 hours should be avoided and infectious episodes should be carefully monitored. Fructose or sucrose should be avoided during acute episodes.','56'),('OMIM:609060','COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 1','GFM1 (85476),SLC7A7 (9056),COG6 (57511)','intrinsic','A number sign (#) is used with this entry because combined oxidative phosphorylation deficiency-10 (COXPD10) is caused by homozygous or compound heterozygous mutation in the MTO1 gene (614667) on chromosome ','Optic neuropathy and retinopathy, poor feeding necessitating a gastrostomy tube, and peripheral neuropathy with axonal degeneration. Subsequent brain imaging showed rapid progression of the cerebellar atrophy, as well as delayed myelination,  Treatment with coenzyme Q10 resulted in some clinical improvement.','76'),('OMIM:259700','OSTEOPETROSIS, AUTOSOMAL RECESSIVE 1','TCIRG1 (10312),RAB27A (5873)','extrinsic','low blood cell production, and loss of cranial nerve function causing blindness, deafness, and/or facial nerve paralysis. Affected individuals may experience frequent infections of teeth and the bone in the jaw. ','Rituximab , Thiotepa, MUROMONAB-CD3, Melphalan, Cyclophosphamide.','62'),('OMIM:260400','SHWACHMAN-DIAMOND SYNDROME','SBDS (51119),PCCA (5095),GBA (2629),DIS3L2 (129563)','Intrinsic','Chronic, often greasy and foul-smelling diarrhea.','bone marrow failure is hematopoietic cell transplantation','57'),('OMIM:615381','MANDIBULAR HYPOPLASIA, DEAFNESS, PROGEROID FEATURES, AND LIPODYSTROPHYSYNDROME','POLD1 (5424),NCF1 (653361),PEPD (5184),MARS (4141)','extrinsic','mandibular hypoplasia (a small lower jaw),','As fat cannot be stored under the skin it is important to have a healthy diet without excess fat.','55'),('OMIM:232200','GLYCOGEN STORAGE DISEASE IA','G6PC (2538),LYST (1130),IDUA (3425),PEPD (5184),NPC1 (4864)','extrinsic','ast-induced hypoglycemia (tremors, seizures, cyanosis, and apnea). Patients present disturbed glucose homeostasis usually characterized by poor tolerance to fasting, significant hepatomegaly (sometimes eight to ten cm below the right costal margin), growth retardation (short stature and delayed puberty), generally improved by an appropriate diet, osteopenia and, in some cases, osteoporosis, round doll-like facial appearance with full cheeks, mild hypotonia, nephromegaly, and platelet dysfunction that may lead to frequent epistaxis. Diarrhea may be encountered. Late complications are hepatic (adenomas with rare but possible transformation into hepatocellular carcinoma) and renal (glomerular hyperfiltration leading to proteinuria and sometimes to renal failure), but also include anemia, sometimes severe, and a risk of hypoglycemic brain damage. Pulmonary hypertension has been reported in few cases.','Pay scrupulous attention to the dental and oral health of patients with glycogen-storage disease type Ib to reduce incidence of infection.','77'),('OMIM:212065','CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IA','PMM2 (5373),KCNQ1OT1 (10984),NPC1 (4864)','extrinsic','MGAT2-CDG is a form of congenital disorders of N-linked glycosylation characterized by facial dysmorphism (large, posteriorly rotated ears with prominent antihelices, convex nasal ridge, open mouth, large and crowded teeth), stereotypic hand movements, seizures, and varying degrees of developmental delay. A bleeding tendency is also observed and this results from diminished platelet aggregation. The disease is caused by loss-of-function mutations in the gene MGAT2 ','It can be treated as orally with mannose  and CDG lli with fucose,and Monitoring of Mannose uptake by Blood assay in recommended.  ','63'),('OMIM:229700','FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY','FBP1 (2203),TMEM70 (54968),CECR1 (51816),HPLH1 (27259)','Intrinsic','Hepatomegaly, Hyperventilation, Hypoglycemia, Irritability.','FBP deficiency management aims at avoiding hypoglycemia and lactic acidosis through frequent feeding, enriched with glucose or maltodextrin, especially in illness associated with fever. Prevention and treatment of metabolic decompensation (with glucose orally or intravenously) is essential. Fasting periods longer than 8 hours should be avoided and infectious episodes should be carefully monitored. Fructose or sucrose should be avoided during acute episodes.','56'),('OMIM:609060','COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 1','GFM1 (85476),SLC7A7 (9056),COG6 (57511)','intrinsic','A number sign (#) is used with this entry because combined oxidative phosphorylation deficiency-10 (COXPD10) is caused by homozygous or compound heterozygous mutation in the MTO1 gene (614667) on chromosome ','Optic neuropathy and retinopathy, poor feeding necessitating a gastrostomy tube, and peripheral neuropathy with axonal degeneration. Subsequent brain imaging showed rapid progression of the cerebellar atrophy, as well as delayed myelination,  Treatment with coenzyme Q10 resulted in some clinical improvement.','76'),('OMIM:259700','OSTEOPETROSIS, AUTOSOMAL RECESSIVE 1','TCIRG1 (10312),RAB27A (5873)','extrinsic','low blood cell production, and loss of cranial nerve function causing blindness, deafness, and/or facial nerve paralysis. Affected individuals may experience frequent infections of teeth and the bone in the jaw. ','Rituximab , Thiotepa, MUROMONAB-CD3, Melphalan, Cyclophosphamide.','62'),('OMIM:260400','SHWACHMAN-DIAMOND SYNDROME','SBDS (51119),PCCA (5095),GBA (2629),DIS3L2 (129563)','Intrinsic','Chronic, often greasy and foul-smelling diarrhea.','bone marrow failure is hematopoietic cell transplantation','57'),('OMIM:615381','MANDIBULAR HYPOPLASIA, DEAFNESS, PROGEROID FEATURES, AND LIPODYSTROPHYSYNDROME','POLD1 (5424),NCF1 (653361),PEPD (5184),MARS (4141)','extrinsic','mandibular hypoplasia (a small lower jaw),','As fat cannot be stored under the skin it is important to have a healthy diet without excess fat.','55'),('OMIM:232200','GLYCOGEN STORAGE DISEASE IA','G6PC (2538),LYST (1130),IDUA (3425),PEPD (5184),NPC1 (4864)','extrinsic','ast-induced hypoglycemia (tremors, seizures, cyanosis, and apnea). Patients present disturbed glucose homeostasis usually characterized by poor tolerance to fasting, significant hepatomegaly (sometimes eight to ten cm below the right costal margin), growth retardation (short stature and delayed puberty), generally improved by an appropriate diet, osteopenia and, in some cases, osteoporosis, round doll-like facial appearance with full cheeks, mild hypotonia, nephromegaly, and platelet dysfunction that may lead to frequent epistaxis. Diarrhea may be encountered. Late complications are hepatic (adenomas with rare but possible transformation into hepatocellular carcinoma) and renal (glomerular hyperfiltration leading to proteinuria and sometimes to renal failure), but also include anemia, sometimes severe, and a risk of hypoglycemic brain damage. Pulmonary hypertension has been reported in few cases.','Pay scrupulous attention to the dental and oral health of patients with glycogen-storage disease type Ib to reduce incidence of infection.','77'),('OMIM:212065','CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IA','PMM2 (5373),KCNQ1OT1 (10984),NPC1 (4864)','extrinsic','MGAT2-CDG is a form of congenital disorders of N-linked glycosylation characterized by facial dysmorphism (large, posteriorly rotated ears with prominent antihelices, convex nasal ridge, open mouth, large and crowded teeth), stereotypic hand movements, seizures, and varying degrees of developmental delay. A bleeding tendency is also observed and this results from diminished platelet aggregation. The disease is caused by loss-of-function mutations in the gene MGAT2 ','It can be treated as orally with mannose  and CDG lli with fucose,and Monitoring of Mannose uptake by Blood assay in recommended.  ','63'),('OMIM:229700','FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY','FBP1 (2203),TMEM70 (54968),CECR1 (51816),HPLH1 (27259)','Intrinsic','Hepatomegaly, Hyperventilation, Hypoglycemia, Irritability.','FBP deficiency management aims at avoiding hypoglycemia and lactic acidosis through frequent feeding, enriched with glucose or maltodextrin, especially in illness associated with fever. Prevention and treatment of metabolic decompensation (with glucose orally or intravenously) is essential. Fasting periods longer than 8 hours should be avoided and infectious episodes should be carefully monitored. Fructose or sucrose should be avoided during acute episodes.','56'),('OMIM:609060','COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 1','GFM1 (85476),SLC7A7 (9056),COG6 (57511)','intrinsic','A number sign (#) is used with this entry because combined oxidative phosphorylation deficiency-10 (COXPD10) is caused by homozygous or compound heterozygous mutation in the MTO1 gene (614667) on chromosome ','Optic neuropathy and retinopathy, poor feeding necessitating a gastrostomy tube, and peripheral neuropathy with axonal degeneration. Subsequent brain imaging showed rapid progression of the cerebellar atrophy, as well as delayed myelination,  Treatment with coenzyme Q10 resulted in some clinical improvement.','76'),('OMIM:259700','OSTEOPETROSIS, AUTOSOMAL RECESSIVE 1','TCIRG1 (10312),RAB27A (5873)','extrinsic','low blood cell production, and loss of cranial nerve function causing blindness, deafness, and/or facial nerve paralysis. Affected individuals may experience frequent infections of teeth and the bone in the jaw. ','Rituximab , Thiotepa, MUROMONAB-CD3, Melphalan, Cyclophosphamide.','62'),('OMIM:260400','SHWACHMAN-DIAMOND SYNDROME','SBDS (51119),PCCA (5095),GBA (2629),DIS3L2 (129563)','Intrinsic','Chronic, often greasy and foul-smelling diarrhea.','bone marrow failure is hematopoietic cell transplantation','57'),('OMIM:614727','CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIK','TMEM165 (55858),PIGM (93183),ABCB11 (8647),ERCC8 (1161)','Intrinsic','Common neurological symptoms include diminished muscle tone (hypotonia), seizures, deficits in attaining developmental milestones (developmental disability), varying degrees of cognitive impairment, and underdevelopment of the cerebellum (cerebellar hypoplasia), which can cause problems with balance and coordination. Additional common symptoms include abnormal fat distribution, defects in blood clotting that can cause abnormal bleeding or clotting (coagulation defects), gastrointestinal symptoms such as vomiting and diarrhea, eye abnormalities such as crossed eyes (strabismus) and retinal degeneration, and abnormal or distinctive facial features (facial dysmorphism).liver abnormalities, heart abnormalities such as disease of the heart muscle (cardiomyopathy), stroke-like episodes, and excessive loss of proteins from the gastrointestinal tract (protein-losing enteropathy), which can cause swelling due to fluid retention (edema).','Treatment may require the coordinated efforts of a team of specialists. Pediatricians, neurologists, surgeons, cardiologists, speech pathologists, ophthalmologists, gastroenterologists, and other healthcare professionals may need to systematically and comprehensively plan an affect child’s treatment.','72'),('OMIM:228000','FARBER LIPOGRANULOMATOSIS','ASAH1 (427),ABCD3 (5825),CECR1 (51816),PEX1 (5189),IDUA (3425)','extrinsic','The liver, heart and kidneys may also be affected. Other symptoms may includevomiting, arthritis, swollen lymph nodes, swollen joints, joint contractures (chronic shortening of muscles or tendons around joints), hoarseness and xanthomas which thicken around joints as the disease progresses. Patients with breathing difficulty may require a breathing tube.','There is no specific treatment for Farber disease. Corticosteroids may be prescribed to relieve pain. Bone marrow transplants may improve granulomas (small masses of inflamed tissue) on patients with little or no lung or nervous system complications. Older patients may have granulomas surgically reduced or removed.','53'),('OMIM:615234','ANEMIA, HYPOCHROMIC MICROCYTIC, WITH IRON OVERLOAD 2','STEAP3 (55240),PIGM (93183),PEPD (5184),DHFR (1719)','Intrinsic','Fatigue and diminished capability to perform hard labor,Dysphagia with solid foods (from esophageal webbing),Worsened symptoms of comorbid cardiac or pulmonary disease,Cold intolerance,Craving ice (in some cases, cold celery or other cold vegetables) to suck or chew.','A restrictive red blood cell transfusion strategy is recommended for hospitalized patients with coronary heart disease, with the trigger hemoglobin threshold lowered to 7-8 g/dL,Erythropoiesis-stimulating agents are not recommended for patients with mild to moderate anemia and either congestive heart failure or coronary heart disease.','63'),('OMIM:607016','SCHEIE SYNDROME','IDUA (3425),TMEM70 (54968),AGPAT2 (10555),SLC30A10 (55532),PTRF (284119)','extrinsic','Broad mouth with full lips,Claw hands and deformed feet,Cloudy cornea and progressive loss of vision, resulting in blindness,Coarsened facial features,Increased body hair (hirsutism),','Enzyme replacement therapy for patients with a defect in the enzyme a-L-iduronidase (lauonidase) is now possible. This includes individuals with Scheie syndrome, but also Hurler and Hurler-Scheie syndromes,Early recognition and treatment of spinal cord compression can prevent permanent nerve damage. Treatment is also given for heart problems caused by leaky valves.','73'),('OMIM:615924','ENCEPHALOPATHY, PROGRESSIVE, WITH OR WITHOUT LIPODYSTROPHY','BSCL2 (26580)MARS (4141).,NPC1 (4864),SLC30A10 (55532)','Intrinsic','While all kinds of acquired lipodystrophy cause a loss of body fat, exactly what that means for each person is different.','No specific treatment for progressive lipodystrophy is effective. Symptomatic therapy should be prescribed as necessary for the treatment of renal complications and associated autoimmune disorders in progressive lipodystrophy patients,Renal and immunologic disturbances may warrant inpatient care at times.','54'),('OMIM:231050','GELEOPHYSIC DYSPLASIA 1','ADAMTSL2 (9719),ALDH7A1 (501),PCCA (5095','Intrinsic','Geleophysic dysplasia, a progressive condition resembling a lysosomal storage disorder, is characterized by short stature, short hands and feet, progressive joint limitation and contractures, distinctive facial features, progressive cardiac valvular disease, and thickened skin','Treatment of manifestations: Regular physiotherapy to prevent joint limitation; cardiac valve replacement as needed; tracheostomy as required','64'),('OMIM:614866','PEROXISOME BIOGENESIS DISORDER 5A (ZELLWEGER)','PEX2 (5828),SLC39A4 (55630),CFTR (1080),LMNA (4000),PCCA (5095','extrinsic','Geleophysic dysplasia, a progressive condition resembling a lysosomal storage disorder, is characterized by short stature, short hands and feet, progressive joint limitation and contractures, distinctive facial features, progressive cardiac valvular disease, and thickened skin','For many of the peroxisomal disorders, there is no standard course of treatment, with supportive treatment strategies focusing on alleviation of complications and symptoms. Bone marrow transplants may be effective for children with X-ALD if administered early in the course of the childhood form of the disease. Physical and psychological therapies are important for all types of peroxisomal disorders.','74'),('OMIM:613730','HEMORRHAGIC DESTRUCTION OF THE BRAIN, SUBEPENDYMAL CALCIFICATION,AND CATARACTS','JAM3 (83700),OCLN (100506658),PYGL (5836)','extrinsic','A syndrome characterized by congenital cataracts and severe brain abnormalities apparently resulting from hemorrhagic destruction of the brain parenchyma, including the cerebral white matter and basal ganglia. Patients manifest profound developmental delay, and other neurologic features included seizures, spasticity, and hyperreflexia. The clinical course is very severe resulting in death in infancy. Brain imaging shows multifocal intraparenchymal hemorrhage with associated liquefaction and massive cystic degeneration, and calcification in the subependymal region and in brain tissue.','No treatment has been reported.','55'),('OMIM:606664','GLYCINE N-METHYLTRANSFERASE DEFICIENCY','GNMT (27232),FAH (2184),HMOX1 (3162),PRF1 (5551)','extrinsic','Glycine N-methyltransferase (GNMT) deficiency in humans is an autosomal recessive defect.Autosomal recessive inheritance,Elevated hepatic transaminases,Hepatomegaly,Hypermethioninemia.','There are usually no symptoms, treatment may not be needed. It is important, however, to have a careful follow-up. A low methionine diet (300 mg/day) can correct the biochemical abnormalities. In general, methionine restriction should be done when levels are greater than 800 ?mol/L. The aim of the diet should be to maintain methionine levels around 500–600 ?mol/L','65'),('OMIM:230800','GAUCHER DISEASE, TYPE I','GBA (2629),AGPAT2 (10555)','extrinsic','The major symptoms include enlargement of the liver and spleen (hepatosplenomegaly),Delayed skeletal maturation, Diaphragmatic paralysis,Hemiplegia/hemiparesis,a low number of red blood cells (anemia), easy bruising caused by a decrease in blood platelets (thrombocytopenia), chronic fatigue, lung disease, and bone disease such as bone pain, fractures, and arthritis. People with GD1 may be at in increased risk for Parkinson disease, peripheral neuropathy, certain cancers, and osteoporosis','The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition.Miglustat (Brand name: Zavesca),Velaglucerase-alfa (Brand name: VPRIV),Taliglucerase alfa (Brand name: Elelyso For Injection),Imiglucerase (Brand name: Cerezyme®),Eliglustat (Brand name: Cerdelga)','75'),('OMIM:603903','SICKLE CELL ANEMIA','HBB (3043),PIGM (93183),LMNA (4000)','intrinsic','excessive fatigue or irritability (from anemia),fussiness (in babies),bedwetting (from associated kidney problems) jaundice (yellowing of the eyes and skin) swelling and pain in hands and feet frequent infections ,chest pain.Anemia,Vision problems,Delayed growth,Frequent infections,Painful swelling of hands and feet,Episodes of pain.','Medications used to treat sickle cell anemia include:Antibiotics,Pain-relieving medications,Hydroxyurea (Droxia, Hydrea).','56'),('OMIM:607115','CINCA SYNDROME','NLRP3 (114548),TMEM70 (54968),SERPINA1 (5265)','Intrinsic','The symptoms of CINCA syndrome start at birth, or are observed within the first weeks of life. The first symptoms are usually a skin rash and fever. Individuals with CINCA syndrome may also have chronic meningitis (inflammation of the membranes surrounding the brain), which may lead to headaches, seizures, and vomiting. Hearing loss, vision loss, and intellectual disability, may also occur.','The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition:Rilonacept (Brand name: Arcalyst®) ,Anakinra (Brand name: Kineret).','66'),('OMIM:230350','GALACTOSE EPIMERASE DEFICIENCY','GALE (2582),LYST (1130),GNPTAB (79158),KIT (3815),ALMS1 (7840)','Intrinsic','Infantile jaundice\nInfantile hypotonia\nDysmorphic features\nSensorineural hearing loss\nImpaired growth\nCognitive deficiencies','Dietary restriction is the only current treatment available for GALE deficiency. As glycoprotein and glycolipid metabolism generate endogenous galactose, however, Type III galactosemia may not be resolved solely through dietary restriction.[5]','76'),('OMIM:256040','AUTOINFLAMMATION, LIPODYSTROPHY, AND DERMATOSIS SYNDROME','PSMB8 (5696),NPHP3 (27031),PHKG2 (5261),C15ORF41 (84529)','Intrinsic',' macroglossia\n• thick lower lip vermilion\n• abnormality of the face\n• respiratory insufficiency\n• hepatomegaly\n• lymphadenopathy','Bromfenac,Rosiglitazone,Drospirenone,diuretics','57'),('OMIM:608540','CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IK','ALG1 (56052),SLC7A7 (9056),ALG13 (79868),NPC1 (4864),SMPD1 (6609),IFT172 (26160)','extrinsic',' nephropathy\n• hypogonadism\n• microcephaly\n• global developmental delay\n• hepatic failure\n• hypertrophic cardiomyopathy','No treatment is available for most of these disorders. Mannose supplementation relieves the symptoms in PMI-CDG (CDG-Ib) for the most part,[31] even though the hepatic fibrosis may persist.[32] Fucose supplementation has had a partial effect on some SLC35C1-CDG (CDG-IIc or LAD-II) patients','67'),('OMIM:251100','METHYLMALONIC ACIDURIA, CBLA TYPE','MMAA (166785),PEPD (5184),FGA (2243), LYZ (4069),IFT172 (26160)','extrinsic','hepatomegaly, lethargy, vomiting, respiratory distress, chyluria, pneumatouria, traumatic hematuria','Metronidazole,Hydroxocobalamin ,Biotin,Vitamin B12,Methylcobalamin','77'),('OMIM:609628','MAJEED SYNDROME','LPIN2 (9663),ABCD3 (5825),SLC22A5 (6584)','extrinsic','proteinuria\n• edema\n• acne\n• microscopic hematuria\n• metaphyseal irregularity\n','Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors','58'),('OMIM:613327','LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 4','PTRF (284119),GNPTAB (79158),BOLA3 (388962),FGA (2243), LYZ (4069)','extrinsic','hirsutism,hyperinsulinemia,insulin resistance,osteopenia, osteoporosis ','Metformin is the main drug used for treatment, as it is normally used for patients with hyperglycemia.[12] Metformin reduces appetite and improves symptoms of hepatic steatosis and polycystic ovary syndrome.[2] Leptin can also be used to reverse insulin resistance and hepatic steatosis, to cause reduced food intake, and decrease blood glucose levels.[13]','80'),('OMIM:257200','NIEMANN-PICK DISEASE, TYPE A','SMPD1 (6609),SOX10 (6663),ITK (3702),HPLH1 (27259)','intrinsic','cherry red spot of the macula,osteoporosis,xanthomatosis,intellectual disability ','Prednisolone,1-Deoxynojirimycin,Ezetimibe , insulin,Methylprednisolone','78'),('OMIM:610717','NEUTRAL LIPID STORAGE DISEASE WITH MYOPATHY','PNPLA2 (57104),SGSH (6448),PYGL (5836),DIS3L2 (129563)','intrinsic','sensorineural hearing impairment,neck muscle weakness, diabetes mellitus,areflexia','Clofibric acid, Bezafibrate','59'),('OMIM:267000','PERLMAN SYNDROME','DIS3L2 (129563),SERPINA1 (5265),ABCB11 (8647),SLC37A4 (2542)','intrinsic','tall stature,open mouth, macrocephaly,abnormality of the philtrum,round face',' Miconazole,hydroxyitraconazole,Itraconazole,Doxil,Mycophenolate mofetil','69'),('OMIM:602390','HEMOCHROMATOSIS, TYPE 2A','HFE2 (148738),PEX14 (5195),LMNA (4000),ERCC8 (1161),PTRF (284119)','extrinsic',' hepatomegaly,increased serum iron, hypogonadotrophic hypogonadism,increased serum ferritin','Treatment is based on the symptoms and severity of the disease. Iron chelators may be used to bind excess iron in tissues and allow for excretion of the excess metal.[31] Individuals with hemochromatosis type 4B may be treated with therapeutic phlebotomy. However, individuals with hemochromatosis type 4A may not require treatment. Additionally, therapeutic phlebotomy may not be tolerated in individuals with type 4A because anemia may develop despite the elevated serum ferritin levels typically found in these individuals','79'),('OMIM:613985','BETA-THALASSEMIA','HBB (3043), LCRB (387281),SC5D (6309),SLC25A20 (788)','extrinsic','fatigue, weakness, or shortness of breath,a pale appearance or a yellow color to the skin (jaundice),deformities of the facial bones,a swollen abdomen.','Surgery to remove the gallbladder,Regular blood transfusions,Medicines to reduce extra iron from your body (called iron chelation therapy),Genetic tests,Bone marrow transplant','68'),('OMIM:212138','CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY','SLC25A20 (788),NLRP3 (114548),NLRP3 (114548),SLC25A20 (788)','extrinsic','life-threatening, inherited disorder of fatty acid oxidation which usually presents in the neonatal period with severe hypoketotic hypoglycemia, hyperammonemia, cardiomyopathy and/or arrhythmia, hepatic dysfunction, skeletal muscle weakness, and encephalopathy.','Strict avoidance of fasting along with the institution of a low long-chain fat diet and medium chain triglyceride (MCT) supplementation is necessary. However, the MCT formula should be as low as possible in C10 and C12 fatty acids as high dietary intake of these can lead to decompensation. Carnitine supplementation is also recommended. During an acute episode, intravenous glucose is administered in order to inhibit lipolysis','80'),('OMIM:269921','SIALURIA','GNE (10020),SLC22A5 (6584),SLC25A19 (60386)','intrinsic','mostly in infancy, including transient failure to thrive, slightly prolonged neonatal jaundice, equivocal or mild hepatomegaly, microcytic anemia, frequent upper respiratory infections, gastroenteritis, dehydration and flat and coarse facies.','Urological Surgery, Kidney Doctors,Nephrology,Pediatric Nephrology ','70'),('OMIM:269921','SIALURIA','GNE (10020),SLC22A5 (6584),SLC25A19 (60386)','intrinsic','mostly in infancy, including transient failure to thrive, slightly prolonged neonatal jaundice, equivocal or mild hepatomegaly, microcytic anemia, frequent upper respiratory infections, gastroenteritis, dehydration and flat and coarse facies.','Urological Surgery, Kidney Doctors,Nephrology,Pediatric Nephrology ','70'),('OMIM:252940','MUCOPOLYSACCHARIDOSIS, TYPE IIID','GNS (2799),SLC7A7 (9056),IL1RN (3557),CASR (846)','Intrinsic','Coarse facial features,Asymmetric septal hypertrophy ,Coarse facial features,Depressed nasal bridge,Diarrhea',' Medical treatment is supportive and is directed toward improving the patients quality of life. Because of the varied symptoms seen in mucopolysaccharidosis (MPS) type III, a multidisciplinary approach is indicated (see Consultations). Currently, specific therapies such as bone marrow transplantation (BMT) and enzyme replacement therapy (ERT) are not options for patients with Sanfilippo syndrome','50'),('OMIM:602361','GRACILE BONE DYSPLASIA','FAM111A (63901),SGSH (6448),NPHP3 (27031),GALE (2582),CASR (846)','extrinsic','Differential diagnosis includes the hypo/akinesia sequence, Hallermann-Streiff-FranÁois syndrome, Kenny-Caffey syndrome and other slender bone dysplasias, and some cases of osteogenesis imperfecta with slender bones ','There is no treatment for osteocraniostenosis.','62'),('OMIM:249100','FAMILIAL MEDITERRANEAN FEVER','MEFV (4210),PEX14 (5195),GNPTAB (79158),CECR1 (51816),PRF1 (5551)','extrinsic','Differential diagnoses include hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), TNF receptor-associated periodic syndrome and periodic fever (TRAPS), Marshalls syndrome with periodic fever, transthyretin-related amyloidosis and Behçets disease','Colchicine (oral or by I.V.) is the drug used to treat FMF. It reduces or eliminates FMF attacks and prevents the occurrence of amyloidosis type AA (see this term). Dosage ranges up to 0.03mg/kg/body weight/daily, or to a maximum of 3mg/daily, and must be taken regularly on a life-long basis. During an attack a nonsteroidal anti-inflammatory drug can be administered.Patients intolerant to colchicine have no alternative of matching efficacy, but Anakinra, interferon-alpha and selective serotonin reuptake inhibitors (SSRIs) have shown encouraging results in some patients.','73'),('OMIM:105200','AMYLOIDOSIS, FAMILIAL VISCERAL','FGA (2243), LYZ (4069), APOA1 (335),KIT (3815),GALE (2582),SMPD1 (6609)','intrinsic','Amyloid deposition in the kidneys can cause nephrotic syndrome, which results from a reduction in the kidneys ability to filter and hold on to proteins. The nephrotic syndrome occurs with or without elevations in creatinine and blood urea concentration,[6] two biochemical markers of kidney injury. In AA amyloidosis the kidneys are involved in 91–96% of people,[7] symptoms ranging from protein in the urine to nephrotic syndrome and rarely renal insufficiency.','Treatment depends on the type of amyloidosis that is present. Treatment with high dose melphalan, a chemotherapy agent, followed by stem cell transplantation has showed promise in early studies and is recommended for stage I and II AL amyloidosis.[10] However, only 20–25% of people are eligible for stem cell transplant. Chemotherapy and steroids, with melphalan plus dexamethasone, is mainstay treatment in AL people not eligible for transplant','51'),('OMIM:615630','SHORT-RIB THORACIC DYSPLASIA 10 WITH OR WITHOUT POLYDACTYLY','IFT172 (26160),IDUA (3425),SERPINA1 (5265),CFTR (1080)','intrinsic','Short thorax,Abnormality of the ribs,Micromelia,Skeletal dysplasia','The Vertical Expandable Prosthetic Titanium Rib (VEPTR) was approved by the FDA in 2004 as a treatment for thoracic insufficiency syndrome (TIS) in pediatric patients. TIS is a congenital condition where severe deformities of the chest, spine, and ribs prevent normal breathing and lung development. The VEPTR is an implanted, expandable device that helps straighten the spine and separate ribs so that the lungs can grow and fill with enough air to breathe.','74'),('OMIM:220110','MITOCHONDRIAL COMPLEX IV DEFICIENCY','FASTKD2 (22868), TACO1 (51204), COX20 (116228), SCO1 (6341), COX10 (1352), COX14 (84987), COX6B1 (1340), PET100 (100131801), APOPT1 (84334)','extrinsic',' liver dysfunction, hypotonia, muscle weakness, exercise intolerance, developmental delay, delayed motor development and mental retardation','The goals of treatment are to improve symptoms and slow progression of the disease; the effectiveness of treatment varies with each individual,Prognosis varies depending on the form of COX deficiency present.[4] Individuals with benign infantile mitochondrial myopathy may experience spontaneous recovery (although early diagnosis and intensive treatment is still needed until this point), while there may be rapid demise in individuals with Leigh syndrome','63'),('OMIM:278000','LYSOSOMAL ACID LIPASE DEFICIENCY','LIPA (3988),BOLA3 (388962)','intrinsic',' diarrhoea, stomach pain, vomiting, or poor growth',' liver transplantation was necessary in most patients.[3]','52'),('OMIM:207900','ARGININOSUCCINIC ACIDURIA','ASL (435),COG6 (57511),ITK (3702),GBA (2629)','intrinsic','Differential diagnoses include other urea cycle disorders such as carbamoyl-phosphate synthetase 1 deficiency, ornithine transcarbamylase deficiency, citrullinemia type I and arginase deficiency ','During an acute hyperammonemic episode, oral proteins must be avoided and intravenous (I.V.) lipids, glucose and insulin (if needed) should be given to promote anabolism. I.V. nitrogen scavenging therapy (with sodium benzoate and/or sodium phenylacetate) should normalize ammonia levels, but if unsuccessful, hemodialysis is recommended. Long-term management involves dietary protein restriction as well as arginine supplementation. In those with frequent episodes of metabolic decompensation or with hyperammonemia even when following a protein-restricted diet, daily oral nitrogen scavenging therapy may be successful. Orthotopic liver transplantation offers long-term relief of hyperammonemia but does not seem to sufficiently correct neurological complications. Arterial hypertension can be treated by restoring nitric oxide deficiency.','75'),('OMIM:272800','TAY-SACHS DISEASE','HEXA (3073)','intrinsic','Characteristic features include muscle weakness, loss of muscle coordination (ataxia) and other problems with movement, speech problems, and mental illness.',' A treatment aimed at inhibiting gangliosides synthesis (Miglustat) is currently being investigated for the slowly progressive forms.','64'),('OMIM:237500','DUBIN-JOHNSON SYNDROME','ABCC2 (1244),ATPAF2 (91647)','intrinsic','conjugated hyperbilirubinemia, Rotor syndrome ','There is no curative treatment for DJS, even though short-term administration of phenobarbital has been reported to reduce serum bilirubin level in some cases.','53'),('OMIM:211600','CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 1','ATP8B1 (5205),IL1RN (3557),PHKA2 (5256)','intrinsic','Progressive familial intrahepatic cholestasis (PFIC) is a disorder that causes progressive liver disease, which typically leads to liver failure. In people with PFIC, liver cells are less able to secrete a digestive fluid called bile. The buildup of bile in liver cells causes liver disease in affected individuals.','Initial treatment is supportive, with the use of agents to treat cholestasis and pruritus, including the following:Ursodeoxycholic acid,Cholestyramine,Rifampin,Naloxone','76'),('OMIM:607906','CONGENITAL DISORDER OF GLYCOSYLATION, TYPE II','ALG2 (85365),PSAP (5660),LMNA (4000),DIS3L2 (129563)','intrinsic',' Infants usually develop ataxia, psychomotor delay and extraneurological manifestations including failure to thrive, enteropathy, hepatic dysfunction, coagulation abnormalities and cardiac and renal involvement. ','Pediatricians, neurologists, surgeons, cardiologists, speech pathologists, ophthalmologists, gastroenterologists, and other healthcare professionals may need to systematically and comprehensively plan an affect child’s treatment.','65'),('OMIM:614185','GELEOPHYSIC DYSPLASIA 2','FBN1 (2200),KCNQ1OT1 (10984),CECR1 (51816),ALG13 (79868),PTRF (284119),PHKA2 (5256)','extrinsic','Mild to moderate intellectual disability has been reported and, in some cases, affected infants and young children may experience delays in reaching developmental milestones. Behavioral abnormalities including difficulties with social interactions, poor communications skills, hyperactivity, stubbornness, and/or repetitive behaviors have also been described.','Regular physiotherapy to prevent joint limitation; cardiac valve replacement as needed; tracheostomy as required. Surveillance: Annual multidisciplinary examination to access height and range of motion of the joints; echocardiography for evidence of valvular stenosis and/or arterial narrowing; clinical assessment for evidence of tracheal stenosis and respiratory compromise; clinical assessment and ultrasound examination, if needed, to assess liver size.','54'),('OMIM:610768','CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IM','DOLK (22845),SLC22A5 (6584),PHKA2 (5256)','extrinsic','liver abnormalities, heart abnormalities such as disease of the heart muscle (cardiomyopathy), stroke-like episodes, and excessive loss of proteins from the gastrointestinal tract (protein-losing enteropathy), which can cause swelling due to fluid retention (edema). Fluid accumulation around the lungs or hearts (pleural or pericardial effusions) has also been reported.','No treatment is available for most of these disorders. Mannose supplementation relieves the symptoms in PMI-CDG (CDG-Ib) for the most part, even though the hepatic fibrosis may persist. Fucose supplementation has had a partial effect on some SLC35C1-CDG (CDG-IIc or LAD-II) patients.','77'),('OMIM:614859','PEROXISOME BIOGENESIS DISORDER 3A (ZELLWEGER)','PEX12 (5193),CPOX (1371),FAH (2184)','extrinsic','The most common features of Zellweger syndrome include enlarged liver, high levels of copper and iron in the blood, and vision disturbances. Other  symptoms include unusual facial features, mental retardation, seizures, and the inability to suck, and/or swallow. Jaundice and gastrointestinal bleeding may also occur. ','There is no cure for Zellweger syndrome but there are some treatments.Treatments focus on symptomatic therapy, and  may include: gastrostomy to provide adequate  calories, hearing aids, cataract removal in infancy,  glasses, vitamin supplementation, primary bile acid therapy, anti-epileptic drugs, and possibly monitoring for hyperoxaluria.” (Gene Reviews) Surveillance includes annual hearing and  ophthalmologic  evaluations, monitoring of coagulation factors, and tests of liver function.Avoidance of cows milk products is recommended to reduce exposure to phytanic acid.','66'),('OMIM:253200','MUCOPOLYSACCHARIDOSIS TYPE VI','ARSB (411),IDUA (3425).LBR (3930)','extrinsic','In addition to multiple sulfatase deficiency, the differential diagnosis should also include other forms of MPS (MPS 1, 2, 4A, 7), sialidosis and mucolipidosis','Currently there is no cure for these disorders. Medical care is directed at treating systemic conditions and improving the persons quality of life. Physical therapy and daily exercise may delay joint problems and improve the ability to move.Changes to the diet will not prevent disease progression, but limiting milk, sugar, and dairy products has helped some individuals experiencing excessive mucus.','55'),('OMIM:174050','POLYCYSTIC LIVER DISEASE','PRKCSH (5589), SEC63 (11231),NPHP3 (27031),HFE (3077),SLC25A19 (60386)','extrinsic','Differential diagnoses include multiple liver cysts, found in association with autosomal dominant polycystic kidney disease (ADPKD; see this term), but PCLD is genetically distinct from ADPKD with liver cysts. Simple liver cysts are also a differential diagnosis. Caroli disease (see this term), characterized by cysts communicating with the biliary tract, is differentiated by using imaging with contrast agents specifically excreted into the bile.','Most patients are asymptomatic and do not require treatment. For those with symptoms, management depends on the extent, distribution, and anatomy of the cysts and may include percutaneous cyst aspiration, alcohol sclerosis, cyst fenestration, partial hepatectomy, and even liver transplantation (in rare cases where the massively enlarged liver considerably alters the quality of life). Any form of estrogen therapy should be stopped immediately. Recently, lanreotide and long acting octreotide (somatostatin analogues) have been shown to be safe and effective treatments for PCLD that reduce moderate polycystic liver volume and prevent its growth.','78'),('OMIM:255120','CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY','CPT1A (1374),PEX14 (5195),ERCC8 (1161),LBR (3930)','intrinsic','The differential diagnosis for the myopathic form should include McArdle disease, Duchenne muscular dystrophy, and cytochrome c oxidase deficiency (see these terms) among others, and carnitine-acylcarnitine translocase deficiency (CACT) and very-long-chain acyl-CoA dehydrogenase deficiency (see these terms) for the infantile and neonatal forms','Treatment is based on avoidance of prolonged fasting (>12 hr) and a low-fat and high-carbohydrate diet.','67'),('OMIM:149000','KLIPPEL-TRENAUNAY-WEBER SYNDROME','KTWS (791122),ABCD3 (5825),MIF (4282),CASR (846)','extrinsic','The differential diagnosis should include venous dysplasias, lymphedema and bone tumors.','In childhood, during the growth period, treatment of the AVM should be performed and may lead to spontaneous correction of the LLD. Intraosseous AVMs should be treated by direct puncture and occlusion, or possibly by catheter embolization, but surgery should be avoided as the risk of hemorrhage is high. Soft tissue fistulas can be treated by catheter embolization or by surgery with resection of the fistulous area, alone or in combination with endovascular procedures. Orthopedic procedures should stop the bone elongation during the growth period or correct the LLD in adults. Epiphyseal staples are also effective at stopping growth. Contralateral limb elongation using the Ilizarov technique is feasible in adults.','56'),('OMIM:102700','SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY','ADA (100)','extrinsic','Differential diagnosis includes all forms of SCID.','Treatment is based on allogenic hematopoietic stem cell transplantation (HSCT), enzyme replacement therapy with pegylated adenosine deaminase enzyme or gene therapy by infusion of CD34+ marrow cells that have been transduced with an ADA-containing vector.','65'),('OMIM:214900','CHOLESTASIS-LYMPHEDEMA SYNDROME','LCS1 (84565),SERPINA1 (5265),PYGL (5836)','extrinsic','Cholestasis-lymphedema syndrome is a rare genetic disorder characterized by neonatal intrahepatic cholestasis, often lessening and becoming intermittent with age, and severe chronic lymphedema which mainly affects the lower limbs. Patients often present with fat malabsorption leading to failure to thrive, fat soluble vitamin deficiency with bleeding, rickets, and neuropathy. In 25% of cases, cirrhosis occurs during childhood or later in life.\n\n','vitamin K treatment was available','52'),('OMIM:308230','IMMUNODEFICIENCY WITH HYPER-IGM, TYPE 1','CD40LG (959),PEX14 (5195),PRF1 (5551)','intrinsic','Differential diagnoses include graft-versus-host disease, histiocytosis, Job syndrome, Netherton syndrome, and severe combined immunodeficiencies (see these terms), particularly those associated with maternal T-cell engraftment.','Initial treatment is based on immunosuppressive drugs including prednisone and cyclosporin followed by hematopoietic stem cell transplantation, in a centre recognized as treating such disorders ideally using HLA-identical family donors or, if this is not available, other appropriate donors after use of appropriate conditioning regimens.','62'),('OMIM:607626','ICHTHYOSIS, LEUKOCYTE VACUOLES, ALOPECIA, AND SCLEROSING CHOLANGITIS','CLDN1 (9076),ABCB4 (5244)','extrinsic','Abnormality of the eyelashes,Aplasia/Hypoplasia of the eyebrow,Hepatomegaly,Ichthyosis,Splenomegaly,Abnormality of dental enamel,Acanthosis nigricans,Portal hypertension,Reduced number of teeth,Abnormality of blood and blood-forming tissues','Liver transplant and hydrating the skin through skin creams, exposure to sunlight and retinoid use','72'),('OMIM:615846','AICARDI-GOUTIERES SYNDROME 7','IFIH1 (64135),PEX1 (5189),PEPD (5184),PSMB8 (5696)','intrinsic','The principle differential diagnoses are TORCH congenital infections (toxoplasma, rubella, CMV, HSV1 and HSV2).','Treatment is symptomatic (management of the feeding problems, psychomotor delay and, if present, epilepsy).','54'),('OMIM:612714','EXOCRINE PANCREATIC INSUFFICIENCY, DYSERYTHROPOIETIC ANEMIA, AND CALVARIALHYPEROSTOSIS','COX4I2 (84701),PSAP (5660),GBA (2629)','extrinsic','Dyserythropoietic anemia,Calvarial hyperostosis,Exocrine pancreatic insufficiency ,Steatorrhea ,\nFailure to thrive ,Box-shaped skull ,Localized scaly perineal rash,Small spots of increased pigmentation ,Susceptibility for tooth decay,Abnormal teeth eruption,Delayed bone age, \nOsteopenia ,Asthma ,Jaundice.\nDyserythropoietic anemia,Calvarial hyperostosis,Exocrine pancreatic insufficiency ,Steatorrhea ,\nFailure to thrive ,Box-shaped skull ,Localized scaly perineal rash,Small spots of increased pigmentation ,Susceptibility for tooth decay,Abnormal teeth eruption,Delayed bone age, \nOsteopenia ,Asthma ,Jaundice.','Pancreatic enzyme supplement. Red blood cell transfusions may be needed to alleviate severe anemia','64'),('OMIM:265800','PYCNODYSOSTOSIS','CTSK (1513)','intrinsic',' Patients present with characteristic cranial malformations: a voluminous skull with wormian bones present and persistence of the anterior fontanelle, and a small mandible. Dental abnormalities such as decayed, poorly located or abnormally shaped (pointed or conical) teeth and delayed tooth eruption may be observed. Nails are sometimes irregular and cracked.',' Differential diagnoses include osteoporosis, osteopetrosis, cleidocranial dysplasia and idiopathic acroosteolysis (see these terms). Management is symptomatic and multidisciplinary. It includes orthopedic monitoring, treatment of fractures, of which consolidation is sometimes slow, and static vertebral surveillance to detect frequent spondylolisthesis. The prognosis is favorable; the disease is not progressive.','74'),('OMIM:600649','CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, INFANTILE','CPT2 (1376),CTLA4 (1493),LMNA (4000)','intrinsic','The differential diagnosis for the myopathic form should include McArdle disease, Duchenne muscular dystrophy, and cytochrome c oxidase deficiency (see these terms) among others, and carnitine-acylcarnitine translocase deficiency (CACT) and very-long-chain acyl-CoA dehydrogenase deficiency (see these terms) for the infantile and neonatal forms','Treatment is based on avoidance of prolonged fasting (>12 hr) and a low-fat and high-carbohydrate diet.','56'),('OMIM:264470','PEROXISOMAL ACYL-COA OXIDASE DEFICIENCY','ACOX1 (51),GLB1 (2720)ABCB4 (5244).,C15ORF41 (84529)','extrinsic','Differential diagnoses include Usher syndrome (see this term) and all causes of neonatal hypotonia. The other peroxisomal disorders should also be discarded, especially neonatal adrenoleukodystrophy (see this term), which presents similar clinical manifestations.','No specific treatment is available. Multidisciplinary supportive care should be offered.','66'),('OMIM:248500','MANNOSIDOSIS, ALPHA B, LYSOSOMAL','MAN2B1 (4125),EIF2AK3 (9451),SLC37A4 (2542),C15ORF41 (84529)','intrinsic','The principle differential diagnoses are other lysosomal storage diseases, such as the various forms of mucopolysaccharidosis.','Management should be proactive, preventing complications and treating manifestations. Infections must be treated frequently. Otolaryngological treatment of fluid in the middle ear is often needed and use of hearing aids is invariably required. Early educational intervention for development of social skills is needed and physiotherapy is important to improve bodily function. Orthopedic surgery may be necessary.','76'),('OMIM:606593','LIG4 SYNDROME','LIG4 (3981),SERPINA1 (5265),SMPD1 (6609)','intrinsic','Differential diagnoses include other rare DNA damage response diseases such as Seckel syndrome, Nijmegen breakage syndrome (NBS), Cernunnos-XLF deficiency and Fanconi anemia ','Supportive treatment is with prophylactic antibiotics and anti-virals. Hematopoietic stem cell transplantation may be indicated in some patients using modified conditioning regimens without radiotherapy.','58'),('OMIM:606056','CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIB','MOGS (7841)','intrinsic','Dysmorphic features,Psychomotor retardation,Hypotonia,Seizures,Liver disease,Coagulopathy,Early death,Generalized edema,Hypoventilation,Apnea,Demyelinating polyneuropathy.','No treatment is available for most of these disorders. Mannose supplementation relieves the symptoms in PMI-CDG (CDG-Ib) for the most part, even though the hepatic fibrosis may persist. Fucose supplementation has had a partial effect on some SLC35C1-CDG (CDG-IIc or LAD-II) patients.','68'),('OMIM:240500','IMMUNODEFICIENCY, COMMON VARIABLE, 2','TNFRSF13B (23495),SLC7A7 (9056),LYST (1130),FUCA1 (2517)','extrinsic','The symptoms of CVID vary between people affected. Its main features are hypogammaglobulinemia and recurrent infections. Hypogammaglobulinemia manifests as a significant decrease in the levels of IgG antibodies, usually alongside IgA antibodies; IgM antibody levels are also decreased in about half of people. Infections are a direct result of the low antibody levels in the circulation, which do not adequately protect them against pathogens. The microorganisms that most frequently cause infections in CVID are bacteria Haemophilus influenzae, Streptococcus pneumoniae and Staphylococcus aureus. Pathogens less often isolated from people include Neisseria meningitidis, Pseudomonas aeruginosa and Giardia lamblia. Infections mostly affect the respiratory tract (nose, sinuses, bronchi, lungs) and the ears; they can also occur at other sites, such as the eyes, skin and gastrointestinal tract. These infections respond to antibiotics but can recur upon discontinuation of antibiotics. Bronchiectasis can develop when severe, recurrent pulmonary infections are left untreated.','Treatment consists of immunoglobulin replacement therapy, which replenishes Ig subtypes that the person lack. This treatment is given at frequent intervals for life, and is thought to help reduce bacterial infections and boost immune function.Before therapy begins, plasma donations are tested for known blood-borne pathogens, then pooled and processed to obtain concentrated IgG samples. Infusions can be administered in three different forms: intravenously (IVIg). subcutaneously (SCIg), and intramuscularly (','78'),('OMIM:607685','HYPEREOSINOPHILIC SYNDROME, IDIOPATHIC','PDGFRA (5156),SMPD1 (6609),GNPTAB (79158),GBA (2629),PSMB8 (5696),PTRF (284119),PNPLA2 (57104)','PDGFRA (5156),SMPD1 (6609),GNPTAB (79158),GBA (2629),PSMB8 (5696),PTRF (284119),PNPLA2 (57104)','Differential diagnoses include drug allergies and parasitic infections, solid and hematological malignancies (i.e. chronic myeloid leukemia), eosinophilic granulomatosis with polyangiitis and human T cell lymphotropic virus infection','Treatment consists of immunoglobulin replacement therapy, which replenishes Ig subtypes that the person lack. This treatment is given at frequent intervals for life, and is thought to help reduce bacterial infections and boost immune function.Before therapy begins, plasma donations are tested for known blood-borne pathogens, then pooled and processed to obtain concentrated IgG samples. Infusions can be administered in three different forms: intravenously (IVIg). subcutaneously (SCIg), and intramuscularly (','51'),('OMIM:615122','LYMPHOPROLIFERATIVE SYNDROME 2','CD27 (939),MIF (4282),PEX14 (5195),ALDH7A1 (501),ERCC8 (1161)','extrinsic','Diagnosis is based on clinical, laboratory and genetic findings. A definitive diagnosis is established in the presence of both of the required diagnostic criteria, i.e. chronic non-malignant, non-infectious lymphadenopathy and/or splenomegalyand elevated TCR alpha/beta-double-negative T cells (DNTs) with normal or elevated lymphocyte counts, along with one primary accessory criterion, including defective lymphocyte apoptosis, and germline or somatic mutations in FAS, FASLG or CASP10.','Some patients may require chronic immunosuppressive therapies with sirolimus and mycophenolate mofetil.','61'),('OMIM:275630','CHANARIN-DORFMAN SYNDROME','ABHD5 (51099),ITCH (83737),PRKCD (5580),SC5D (6309),TMEM165 (55858)','extrinsic','Additional features of this condition include an enlarged liver (hepatomegaly), clouding of the lens of the eyes (cataracts), difficulty with coordinating movements (ataxia), hearing loss, short stature, muscle weakness (myopathy), involuntary movement of the eyes (nystagmus), and mild intellectual disability.','Drugs derived from Vitamin A (retinoids) such as tretinoin, motretinide, and etretinate can be effective against skin symptoms of Chanarin Dorfman syndrome, but can cause toxic effects on the bones in some cases, especially if taken by pregnant women. A synthetic derivative of Vitamin A, isotretinoin, when taken by pregnant women, can cause severe birth defects to the fetus. These Vitamin A compounds have not yet been approved by the Food and Drug Administration (FDA) for treatment of ichthyosis.','71'),('OMIM:251000','METHYLMALONIC ACIDURIA DUE TO METHYLMALONYL-COA MUTASE DEFICIENCY','MUT (4594),COG6 (57511),HFE (3077),TMEM165 (55858)','extrinsic','Most common signs and symptoms are lethargy, failure to thrive, recurrent \nvomiting, dehydration which leads to profound metabolic acidosis, respiratory \ndistress, hypotonia and death if not recognized. Complications of acute episodes can include metabolic stroke, extrapyramidal signs, dystonia and bilateral lucencies of globus pallidus. Survivors may have significant neurological damage. Renal failure may appear during childhood. Clinical spectrum is wide, ranging\nfrom fatal neonatal disease to asymptomatic individuals. Patients do not have to have clinical crises in o\nrder to have neurological or other organ compromise. ','Protein restricted diet, OH\n-\nCbl injections, carnitine supplementation and oral \nantibiotic therapy to decrease gut production of propionate. Special medical foods \n(formula) deficient in methionine, threonine, valine, isoleucine, odd chain fatty \nacids and cholesterol. Liver transplant and liver/kidney transplant. ','53'),('OMIM:258480','OPSISMODYSPLASIA','INPPL1 (3636),ITCH (83737),PSAP (5660)','intrinsic','Hypotonia,Recurrent respiratory infections,Short stature,Short hands,Short fingers,Facial abnormalities,Short nose,Depressed nasal bridge\nShort rhizomelic limbs\nNarrow thorax\nDelayed bone age\nLarge head','Treatment of other features of Chanarin Dorfman syndrome is symptomatic and supportive.','63'),('OMIM:232240','GLYCOGEN STORAGE DISEASE IC','SLC37A4 (2542)','extrinsic','Muscle weakness,Myopathy','we now suspect that such treatment\nwas unnecessary ... TE , Yunis E , Brown BI , Kendall RS , Tzakis A . Liver transplantation for Type\nIV glycogen storage disease. ... Continuing lessons from glycogen storage diseases.','73'),('OMIM:269920','INFANTILE SIALIC ACID STORAGE DISORDER','SLC17A5 (26503),SNX10 (29887),ABCB4 (5244),SLC25A20 (788)','extrinsic','Symptoms present by eight months of age and are marked by developmental delay followed by neurological complications such as seizures, involuntary eye movements, and ataxia, involuntary muscle movements and failure to gain weight and grow at the expected rate (failure to thrive). Babies with this condition also have and enlarged liver and spleen (hepatosplenomegaly) and enlarged heart (cardiomegaly).','There is no treatment for ISSD. Treatment is limited to controlling the symptoms of this disorder such as administering anti-convulsant medication to control seizure episodes.','55'),('OMIM:614922','COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 11','RMND1 (55005),SERPINA1 (5265),SLC25A20 (788)','intrinsic','Combined oxidative phosphorylation deficiency is a disease that affects many parts of the body. Onset occurs at or soon after birth in most cases, and features can include growth retardation, small head (microcephaly), increased muscle tone, floppiness of the trunk and head, brain disease (encephalopathy), enlarged heart muscle (cardiomyopathy), and liver dysfunction. There are many subtypes, caused by many different gene mutations. It is inherited in an autosomal recessive pattern.','Treatment is supportive','65'),('OMIM:250950','3-@METHYLGLUTACONIC ACIDURIA, TYPE I','AUH (549),LYST (1130),PEX1 (5189)IL1RN (3557),DIS3L2 (129563).','AUH (549),LYST (1130),PEX1 (5189)IL1RN (3557),DIS3L2 (129563).','Speech delay,Delayed mental development ,Delayed development of motor skills,Metabolic acidosis ,Abnormal muscle tone ,Arm spasms ,Leg spasms ,Arm weakness ,Leg weakness \nIncreased urine level of 3-methylglutaconic acid ,Fetal growth failure ,Growth failure after birth \nOptic atrophy ,Dilated cardiomyopathy - usually starts before 3 years of age,Heart failure ,Long QT syndrome ,Sudden death due to heart failure ,Microvesicular hepatic steatosis ,Hypospadias, \nSmall wasted testicles,Undescended testes ,Nonprogressive cerebellar ataxia ,Nonprogressive mental retardation - mild to very mild ,Normochromic microcytic anemia.\n','The best way to care for your baby is to monitor your baby’s heart for any cardiac complications by regularly visiting a cardiologist. A cardiologist can identify changes in your baby’s heart and decide if any additional treatments are necessary. Each baby with 3-methylglutaconic aciduria (3MGA) experiences unique signs and symptoms, so it is important to talk to your baby’s doctor to decide which treatment is right for your baby.','75'),('OMIM:608799','CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IE','DPM1 (8813),GCDH (2639)','extrinsic','Hypotonia (low muscle tone) ,Feeding problems ,Vomiting and diarrhea ,Seizures,Unusual fat distribution (more than usual on buttocks and pelvic area) and inverted nipples,Strabismus (“crossed eyes” or “lazy eyes”), Variable growth and developmental delays,Distinctive facial features,Liver complications ,Osteopenia (low bone mineral density), Death in the first year of life for 20% of individuals','The treatment of most forms of CDG is directed toward the specific symptoms that are apparent in each individual. Treatment may require the coordinated efforts of a team of specialists. Pediatricians, neurologists, surgeons, cardiologists, speech pathologists, ophthalmologists, gastroenterologists, and other healthcare professionals may need to systematically and comprehensively plan an affect child’s treatment.','57'),('OMIM:614741','MITOCHONDRIAL PYRUVATE CARRIER DEFICIENCY','MPC1 (51660),MIF (4282),MVK (4598)','extrinsic','thin upper lip vermilion,progressive microcephaly,epicanthus,long philtrum','An autosomal recessive metabolic disorder characterized by severely delayed psychomotor development, mild dysmorphic features, hepatomegaly, marked metabolic acidosis, hyperlactacidemia with normal lactate/pyruvate, and encephalopathy.','67'),('OMIM:615238','LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 5','CIDEC (63924),FAH (2184),NCF2 (4688),SMPD1 (6609)','intrinsic','Common symptoms of FPL include selective, progressive loss of subcutaneous fat in the arms and legs and chest and trunk regions, abnormal accumulation of subcutaneous fat in other areas, and a variety of metabolic complications. Generally, women are more severely affected than men by the metabolic complications of FPL. Additional symptoms including those affecting the liver or heart may also occur.','Treatment may require the coordinated efforts of a team of specialists. Pediatricians, plastic surgeons, cardiologists, endocrinologists, nutritionists, and other healthcare professionals may need to systematically and comprehensively plan an affect child’s treatment.','77'),('OMIM:142680','PERIODIC FEVER, FAMILIAL, AUTOSOMAL DOMINANT','TNFRSF1A (7132),COG6 (57511),IDUA (3425),C15ORF41 (84529),PNPLA2 (57104)','extrinsic','Differential diagnoses include other forms of FLPD as well as Cushing syndrome (see these terms), type 2 diabetes, metabolic syndrome and acquired lipodystrophy','Treatment consists of correcting metabolic abnormalities and managing complications. Monitoring diet (reduced intake of dietary fats and carbohydrates) and maintaining daily physical activity can improve the metabolic complications of lipodystrophy. Insulin sensitizers (mainly metformin) and lipid-lowering drugs (statins, or fibrates in case of major hypertriglyceridemia) can also be helpful. Diabetes may require other non-specific treatments, along with insulin. Treatment with metreleptin has resulted in regression of hepatic steatosis and an improvement in metabolic homeostasis, but is only approved in Japan and for the treatment of generalized forms of lipodystrophies in the US (and through compassionate programs in other countries). Regular cardiac monitoring is recommended. Ethinylestradiol should be avoided in women with FPLD2. Plastic surgery can help some patients.','59'),('OMIM:235555','BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2','AKR1D1 (6718),COG6 (57511),NPHP3 (27031),NCF2 (4688),GNE (10020).','Intrinsic','progressive familial intrahepatic cholestasis, diseases that present with neonatal cholestasis, which includes alpha-1-antitrypsin deficiency (ZZ phenotype), tyrosinemia type 1, biliary atresia, choledochal cyst, cystic fibrosis, Alagille syndrome, galactosemia and hereditary fructose intolerance or diseases that present with growth failure (panhypopituitarism) (see these terms).','Treatment is based on oral bile acid therapy, which leads to gradual resolution of biochemical and histologic abnormalities and prevents progression of the disease. Cholic acid therapy creates a pool of bile acids which stimulates bile flow and facilitates fat soluble vitamin absorption and suppresses atypical bile acid synthesis thereby reducing the production of toxic bile acid metabolic intermediates. Ursodeoxycholic acid (UDCA) may be used but is not the therapy of choice because UDCA does not suppress atypical bile acid synthesis and the toxic metabolites that may injure the liver continue to be produced.','69'),('OMIM:609016','LONG-CHAIN 3-HYDROXYACYL-COA DEHYDROGENASE DEFICIENCY','HADHA (3030),GCDH (2639),GLB1 (2720),IDUA (3425),SMPD1 (6609)','Intrinsic','typically appear during infancy or early childhood and can include feeding difficulties, lack of energy (lethargy), low blood sugar (hypoglycemia), weak muscle tone (hypotonia), liver problems, and abnormalities in the light-sensitive tissue at the back of the eye (retina).','Most patients also are provided with uncooked cornstarch and medium-chain triglyceride (MCT) oil supplementation to further decrease exposure to fasting. Oral supplementation with docosahexanoic acid ethyl ester (DHA) may be considered to improve visual function.','79'),('OMIM:300331','THROMBOCYTOSIS, FAMILIAL X-LINKED','THCYTX (84434),SNX10 (29887),ABCB4 (5244)','extrinsic','causes of thrombocytosis with myeloproliferative neoplasm including chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, sporadic or familial ET and myelodysplasic disorders with thrombocytosis including sideroblastic anemia or 5q- syndrome (see these terms), although these can be excluded by the presence of myeloproliferation. Differential diagnoses also include causes of secondary thrombocytosis including iron deficiency, malignancy, chronic inflammatory disease, splenectomy or aspleny and protracted marrow regeneration.','Treatment is based on low dose aspirin at diagnosis. There is no consensus for using platelet lowering therapy despite an increased risk of thrombosis. Patients may have an increased risk of thrombotic events and hemorrhage.','71'),('OMIM:218330','CRANIOECTODERMAL DYSPLASIA 1','IFT122 (55764),SH2D1A (4068)','Intrinsic','long head (dolichocephaly) owing to abnormal fusion of skull bones (sagittal craniosynostosis),Funnel chest (pectus excavatum); narrow thorax (between the neck and abdomen),Abnormally wide space between the inner corners of eyes (telecanthus),Excessive thirst,Enlarged liver,Frequent respiratory tract and lung infections.','Surgery to correct skeletal abnormalities,Growth hormone therapy,Oral medication and supplements for renal insufficiency,Dental care to correct tooth abnormalities,Vision care and aids, if vision is impaired.','61'),('OMIM:131300','CAMURATI-ENGELMANN DISEASE','TGFB1 (7040),SLC37A4 (2542)','extrinsic',' include bone pain, particularly in the legs; skeletal abnormalities; and/or weakness and underdevelopment (hypoplasia) of various muscles. Pain and weakness of the leg muscles may result in an unusual \"waddling\" walk (gait)','No disease-modifying treatment is available. Corticosteroids are reported to relieve the symptoms of CED. Analgesics and non-pharmacological methods can be used to treat pain. NSAIDs and bisphosphonates have been found to be ineffective.','51'),('OMIM:135500','ZIMMERMANN-LABAND SYNDROME 1','KCNH1 (3756),GCDH (2639),PYGL (5836)','Intrinsic','The differential diagnosis includes other defined syndromes of hirsutism and coarsening of the face. Isolated gingival fibromatosis has been documented as a dominantly transmissible trait.','Treatment consists of surgical removal of the hyperplasic fibrous tissue and appropriate orthodontic treatment to improve esthetic appearance and eruption of the non-erupted teeth.','72'),('OMIM:253220','MUCOPOLYSACCHARIDOSIS TYPE VII','GUSB (2990),EIF2AK3 (9451),HSD17B4 (3295),SMPD1 (6609)','Intrinsic','in the head, neck, and face: coarse (Hurler-like) facies and macrocephaly, frontal prominence, premature closure of sagittal lambdoid sutures, and J-shaped sella turcica,in the nose: anteverted nostrils and a depressed nostril bridge','Bone marrow or cord blood transplantation, which endogenously restores production of missing functional enzyme,Enzyme replacement therapy, which supplements exogenously deficient enzyme produced by recombinant DNA technology,Gene transfer and modified fibroblast implants that supply patient with a functional gene for the deficient enzyme','61'),('OMIM:133540','COCKAYNE SYNDROME, TYPE B','ERCC6 (2074),SH2D1A (4068),NCF2 (4688),HMOX1 (3162),HFE2 (148738)','extrinsic','short stature , premature aging (progeria), severe photosensitivity, and moderate to severe learning delay','There is no permanent cure for this syndrome, although patients can be treated according to their specific symptoms. The prognosis for those with Cockayne syndrome is poor, as death typically occurs by the age of 12 Treatment usually involves physical therapy and minor surgeries to the affected organs, like cataract removal. Also wearing high-factor sunscreen and protective clothing is recommended as patients with Cockayne syndrome are very sensitive to UV radiation','51'),('OMIM:252920','MUCOPOLYSACCHARIDOSIS TYPE IIIB','NAGLU (4669),LYST (1130)','Intrinsic','Affected individuals can have severe neurological symptoms, including progressive dementia, aggressive behavior, hyperactivity, seizures, deafness, loss of vision, and an inability to sleep for more than a few hours at a time. MPS IIIB is caused by alterations ( mutations ) in the NAGLU gene. ','No treatment for the underlying cause is available ','71'),('OMIM:231680','MULTIPLE ACYL-COA DEHYDROGENASE DEFICIENCY','ETFA (2108), ETFB (2109), ETFDH (2110),GCDH (2639),HFE2 (148738)','Intrinsic','Symptoms and age at presentation of late-onset MADD are highly variable and characterized by recurrent episodes of lethargy, vomiting, hypoglycemia, metabolic acidosis, and hepatomegaly often preceded by metabolic stress. Muscle involvement in the form of pain, weakness, and lipid storage myopathy also occurs ','Urinary organic acid analysis usually displays various combinations of increased dicarboxylic acids, glutaric acid, ethylmalonic acid, 2-hydroxyglutarate, and glycine conjugates. Blood acylcarnitines show increased C4-C18 species although patients may be severely carnitine depleted, which may limit the degree of these abnormalities. Fibroblast fatty acid oxidation flux and fibroblast acylcarnitine analysis following incubation with palmitic acid is usually abnormal. Final confirmation is by mutation analysis. Newborn screening programs are available in Austria, Belgium, Hungary, Iceland, Portugal and Spain. ','62'),('OMIM:312750','RETT SYNDROME','MECP2 (4204),PIGA (5277),MARS (4141)','extrinsic','Slowed growth,Loss of normal movement and coordination,Loss of communication abilities, Loss of communication abilities,Abnormal hand movements,Unusual eye movements,Cognitive disabilities,Seizures,\nAbnormal curvature of the spine (scoliosis),\nIrregular heartbeat.','Regular medical care,Medications Physical therapy,Occupational therapy,Speech-language therapy,Nutritional support,Behavioral intervention,Support services .','52'),('OMIM:214110','PEROXISOME BIOGENESIS DISORDER 2A (ZELLWEGER)','PEX5 (5830),ABCB11 (8647),HFE2 (148738)','Intrinsic','Zellweger syndrome can also affect the function of many other organ systems. Patients can show craniofacial abnormalities (such as a high forehead, hypoplastic supraorbital ridges, epicanthal folds, midface hypoplasia, and a large fontanel), hepatomegaly (enlarged liver), chondrodysplasia punctata (punctate calcification of the cartilage in specific regions of the body), eye abnormalities, and renal cysts Newborns may present with profound hypotonia (low muscle tone), seizures, apnea, and an inability to eat. ','Zellweger syndrome patients show elevated very long chain fatty acids in their blood plasma. Cultured primarily skin fibroblasts obtained from patients show elevated very long chain fatty acids, impaired very long chain fatty acid beta-oxidation, phytanic acid alpha-oxidation, pristanic acid alpha-oxidation, and plasmalogen biosynthesis ','73'),('OMIM:607765','BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1','HSD3B7 (80270),KCNQ1OT1 (10984),PIGA (5277)','extrinsic','night blindness,osteoporosis,jaundice,abnormal bleeding,abnormality of coagulation,malabsorption.','Treatment may require the coordinated efforts of a team of specialists. Pediatricians, neurologists, liver specialists (hepatologists), nutritionists, and other healthcare professionals may need to systematically and comprehensively plan an affect child’s treatment. Genetic counseling may be of benefit for affected individuals and their families.','63'),('OMIM:230400','GALACTOSEMIA','GALT (2592),SLC7A7 (9056)','Intrinsic','Refusal to eat ,Spitting up or vomiting ,Yellowing of the skin (jaundice) Lethargy ,Cataracts ,Learning disabilities ,Neurological impairments .','Lactose and galactose-free diet,Special lactose-free formula,  Calcium supplements, Monitoring health ,Informing friend, relatives, teachers and child-care providers.','53'),('OMIM:266510','PEROXISOME BIOGENESIS DISORDER 3B','PEX12 (5193),PSAP (5660)','Intrinsic',' developmental delay , mental retardation , and vision and hearing impairment are common in those who have these disorders. Acquisition of speech appears to be especially difficult, and because of the reduced communication abilities, autism is common in those who live longer. Peroxisomal disorder patients have decreased muscle tone ( hypotonia ), which in the most severe cases is generalized, while in less severe cases, is usually restricted to the neck and trunk muscles. Sometimes this lack of control is only noticeable by a curved back in the sitting position. Head control and independent sitting is delayed, with most patients unable to walk independently.\n','There is nospecific therapy for FJN other thancorrection of water and electrolyte imbalances that may occur. Dialysis followed by transplantation is the preferred approach for end-stage renal disease. The tubule injury does not recur in the transplanted kidney, which lacks the underlying abnormality ','74'),('OMIM:616217','NEPHRONOPHTHISIS 19','DCDC2 (51473),PIEZO1 (9780)','Intrinsic','hepatic fibrosis ,cholestasis ,bile duct proliferation,splenomegaly,hepatomegaly.',' Dialysis followed by transplantation is the preferred approach for end-stage renal disease. The tubule injury does not recur in the transplanted kidney, which lacks the underlying abnormality ','64'),('OMIM:191900','MUCKLE-WELLS SYNDROME','NLRP3 (114548),DLD (1738)','Intrinsic','Muckle–Wells syndrome (MWS), also known as urticaria-deafness-amyloidosis syndrome (UDA), is a rare autosomal dominant disease which causes sensorineural deafness, recurrent hives, and can lead to amyloidosis. Individuals with MWS often have episodic fever, chills, and joint pain.','Treatment with anakinra, an interleukin 1 receptor antagonist, can lead to an improvement in the hearing loss. Rilonacept (Arcalyst) a dimeric fusion protein for the treatment of CAPS. Canakinumab, a monoclonal antibody against interleukin-1? .','54'),('OMIM:263300','POLYCYTHEMIA VERA','JAK2 (3717),IDUA (3425),ABCB11 (8647),SH2D1A (4068)','Intrinsic','Headaches ,Double vision or seeing dark or blind spots that come and go ,Itching all over your body, especially after youve been in warm or hot water ,Sweating, especially at night,Reddened face that looks like sunburn or blushing ,Weakness ,Dizziness ,Weight loss ,Shortness of breath,Tingling or burning in your hands or feet ,Painful swelling of a joint .','Phlebotomy,Low-dose,Medicine to lower blood cells. ','77'),('OMIM:609241','SCHINDLER DISEASE, TYPE I','NAGA (4668),CPOX (1371),PSAP (5660),GLB1 (2720),LCRB (387281','extrinsic','Type I infantile form, infants will develop normally until about a year old. At this time, the affected infant will begin to lose previously acquired skills involving the coordination of physical and mental behaviors. Additional neurological and neuromuscular symptoms such as diminished muscle tone, weakness, involuntary rapid eye movements, vision loss, and seizures may become present. With time, the symptoms worsen and children affected with this disorder will experience a decreased ability to move certain muscles due to muscle rigidity. The ability to respond to external stimuli will also decrease. Other symptoms include neuroaxonal dystrophy from birth, discoloration of skin, Telangiectasia or widening of blood vessels.','Amniocentesis or chorionic villus sampling can be used to screen for the disease before birth. After birth, urine tests, along with blood tests and skin biopsies can be used to diagnose Schindler disease. Genetic testing is also always an option, since different forms of Schindler disease have been mapped to the same gene on chromosome 22, though different changes (mutations) of this gene are responsible for the infantile- and adult-onset forms of the disease .','75'),('OMIM:269840','SELECTIVE T-CELL DEFECT','ZAP70 (7535),HFE2 (148738),LCRB (387281','extrinsic','\n    Weight loss,    Fever,    Diarrhoea,    Splenomegaly,    Recurrent infections .','Approach Considerations,Medical Care,Surgical Care,Consultations,Diet.','65'),('OMIM:601859','AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME','FAS (355), FASLG (356),LCRB (387281','Intrinsic','Autoimmune lymphoproliferative syndrome (ALPS) is a rare, inherited disorder characterized by non-malignant lymphoproliferation, multilineage cytopenias, and a lifelong increased risk of Hodgkins and non-Hodgkins lymphoma. ','Approach Considerations ,Pharmacologic Therapy ,Stem Cell Transplantation ,Diet and Activity ,Prevention .','55'),('OMIM:250250','CARTILAGE-HAIR HYPOPLASIA','RMRP (6023),ABCD3 (5825),CECR1 (51816),SC5D (6309)','extrinsic','Cartilage-hair hypoplasia is a disorder of bone growth characterized by short stature (dwarfism) with other skeletal abnormalities; fine, sparse hair (hypotrichosis); and abnormal immune system function (immune deficiency) that can lead to recurrent infections. ','T-cell immune reconstitution using bone marrow transplantation (BMT) is performed. BMT corrects the immunodeficiency but not the skeletal abnormalities. BMT can prevent lymphoma. Recently, Bordon et al reported in the outcome of 16 patients with cartilage hair-hypoplasia who received BMT ','76'),('OMIM:219800','CYSTINOSIS, NEPHROPATHIC','CTNS (1497),PIGA (5277),SC5D (6309),LCRB (387281','Intrinsic','Multiorgan involvement: May be mild to severe ,Polyuria, polydipsia, dehydration, vomiting, metabolic acidosis ,Hypophosphatemic rickets ,Constipation ,Failure to thrive, poor/loss of appetite ,Craves salty and hot and spicy foods; prefers specific food textures ,May have recurrent bouts of fever and manifestations of heat intolerance ,Left untreated, renal failure develops by age 7-10 years .','Serum electrolyte levels: To detect the presence of acidosis (hyperchloremic, normal anion gap) and severity of hypokalemia, hyponatremia, hypophosphatemia, and low bicarbonate concentration ,Blood gases: To detect metabolic acidosis and the degree of respiratory compensation ,Urine testing: Findings include low osmolality, glycosuria, and tubular proteinuria (including generalized amino aciduria) ,Urine electrolyte levels: To detect the loss of bicarbonate and phosphaturia ,Cystine levels in polymorphonuclear leukocytes or cultured fibroblasts (for fetuses: chorionic villi or cultured amniotic fluid cells): Confirms diagnosis of cystinosis .','66'),('OMIM:253000','MUCOPOLYSACCHARIDOSIS, TYPE IVA','GALNS (2588),YARS2 (51067),ABCB11 (8647)','extrinsic','The rate at which symptoms worsen varies among affected individuals. The first signs and symptoms of MPS IV usually become apparent during early childhood. Affected individuals develop various skeletal abnormalities, including short stature, knock knees, and abnormalities of the ribs, chest, spine, hips, and wrists. ','Diagnosis is based on detection of increased urinary KS excretion (not constant) and galactosyloligoaccharide excretion in MPS IV. It is confirmed by the demonstration of enzymatic deficiency in cultured leucocytes or fibroblasts. Enzymatic study allows other osteochondrodysplasias to be excluded. The distinction between MPS IVand GM1 gangliosidosis type 3 (see this term) is often difficult in children, even if 9 out of 59 GLB1 mutations are associated with MPS IV. ','56'),('OMIM:603554','OMENN SYNDROME','DCLRE1C (64421), RAG1 (5896), RAG2 (5897),HSD17B4 (3295)','Intrinsic','A characteristic symptom is chronic inflammation of the skin, which appears as a red rash (early onset erythroderma). Other symptoms include eosinophilia, failure to thrive, swollen lymph nodes, swollen spleen, diarrhea, enlarged liver, low immunoglobulin levels (except immunoglobulin E, which is elevated), low T cell levels, and no B cells.https://en.wikipedia.org/wiki/Omenn_syndrome#cite_note-Geha-3 ','The only treatment for Omenn syndrome is bone marrow transplantation. Without treatment, it is rapidly fatal in infancy.The disease can be cured by bone marrow transplantation ','77'),('OMIM:312870','SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1','SC5D (6309),SNX10 (29887),CPOX (1371),FUCA1 (2517)','extrinsic','Macrosomia ,Macroglossia ,Advanced bone age ,Organomegaly ,Neonatal hypoglycemia ,Neoplasms ,Congenital diaphragmatic hernia (CDH) ,\"Bulldog\" or \"coarse\" face (protruding jaw and tongue, widened nasal bridge, upturned nasal tip) ,Hands and feet are short and broad with dysplatic nails ,Cutaneous syndactyly ,Polydactyly ,Pectus excavatum ,Talipes ,Vertebral sementation defects ,Supernumerary nipples ,Structural and conductive cardiac defects ,Multicystic dysplastic kidneys ,Hypotonia ,Seizures ,Brain malformations ,Developmental disabilities ,Mental retardation- can be inexistent or mild to severe .','Prompt treatment of neonatal hypoglycemia and airway obstruction resulting from micrognathia and glossoptosis. Care of cleft lip and/or cleft palate or macroglossia and related feeding difficulties, heart defects, skeletal abnormalities, and urogenital abnormalities by appropriate pediatric specialists. Speech therapy as needed. Neurodevelopmental assessment to determine need for special education, occupational therapy, and/or physical therapy. ','67'),('OMIM:253010','MUCOPOLYSACCHARIDOSIS TYPE IVB','GLB1 (2720),EIF2AK3 (9451),DLD (1738),PIGA (5277),CECR1 (51816),C15ORF41 (84529),PHKA2 (5256)','extrinsic','The first signs and symptoms of MPS IV usually become apparent during early childhood. Affected individuals develop various skeletal abnormalities, including short stature, knock knees, and abnormalities of the ribs, chest, spine, hips, and wrists. People with MPS IV often have joints that are loose and very flexible (hypermobile), but they may also have restricted movement in certain joints. A characteristic feature of this condition is underdevelopment (hypoplasia) of a peg-like bone in the neck called the odontoid process. ','Diagnosis is based on detection of increased urinary KS excretion (not constant) and galactosyloligoaccharide excretion in MPS IVB. It is confirmed by the demonstration of enzymatic deficiency in cultured leucocytes or fibroblasts. Enzymatic study allows other osteochondrodysplasias to be excluded. The distinction between MPS IVB and GM1 gangliosidosis type 3 (see this term) is often difficult in children, even if 9 out of 59 GLB1 mutations are associated with MPS IVB. ','57'),('OMIM:613489','CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIJ','COG4 (25839),YARS2 (51067),PIEZO1 (9780)','intrinsic','Hypotonia (low muscle tone),Feeding problems ,Vomiting and diarrhea ,Seizures \nUnusual fat distribution (more than usual on buttocks and pelvic area) and inverted nipples ,Strabismus (“crossed eyes” or “lazy eyes”) ,Variable growth and developmental delays ,Distinctive facial features ,Liver complications ,Osteopenia (low bone mineral density) ,Death in the first year of life for 20% of individuals .','No treatment is available for most of these disorders ','78'),('OMIM:602782','HISTIOCYTOSIS-LYMPHADENOPATHY PLUS SYNDROME','SLC29A3 (55315),ABCD3 (5825),SH2D1A (4068),MARS (4141),C15ORF41 (84529)','extrinsic','Atria septal defect,Cardiomegaly,Mitral valve prolapse,Retroperitoneal fibrosis,Ventricular septal defect,Autosomal recessive inheritance,Camptodactyly,Clinodactyly,Diabetes mellitus,Elbow flexion contracture.','Genetic Testing Registry: Histiocytosis-lymphadenopathy plus syndrome These resources from MedlinePlus offer information about the diagnosis and management of various health conditions,Diagnostic Tests,Drug Therapy,Surgery and Rehabilitation,Genetic Counseling,Palliative Care.','68'),('OMIM:614862','PEROXISOME BIOGENESIS DISORDER 4A (ZELLWEGER)','PEX6 (5190),ATPAF2 (91647),GBA (2629),PYGL (5836)','extrinsic','The part of the brain and spinal cord that contains myelin is called white matter. Destruction of myelin (demyelination) leads to loss of white matter (leukodystrophy). Children with Zellweger syndrome also develop life-threatening problems in other organs and tissues, such as the liver, heart, and kidneys. They may have skeletal abnormalities, including a large space between the bones of the skull (fontanels) and characteristic bone spots known as chondrodysplasia punctata that can be seen on x-ray. ','The focus is on symptomatic therapy, and may include: gastrostomy to provide adequate calories, hearing aids, cataract removal in infancy, glasses, vitamin supplementation, primary bile acid therapy, antiepileptic drugs, and possibly monitoring for hyperoxaluria. ','58'),('OMIM:613673','ANEMIA, DYSERYTHROPOIETIC CONGENITAL, TYPE IV','KLF1 (10661),PIGA (5277),PHKA2 (5256)','extrinsic','Tiredness (fatigue),Weakness ,Pale skin ','Gene therapy, as well as, bone marrow transplant are also possible treatments for the disorder, but each have their own risks at this point in time. Bone marrow transplantation is the more used method between the two, whereas researchers are still trying to definitively establish the results of gene therapy treatment. It generally requires a 10/10 HLA matched donor, however, who is usually a sibling. ','79'),('OMIM:603909','AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IIA','CASP10 (843),ATPAF2 (91647),CPOX (1371),ABCD3 (5825)','Intrinsic','nephrotic ,syndromenephritis ,urticaria ,splenomegaly,eosinophilia .','    Diagnostic Tests\n    Drug Therapy\n    Surgery and Rehabilitation\n    Genetic Counseling\n    Palliative Care','69'),('OMIM:243300','CHOLESTASIS, BENIGN RECURRENT INTRAHEPATIC 1','ATP8B1 (5205),PRKCD (5580),MARS (4141)','Intrinsic','The first episode of cholestasis usually occurs in an affected persons teens or twenties. An attack typically begins with severe itchiness (pruritus), followed by yellowing of the skin and whites of the eyes (jaundice) a few weeks later. Other general signs and symptoms that occur during these episodes include a vague feeling of discomfort (malaise), irritability, nausea, vomiting, and a lack of appetite. A common feature of BRIC is the reduced absorption of fat in the body, which leads to excess fat in the feces (steatorrhea). Because of a lack of fat absorption and loss of appetite, affected individuals often lose weight during episodes of cholestasis. ','Diagnostic Tests,Drug Therapy,Surgery and Rehabilitation,Genetic Counseling,Palliative Care.','59'),('OMIM:277900','WILSON DISEASE','ATP7B (540),LCRB (387281),IFT172 (26160)','extrinsic','Fatigue, lack of appetite or abdominal pain,Jaundice, a yellowing of the skin and the whites of the eye, tendency to bruise easily,Fluid buildup in the legs or abdomen,Problems with speech, swallowing or physical coordination,Uncontrolled movements or muscle stiffness.','Your doctor may recommend medications called chelating agents, which prompt your organs to release copper into your bloodstream. The copper is then filtered by your kidneys and released into your urine. Treatment then focuses on preventing copper from building up again. When liver damage is severe, a liver transplant may be necessary. Medications:Penicillamine (Cuprimine, Depen),Trientine (Syprine),Zinc acetate (Galzin).','80'),('OMIM:272200','MULTIPLE SULFATASE DEFICIENCY','SUMF1 (285362),ATPAF2 (91647),SLC25A20 (788),IFT172 (26160)','Intrinsic','The signs and symptoms of this condition vary widely, prompting researchers to divide it into three types: neonatal, late-infantile, and juvenile,','Funding remains critical and is urgently needed to stop MSD forever. Every donation will help towards achieving our goal to save these children and those of future generations. Time is of the essence for MSD families in an effort to treat their children before harsh symptoms develop and the disease progresses. Months, weeks and days matter in the race for children to be treated','70'),('OMIM:236200','HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY','CBS (875),DLD (1738),PEX1 (5189),GLB1 (2720),SLC25A20 (788)','extrinsic','Extensive atheroma formation at a young age which affects many arteries but not the coronary arteries,in contrast to Marfan syndrome which features upward ectopia lentis, downward dislocation is the typical finding of homocystinuria,Tall, thin build resembling Marfanoid habitus','Betaine (N,N,N-trimethylglycine) is used to reduce concentrations of homocysteine by promoting the conversion of homocysteine back to methionine, i.e., increasing flux through the re-methylation pathway independent of folate derivatives (which is mainly active in the liver and in the kidneys).The re-formed methionine is then gradually removed by incorporation into body protein. The methionine that is not converted into protein is converted to S-adenosyl-methionine which goes on to form homocysteine again. Betaine is, therefore, only effective if the quantity of methionine to be removed is small. Hence treatment includes both betaine and a diet low in methionine','60'),('OMIM:272200','MULTIPLE SULFATASE DEFICIENCY','SUMF1 (285362),PIGA (5277),FASTKD2 (22868), TACO1 (51204), COX20 (116228), SCO1 (6341), COX10 (1352), COX14 (84987), COX6B1 (1340), PET100 (100131801), APOPT1 (84334)','extrinsic','The signs and symptoms of this condition vary widely, prompting researchers to divide it into three types: neonatal, late-infantile, and juvenile,','Funding remains critical and is urgently needed to stop MSD forever. Every donation will help towards achieving our goal to save these children and those of future generations. Time is of the essence for MSD families in an effort to treat their children before harsh symptoms develop and the disease progresses. Months, weeks and days matter in the race for children to be treated','50'),('OMIM:615895','POLYGLUCOSAN BODY MYOPATHY, EARLY-ONSET, WITH OR WITHOUT IMMUNODEFICIENCY','RBCK1 (10616),YARS2 (51067),FASTKD2 (22868), TACO1 (51204), COX20 (116228), SCO1 (6341), COX10 (1352), COX14 (84987), COX6B1 (1340), PET100 (100131801), APOPT1 (84334)','intrinsic','Ptosis,eczema, hepatomegaly,scoliosis,lymphadenopathy.','Methylprednisolone,Prednisolone ,PREDNISOLONE ACETATE \nNitrous oxide ,Lidocaine ','55'),('OMIM:269700','LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 2','BSCL2 (26580),PHKB (5257),TREX1 (11277),GNE (10020)','intrinsic','Patients have accelerated growth, voracious appetite, and advanced bone age during early childhood. The biochemical anomalies found in this syndrome have an abnormal response to insulin (hyperinsulinemia) action and the incapability of producing adipose tissue. Other characteristics include hepatomegaly affecting liver functions, gum hypertrophy, hypertriglyceridemia, arterial hypertension, acanthosis nigricans, hirsutism, cardiac hypertrophy, and nephropathy. Diabetes mellitus usually appears during the pubertal years. Fatty infiltration of the liver occurs early and may lead to cirrhosis and its complications. Umbilical hernia or prominence seems to be a consistent finding. Post-pubertal patients may also develop focal lytic lesions in the appendicular bones. A few patients have been reported to have hypertrophic cardiomyopathy and mental retardation. ','1. Kidney Transplantation 2. Total Parenteral Nutrition 3. Hypophysectomy ','65'),('OMIM:607014','HURLER SYNDROME','IDUA (3425),DLD (1738),TREX1 (11277),GNE (10020)','extrinsic','   line of mental functioning\n    Loss of physical skills\n    Heart problems, including changes in the valves\n    Hearing problems and frequent ear infections\n    Large head size, broad forehead, and heavy eyebrows\n    Deformed bones and stiff joints, especially the spine, hips, knees, wrists, and fingers\n    Short size\n    Breathing problems','Enzyme replacement therapy for Hurler syndrome adds a working form of the missing enzyme to the body. The medicine, called laronidase (Aldurazyme), is given through a vein (IV, intravenously). Talk to your health care provider for more information.Bone marrow transplant has been used in several people with this condition. The treatment has had mixed results.Other treatments depend on the organs that are affected','75'),('OMIM:614872','PEROXISOME BIOGENESIS DISORDER 7A (ZELLWEGER)','PEX26 (55670),','intrinsic','Children with neonatal adrenoleukodystrophy and infantile Refsum disease may not develop symptoms until later during infancy. Some of these children reach adolescence or adulthood although most have some degree of intellectual disability, hearing loss and vision problems. ','eatment may require the coordinated efforts of a team of specialists. Pediatricians, neurologists, endocrinologists, surgeons, specialists who assess and treat hearing problems (audiologists), specialists who assess and treat vision problems (ophthalmologists), specialists who assess and treat skeletal disorders (orthopedists) and other healthcare professionals may need to systematically and comprehensively plan an affect child’s treatment. Children with Zellweger spectrum disorders may require a feeding (gastrostomy) tube to ensure proper intake of calories','59'),('OMIM:608836','CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LETHAL NEONATAL','CPT2 (1376),SMPD1 (6609),GBA (2629),TMEM165 (55858),PEX26 (55670)','extrinsic','The severe infantile hepatocardiomuscular form of CPT II deficiency affects the liver, heart, and muscles. Signs and symptoms usually appear within the first year of life. This form involves recurring episodes of hypoketotic hypoglycemia, seizures, an enlarged liver (hepatomegaly), cardiomyopathy, and arrhythmia ','These resources address the diagnosis or management of CPT II deficiency:\nBabys First Test\nFOD (Fatty Oxidation Disorders) Family Support Group: Diagnostic Approach to Disorders of Fat Oxidation - Information for Clinicians\nGeneReview: Carnitine Palmitoyltransferase II Deficiency\nGenetic Testing Registry: Carnitine palmitoyltransferase II deficiency\nGenetic Testing Registry: Carnitine palmitoyltransferase II deficiency, infantile\nGenetic Testing Registry: Carnitine palmitoyltransferase II deficiency, late-onset\nGenetic Testing Registry: Carnitine palmitoyltransferase II deficiency, lethal neonatal','69'),('OMIM:610333','AICARDI-GOUTIERES SYNDROME 4','RNASEH2A (10535),ABCB11 (8647),HEXA (3073)','intrinsic','Most newborns with Aicardi-Goutieres syndrome do not show any signs or symptoms of the disorder at birth. However, about 20 percent are born with a combination of features that include an enlarged liver and spleen (hepatosplenomegaly), elevated blood levels of liver enzymes, a decrease in blood platelets (thrombocytopenia), and abnormal neurological responses.','These resources from MedlinePlus offer information about the diagnosis and management of various health conditions:\n\n    Diagnostic Tests\n    Drug Therapy\n    Surgery and Rehabilitation\n    Genetic Counseling\n    Palliative Care','79'),('OMIM:222470','TRICHOHEPATOENTERIC SYNDROME 1','TTC37 (9652),DLD (1738),SMPD1 (6609),SLC37A4 (2542),KIT (3815),HSD17B4 (3295)','intrinsic','Tricho-hepato-enteric syndrome is one particular form of intractable diarrhea of infancy, presenting typically in the first month of life. These babies were usually born small for their age and continue to experience failure to thrive, usually with a final short stature. Typical facial features include prominent forehead and cheeks, a broad nasal root and widely spaced eyes (hypertelorism). Their hairs are woolly, easily removed and poorly pigmented. Liver disease is mainly present as cirrhosis or fibrosis, and staining might reveal high iron content of the liver cells (consistent with hemochromatosis). Most evaluated patients had some degree of decrease in intelligence. ','No specific treatment or cure exists. Affected children usually need total parenteral nutrition through a central venous catheter. Further worsening of liver damage should however be avoided if possible. Diarrhea will likely continue even though food stops passing through the gastrointestinal system.They can subsequently be managed with tube feeding, and some may be weaned from nutritional support during adolescence.','53'),('OMIM:607594','IMMUNODEFICIENCY, COMMON VARIABLE, 1','ICOS (29851),ATPAF2 (91647),CPOX (1371),SMPD1 (6609),PRKCD (5580),TMEM165 (55858)','intrinsic','autoimmune manifestations, e.g. pernicious anemia, autoimmune haemolytic anemia (AHA), idiopathic thrombocytopenic purpura (ITP), psoriasis, vitiligo, rheumatoid arthritis, primary hypothyroidism, atrophic gastritis. Autoimmunity is the main type of complication in people with CVID, appearing in some form in up to 50% of individuals,malignancies, particularly Non-Hodgkins lymphoma and gastric carcinoma,enteropathy, which manifests with a blunting of intestinal villi and inflammation, and is usually accompanied by symptoms such as abdominal cramps, diarrhea, constipation and, in some cases, malabsorption and weight loss. Symptoms of CVID enteropathy are similar to those of celiac disease, but dont respond to a gluten-free diet. Infectious causes must be excluded before a diagnosis of enteropathy can be made, as people with CVID are more susceptible to intestinal infections, e.g. by Giardia lamblia,lymphocytic infiltration of tissues, which can cause enlargement of lymph nodes (lymphadenopathy), of the spleen (splenomegaly) and of the liver (hepatomegaly), as well as the formation of granulomas. In the lung this is known as Granulomatous–lymphocytic interstitial lung disease. ','Treatment consists of immunoglobulin replacement therapy, which replenishes Ig subtypes that the person lack. This treatment is given at frequent intervals for life, and is thought to help reduce bacterial infections and boost immune function. Before therapy begins, plasma donations are tested for known blood-borne pathogens, then pooled and processed to obtain concentrated IgG samples. Infusions can be administered in three different forms: intravenously (IVIg):,subcutaneously (SCIg), and intramuscularly (IMIg) ','63'),('OMIM:614882','PEROXISOME BIOGENESIS DISORDER 10A (ZELLWEGER)','PEX3 (8504),SNX10 (29887),HFE (3077)','intrinsic','Affected children present in the newborn period with profound hypotonia, seizures, and inability to feed. Characteristic craniofacial anomalies, eye abnormalities, neuronal migration defects, hepatomegaly, and chondrodysplasia punctata are present. Children with this condition do not show any significant development and usually die in the first year of life ','The treatment can be specific to the disorder, such as in the case of Refsum disease, which includes elimination of the toxic substance.\n\n    Because phytanic acid is exclusively of dietary origin (butter, cheese, beef, lamb, and some fish), its restriction can reduce its blood and tissue levels in 1-2 years, and the neurotoxic events can be significantly limited.\n    Long-term follow-up has shown that dietary restriction improves peripheral-nerve and cardiac function and stabilizes the retinal abnormalities and hearing deficit.\n    In sick patients, phytanic acid levels can be rapidly lowered with plasma exchange; this may reverse some symptoms. Alternative means to decrease phytanic acid levels is w-oxidation by means of the cytochrome P-450 enzyme; however, this line of therapy remains experimental.\n    Extracorporeal apheresis is another therapeutic approach that may result in in long-term improvement or stabilization in patients with progressive Refsum disease. ','73'),('OMIM:608971','SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-POSITIVE, NK CELL-POSITIVE','IL7R (3575), PTPRC (5788)','extrinsic','otitis media,eczema,splenomegaly,diarrhea,hepatomegaly .','Transplant of stem cells taken from the bone marrow of a healthy, matching donor, usually by the age of about 3 months, is generally considered the best treatment for SCID. ','78'),('OMIM:208400','ASPARTYLGLUCOSAMINURIA','AGA (175),SNX10 (29887),PRKCD (5580),SC5D (6309)GNE (10020).','extrinsic','Development of scoliosis\n    Seizures or difficulty with movement\n    Skin and joints may become loose\n    Facial features change progressively; this may include:thickening of the skin,features becoming more prominent,large head broad lower jaw short, broad noserounded cheeks[2]\n    ','No treatment is available to cure or slow down the progression of aspartylglucosaminuria. Bone marrow transplants have been conducted in hope that the bone marrow will produce the missing enzyme. The results of the tests thus far have shown to be inconclusive ','68'),('om567432','heat process','1028,2629','extrinsic','leg soriyasis, pimple big red','daily bath well, be clean, please wash ur dess regularly','58');

UNLOCK TABLES;

/*Table structure for table `ghis` */

DROP TABLE IF EXISTS `ghis`;

CREATE TABLE `ghis` (
  `sid` int(22) NOT NULL AUTO_INCREMENT,
  `uid` varchar(222) DEFAULT NULL,
  `gid` varchar(22) DEFAULT NULL,
  `gtype` varchar(22) DEFAULT NULL,
  `file` varchar(22) DEFAULT NULL,
  PRIMARY KEY (`sid`)
) ENGINE=InnoDB AUTO_INCREMENT=57 DEFAULT CHARSET=latin1;

/*Data for the table `ghis` */

LOCK TABLES `ghis` WRITE;

insert  into `ghis`(`sid`,`uid`,`gid`,`gtype`,`file`) values (9,'suresh','1028','extrinsic','87114983.txt'),(10,'suresh','2629','extrinsic','88898543.txt'),(11,'suresh','9056','intrinsic','58753903.txt'),(12,'suresh','9056','intrinsic','92700243.txt'),(13,'suresh','9056','intrinsic','84321532.txt'),(14,'suresh','9056','intrinsic','96860917.txt'),(15,'suresh','9056','intrinsic','26064737.txt'),(16,'suresh','9056','intrinsic','97234198.txt'),(17,'suresh','9056','intrinsic','88525279.txt'),(18,'suresh','5660','extrinsic','69979753.txt'),(19,'suresh','2235','extrinsic','17699374.txt'),(20,'suresh','2235','extrinsic','19162963.txt'),(21,'suresh','2235','extrinsic','79222463.txt'),(22,'null','2235','extrinsic','55320152.txt'),(23,'suresh','1371','intrinsic','82562061.txt'),(24,'suresh','1371','intrinsic','60968679.txt'),(25,'suresh','1371','intrinsic','40440036.txt'),(26,'suresh','1371','intrinsic','68767693.txt'),(27,'suresh','1371','intrinsic','85482911.txt'),(28,'suresh','1371','intrinsic','90934931.txt'),(29,'suresh','1371','intrinsic','40162448.txt'),(30,'suresh','1371','intrinsic','41709922.txt'),(31,'suresh','1371','intrinsic','24917440.txt'),(32,'suresh','9056','extrinsic','79689746.txt'),(33,'suresh','9056','extrinsic','84154417.txt'),(34,'suresh','9056','extrinsic','68799294.txt'),(35,'suresh','9056','extrinsic','20875577.txt'),(36,'suresh','9056','extrinsic','83994370.txt'),(37,'suresh','9056','extrinsic','78688344.txt'),(38,'suresh','9056','extrinsic','93784240.txt'),(39,'suresh','9056','extrinsic','50608207.txt'),(40,'suresh','9056','extrinsic','87628329.txt'),(41,'suresh','9056','extrinsic','16393532.txt'),(42,'suresh','9056','extrinsic','19648872.txt'),(43,'suresh','2184','extrinsic','95493116.txt'),(44,'suresh','1282','extrinsic','14322353.txt'),(45,'suresh','64324','extrinsic','63513938.txt'),(46,'suresh','64324','extrinsic','85374830.txt'),(47,'suresh','1028','extrinsic','15132713.txt'),(48,'null','55630','extrinsic','49010323.txt'),(49,'suresh','55630','extrinsic','10034170.txt'),(50,'suresh','64324','extrinsic','27713653.txt'),(51,'suresh','8504','extrinsic','46712737.txt'),(52,'suresh','1028','extrinsic','82545620.txt'),(53,'suresh','5195','extrinsic','69410021.txt'),(54,'suresh','9056','extrinsic','18385489.txt'),(55,'suresh','5189','extrinsic','69079473.txt'),(56,'suresh','1028','extrinsic','28546475.txt');

UNLOCK TABLES;

/*Table structure for table `id` */

DROP TABLE IF EXISTS `id`;

CREATE TABLE `id` (
  `gene name` varchar(5000) DEFAULT NULL,
  `gene id` varchar(5000) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

/*Data for the table `id` */

LOCK TABLES `id` WRITE;

insert  into `id`(`gene name`,`gene id`) values ('NSD1','64324'),('CDKN1C','1028'),('H19','283120'),('KCNQ1OT1','10984'),('H19-ICR','105259599'),('NAP1L4','4676'),('PHLDA2','7262'),('IGF2','3481'),('CYP7B1','9420'),('SNX10','29887'),('ATPAF2','91647'),('DNAH8 ','1769'),('PC','5091'),('SLC7A7','9056'),('CPOX','1371'),('HMBS','3145'),('PPOX','5498'),('ALAD ','210'),('FECH','2235'),('UROD','7389'),('UROS','7390'),('PCBD1','5092'),('SPOCK1','6695'),('OCLN','100506658'),('USP18','11274'),('JAM3 ','83700'),('COL4A1','1282'),('DKC1','1736'),('IFNA1','3439'),('GBA','2629'),('PSAP','5660'),('SLC39A4','55630'),('SLC30A4','7782'),('ALB ','213'),('PLIN2','123'),('OTC','5009'),('SLC30A2','7780'),('SLC39A5','283375'),('NCF1','653361'),('NCF4','4689'),('CYBB','1536'),('CYBA','1535'),('NCF2 ','4688'),('IFNG','3458'),('MT-CYB','4519'),('MPO','4353'),('FAH','2184'),('GSTZ1','2954'),('HPD','3242'),('ALAD','210'),('AFP','174'),('CYCS','54205'),('RAB27A','5873'),('UNC13D','201294'),('MLPH','79083'),('MYO5A','4644'),('CCL5','6352'),('AGFG1 ','3267'),('PEX14','5195'),('HSD17B4','3295'),('PEX1','5189'),('PEX3','8504'),('PEX7','5191'),('PEX2','5828'),('PEX1 ','5189'),('PSAP','5660'),('TUFM ','7284'),('CC2D2A','57545'),('TMEM67','91147'),('RPGRIP1L','23322'),('INPP5E','56623'),('GBA ','2629'),('SLC37A4','2542'),('KIT','3815'),('IFNA2','3440'),('MITF','4286'),('MPO','4353'),('ITGB1','3688'),('SYT1','6857'),('CD44','960'),('BMP6 ','654'),('CFTR','1080'),('TGFB1','7040'),('FCGR2A ','2212'),('DNASE1','1773'),('S100A8','6279'),('SLC9A3R1','9368'),('CLCA1','1179'),('DEFB1','1672'),('CLCA4','22802'),('UMOD','7369'),('PKD1 ','5310'),('HNF1B','6928'),('TSC2','7249'),('NPHP1 ','4867'),('INVS ','27130'),('MUC1','4582'),('NPHP4','261734'),('SMN1','6606'),('IGHMBP2','3508'),('NAIP','4671'),('SMN2','6607'),('SCO2','9997'),('SYP','6855'),('COX14','84987'),('VRK1','7443'),('FKTN','2218'),('ZPR1','8882'),('NCAM1','4684'),('COL6A1','1291'),('MSTN','2660'),('VAPB','9217'),('PLEKHG5','57449'),('FST','10468');

UNLOCK TABLES;

/*Table structure for table `inex` */

DROP TABLE IF EXISTS `inex`;

CREATE TABLE `inex` (
  `diseaseid` varchar(5000) DEFAULT NULL,
  `diseasename` varchar(5000) DEFAULT NULL,
  `associategenes` varchar(10000) DEFAULT NULL,
  `tf&mim` varchar(10000) DEFAULT NULL,
  `molecularbasis` varchar(5000) DEFAULT NULL,
  `cure` varchar(5000) DEFAULT NULL,
  `pic` varchar(5000) DEFAULT NULL,
  `list` varchar(5000) DEFAULT NULL,
  `ie` varchar(5000) DEFAULT NULL,
  `ppi` varchar(500) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

/*Data for the table `inex` */

LOCK TABLES `inex` WRITE;

insert  into `inex`(`diseaseid`,`diseasename`,`associategenes`,`tf&mim`,`molecularbasis`,`cure`,`pic`,`list`,`ie`,`ppi`) values ('OMIM:130650','BECKWITH-WIEDEMANN SYNDROME','NSD1 (64324),CDKN1C (1028),H19 (283120),KCNQ1OT1 (10984),H19-ICR (105259599),NAP1L4 (4676),PHLDA2 (7262),IGF2(3481)  ','\"ICR1 A maternally inherited point mutation was identified in ICR1 in both IGF2  & H19  which altered binding of OCT transcription factors\",\"616186\"&\"H19\",\"103280\"&\"KCNQ1OT1\",\"604115\"&\"CDKN1C\",\"600856\"','Caused by mutation in the cyclin-dependent kinase inhibitor 1C gene (CDKN1C, 600856.0001)&Caused by mutation in the nuclear receptor binding SET domain protein 1 (NSD1, 606681.0011)& Caused by mutation in the KCNQ1-overlapping transcript 1 gene (KCNQ1OT1, 604115.0001)&Caused by contiguous gene duplication of imprinted region of 11p15.5&Caused by contiguous gene deletion of imprinted region of 11p15.5 ','1. Patients with Beckwith-Wiedemann syndrome (BWS) may require frequent feedings or diazoxide to treat their hypoglycemia. 2. Infants and children must demonstrate the ability to maintain euglycemia during a fast of age-appropriate duration. The normal duration of fasting for an infant or child depends on body mass and the maturity of counterregulatory responses to hypoglycemia, which include gluconeogenesis, glycogenolysis, and ketogenesis.','Image\\BONE & MUSCLE DISEASE\\1.jpg','BONE & MUSCLE DISEASE','Intrinsic',NULL),('OMIM:613812','BILE ACID SYNTHESIS DEFECT,CONGENITAL,3','CYP7B1 (9420)','\"CYP7B1   gene with protein product: Entrez Gene: 9420 C, Ensembl: ENSG00000172817 C Vega: OTTHUMG00000164387 C, UCSC: uc003xvj.3 D, Protein Resource : O75881 D\",\"603711\"&\"Cholesterol degradation to bile acids in the liver can be initiated by either cholesterol 7a-hydroxylase (CYP7A1) of the classic (neutral) pathway, or by mitochondrial sterol 27-hydroxylase (CYP27A1) of the alternative (or acidic) pathway.\" ',NULL,'Diagnosis is based on serum hepatic enzyme and bilirubin profile, and analysis of urine, serum and bile using liquid secondary ionization mass spectrometry (LSIMS) and gas chromatography - mass spectrometry (GC-MS).','Image\\LIVER & KIDENEY DISEASE\\2.jpg','LIVER & KIDENEY DISEASE','Intrinsic',NULL),('OMIM:615085,259700,259710,611490    ','OSTEOPETROSIS,AUTOSOMAL RECESSIVE 8','SNX10 (29887)','\"SNX10\",\"614780\"',NULL,'Patients may require blood transfusions, treatment for infections and management of their developmental and visual problems. Bone marrow transplant can alleviate many features of the disease but needs to be performed early to minimise optic nerve encroachment.','Image\\BONE & MUSCLE DISEASE\\3.jpg','BONE & MUSCLE DISEASE','Intrinsic',NULL),('OMIM:604273','MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY,NUCLEAR TYPE 1; MC5DN1','ATPAF2 (91647),DNAH8 (1769)','\"ATPAF2,ATP12 Homolog,ATP12p,LP3663,MC5DN1\",\"608918\"',' Caused by mutation in the transmembrane protein 70 gene (TMEM70, 612418.0001) - Caused by mutation in the ATP synthase F1 complex assembly factor-2 gene (ATPAF2, 608918.0001)',NULL,'Image\\OTHERS\\4.jpg','OTHERS','Intrinsic',NULL),('OMIM:266150','PYRUVATE CARBOXYLASE DEFICIENCY','PC (5091)','\"PC\",\"608786\"',NULL,'Treatments in patients with pyruvate carboxylase deficiency (PCD) are aimed at stimulating the pyruvate dehydrogenase complex (PDC) and providing alternative fuels. Correction of the biochemical abnormality can reverse some symptoms, but central nervous system damage progresses regardless of treatment.&The PDC can provide an alternative pathway for pyruvate metabolism PDC activity can be optimized by cofactor supplementation with thiamine and lipoic acid and administration of dichloroacetate. Increased pyruvate metabolism through this pathway can help reduce the pyruvate and lactate levels.&Biotin supplementation is given to help optimize the residual enzyme activity but is usually of little use.&Citrate supplementation reduces the acidosis and provides the needed substrate in the citric acid cycle.&Aspartic acid supplementation allows the urea cycle to proceed and reduces the ammonia level.&One patient reportedly was successfully treated with a continuous nocturnal gastric drip feeding of uncooked cornstarch.','Image\\BONE & MUSCLE DISEASE\\5.jpg','BONE & MUSCLE DISEASE','Intrinsic',NULL),('OMIM:222700','LYSINURIC PROTEIN INTOLERANCE','SLC7A7 (9056)','\"SLC7A7\",\"603593\"','Caused by mutation in the solute carrier family 7 (cationic amino acid transporter, y+ system), member 7 gene (SLC7A7, 603593.0001)','Treatment revolves around protein-restricted diet and supplement of lysine, ornithine, and citrulline. The complication of pulmonary alveolar proteinosis has been reported to be successfully treated by whole lung lavage','Image\\LIVER & KIDENEY DISEASE\\6.jpg','LIVER & KIDENEY DISEASE','Intrinsic',NULL),('OMIM:121300','COPROPORPHYRIA,HEREDITARY','CPOX (1371),HMBS (3145),PPOX (5498),ALAD (210),FECH (2235),UROD (7389),UROS (7390),PCBD1 (5092),SPOCK1 (6695)   ','\"CPOX - Harderoporphyria\",\"612732\"&\"CPOX - Coproporphyria\",\"612732\"','Caused by mutation in the coproporphyrinogen oxidase gene (CPO, 612732.0001)','The goals in managing an acute attack of porphyria are to decrease heme synthesis and to reduce the production of porphyrin precursors.&High oral doses of glucose (400 g/d) can inhibit heme synthesis and are useful for the treatment of mild attacks. Intravenous glucose solutions (eg, 5% or 10% dextrose in water) can be used in patients who cannot eat, but may aggravate hyponatremia.&Nausea and vomiting - Prochloperazine, promazine, or ondansetron&Severe agitation and anxiety - Chlorpromazine','Image\\SKIN DISEASE\\7.jpg','SKIN DISEASE','Intrinsic',NULL),('OMIM:251290','BAND-LIKE CALCIFICATION WITH SIMPLIFIED GYRATION AND POLYMICROGYRIA','OCLN (100506658),USP18 (11274),JAM3 (83700),COL4A1 (1282),DKC1 (1736),IFNA1 (3439)  ','\"OCLN\",\"602876\"','Caused by mutation in the occludin gene (OCLN, 602876.0001)',NULL,'Image\\BRAIN DISEASE\\8.jpg','BRAIN DISEASE','Intrinsic',NULL),('OMIM:230900','GAUCHER DISEASE,TYPE II','GBA (2629),PSAP (5660)','\"GBA\",\"606463\"',NULL,'Treating Gaucher disease minimizes symptoms and permanent damage to your body. There are two types of Gaucher disease treatments currently available: enzyme replacement therapy (ERT) and substrate reduction therapy (SRT).','Image\\BRAIN DISEASE\\9.jpg','BRAIN DISEASE','Intrinsic',NULL),('OMIM:201100','ACRODERMATITIS ENTEROPATHICA,ZINC-DEFICIENCY TYPE','SLC39A4 (55630),SLC39A4 (55630),SLC30A4 (7782),ALB (213),PLIN2 (123),OTC (5009),SLC30A2 (7780),SLC39A5 (283375)   ','\"SLC39A4\",\"607059\"',NULL,'Warm compresses to remove the scale crust, followed by application of white petrolatum to eroded skin lesions, may enhance reepithelialization when used concurrently with zinc replacement.&Warm compresses and petrolatum applied 3 times a day to areas of weeping or crusted dermatitis may enhance re-epithelialization when used concurrently with zinc replacement.','Image\\SKIN DISEASE\\10.jpg','SKIN DISEASE','Intrinsic',NULL),('OMIM:233700','GRANULOMATOUS DISEASE,CHRONIC,AUTOSOMAL RECESSIVE,CYTOCHROME B-POSITIVE,TYPE I','NCF1 (653361),NCF4 (4689),CYBB (1536),CYBA (1535),NCF2 (4688),NCF1 (653361),IFNG (3458),MT-CYB (4519),MPO (4353)   ','\"NCF1\",\"608512\"&\"CYBB\",\"300481\"',NULL,'Patients with superficial or deep infections (vs those with obstructing granulomas) should receive aggressive antibiotics; the initial route is parenteral. Treatment usually requires antibiotic coverage for several weeks and should be associated with clear physical signs of resolution and systemic improvement (eg, decreased WBC count and decreased erythrocyte sedimentation rate if elevated at presentation).&Ciprofloxacin with or without additional drug for staphylococcal infection is a common first choice in patients with chronic granulomatous disease. If no response is noted within the first 24-48 hours, coverage should be broadened to include additional antistaphylococcal agents (including coverage for methicillin-resistant Staphylococcus aureus), gram-negative possibilities, and Nocardia species.','Image\\BONE & MUSCLE DISEASE\\11.jpg','BONE & MUSCLE DISEASE','Intrinsic',NULL),('OMIM:276700','TYROSINEMIA,TYPE I','FAH (2184),GSTZ1 (2954),HPD (3242),ALAD (210),AFP (174),CYCS (54205)        ','\"FAH\",\"613871\"','Caused by mutation in the fumarylacetoacetase gene (FAH, 613871.0001)','There is currently no cure for tyrosinemia type 1. Individuals with this condition need to be on a special diet restricted in two amino acids, tyrosine and phenylalanine, throughout life. Affected individuals may also be treated with a medication called nitisinone. Early diagnosis and prompt treatment are essential for an improved prognosis. ','Image\\SKIN DISEASE\\12.jpg','SKIN DISEASE','Intrinsic',NULL),('OMIM:607624','GRISCELLI SYNDROME,TYPE 2','RAB27A (5873),UNC13D (201294),MLPH (79083),MYO5A (4644),CCL5 (6352),AGFG1 (3267)      ','\"RAB27A\",\"603868\"',' Caused by mutations in the Ras-associated protein RAB27A gene (RAB27A, 603868.0001)','Medical treatment of patients with Griscelli syndrome is difficult. The only real treatment for the hemophagocytic lymphohistiocytosis syndromes of which Griscelli syndrome is a part is stem cell transplantation. For patients with defects in RAB27A, antibiotics and antiviral agents are used with mixed effects. Similarly, medications may not control the neurologic symptoms of the disease.','Image\\SKIN DISEASE\\13.jpg','SKIN DISEASE','Intrinsic',NULL),('OMIM:614887','PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)','PEX14 (5195),HSD17B4 (3295),PEX1 (5189),PEX3 (8504),PEX7 (5191),PEX2 (5828),PEX1 (5189)     ','\"PEX14\",\"601791\"',NULL,'The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition.cholic acid (Brand name: Cholbam) - Manufactured by Asklepion Pharmaceuticals, LLC&FDA-approved indication: Treatment of bile acid synthesis disorders due to single enzyme defects and as adjunctive treatment of peroxisomal disorders including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from d','Image\\BONE & MUSCLE DISEASE\\14.jpg','BONE & MUSCLE DISEASE','Intrinsic',NULL),('OMIM:611721','COMBINED SAPOSIN DEFICIENCY','PSAP (5660)','\"PSAP\",\"176801\"','Caused by mutation in the prosaposin gene (PSAP, 176801.0005)','The diagnosis in the present SapB-d patient was complicated by the early finding of a massive infarction of the left arteria cerebri media, presumably coincidental to the leukodystrophy. However, the finding of high urinary sulfatide eventually led to a molecular diagnosis of SapB-d. ','Image\\BRAIN DISEASE\\15.jpg','BRAIN DISEASE','Intrinsic',NULL),('OMIM:611721','COMBINED SAPOSIN DEFICIENCY','PSAP (5660)','\"PSAP\",\"176801\"','Caused by mutation in the prosaposin gene (PSAP, 176801.0005)','The diagnosis in the present SapB-d patient was complicated by the early finding of a massive infarction of the left arteria cerebri media, presumably coincidental to the leukodystrophy. However, the finding of high urinary sulfatide eventually led to a molecular diagnosis of SapB-d. ','Image\\BRAIN DISEASE\\15.jpg','BRAIN DISEASE','Intrinsic',NULL),('OMIM:610678','COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4','TUFM (7284)','\"TUFM\",\"602389\"','caused by defects in the mitochondrial oxidative phosphorylationdue to protein mistranslation, leading to a failure to assemble adequate amounts of three oxidative phosphorylationcomplexes.','No Treatment / medicine available','Image\\BONE & MUSCLE DISEASE\\17.jpg','BONE & MUSCLE DISEASE','Intrinsic',NULL),('OMIM:216360','COACH SYNDROME','CC2D2A (57545),TMEM67 (91147),RPGRIP1L (23322),INPP5E (56623)  ','\"CC2D2A\",\"612013\"&\"TMEM67\",\"609884\"&\"RPGRIP1L\",\"610937\"','Caused by mutation in the transmembrane protein 67 gene (TMEM67, 609884.0013)&Caused by mutation in the coiled-coil and C2 domains-containing protein 2A gene (CC2D2A, 612013.0006)&Caused by mutation in the RPGRIP1-like gene (RPGRIP1L, 610937.0011)','The main clinical problem for patients with COACH syndrome is progressive portal hypertension and liver failure. Treatment aims to reduce symptoms and prevent complications.','Image\\BRAIN DISEASE\\18.jpg','BRAIN DISEASE','Intrinsic',NULL),('OMIM:231005','GAUCHER DISEASE,TYPE IIIC','GBA (2629)','\"GBA\",\"606463\"','Caused by mutation in the acid beta-glucosidase gene (GBA, 606463.0006)','The treatment for patients with GD type 3 exhibiting clinically significant non neurological manifestations is enzyme substitution therapy (imiglucerase with marketing authorization (MA) since 1997). It appears to slow progression of the neurological symptoms and is effective against the systemic manifestations.','Image\\BONE & MUSCLE DISEASE\\19.JPG','BONE & MUSCLE DISEASE','Intrinsic',NULL),('OMIM:232220','GLYCOGEN STORAGE DISEASE IB','SLC37A4 (2542)','\"SLC37A4\",\"602671\"','Caused by mutation in the glucose-6-phosphate transporter 1 gene (G6PT1, 602671.0001)','Treatment varies depending on the type of GSD. For types of GSD that involve the liver, treatment is aimed at keeping the right level of glucose in the blood. This is often enough to maintain the cells fuel needs and prevent long-term complications associated with poorly controlled GSD. Treatment consists of taking regular doses of uncooked cornstarch and/or nutrition supplements. Cornstarch is a complex carbohydrate that is difficult for the body to digest; therefore it maintains normal blood sugar levels  normal while preventing excess glycogen storage in the liver.','Image\\LIVER & KIDENEY DISEASE\\20.jpg','LIVER & KIDENEY DISEASE','Intrinsic',NULL),('OMIM:154800','MAST CELL DISEASE','KIT (3815),IFNA2 (3440),MITF (4286),MPO (4353),ITGB1 (3688),SYT1 (6857),CD44 (960),BMP6 (654)       ','\"KIT\",\"164920\"','Mastocytosis is a disorder that can occur in both children and adults. It is caused by the presence of too many mast cells in your body.','kin and bone marrow biopsies, 1. Measurement of mast cell mediators in blood and urine,2.Blood count, 3.Liver function studies, 4.Genetic tests, Antihistamines are commonly used. Cromolyn sodium, ketotifen and leukotriene-modifying agents are additional medications which may provide benefit. Epinephrine may be required to treat episodes of low blood pressure.','Image\\SKIN DISEASE\\21.jpg','SKIN DISEASE','Intrinsic',NULL),('OMIM:219700','CYSTIC FIBROSIS','CFTR (1080),TGFB1 (7040),FCGR2A (2212),DNASE1 (1773),S100A8 (6279),SLC9A3R1 (9368),CLCA1 (1179),DEFB1 (1672),CLCA4 (22802)     ','\"FCGR2A\",\"146790\"&\"CFTR\",\"602421\"&\"TGFB1\",\"190180\"','Caused by mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR, 602421.0001)','There is no cure for cystic fibrosis, but treatment can ease symptoms and reduce complications.&Antibiotics to treat and prevent lung infections&Anti-inflammatory medications to lessen swelling in the airways in your lungs&Mucus-thinning drugs to help you cough up the mucus, which can improve lung function&Inhaled medications called bronchodilators that can help keep your airways open by relaxing the muscles around your bronchial tubes&Oral pancreatic enzymes to help your digestive tract absorb nutrients','Image\\RESPIRATION DISEASE\\22.jpeg','RESPIRATION DISEASE','Intrinsic',NULL),('OMIN:173900','POLYCYSTIC KIDNEY DISEASE','UMOD (7369),PKD1 (5310),HNF1B (6928),TSC2 (7249),NPHP1 (4867),INVS (27130),MUC1 (4582),NPHP4 (261734) ','\"PKD1\",\"601313\"','Caused by different genetic flaws: Autosomal dominant polycystic kidney disease (ADPKD) and Autosomal recessive polycystic kidney disease (ARPKD).','Some of the treatment options may include: 1.pain medication, except Ibuprofen, which is not recommended as it may worsen kidney disease, 2.blood pressure medication, 3.antibiotics to treat UTIs, 4.a low sodium diet, 5.diuretics to help remove excess fluid from the body, 6.surgery to drain cysts and help relieve discomfort',NULL,NULL,'Intrinsic',NULL),('OMIN:253300','Spinal Muscular Atrophy-1 (SMA1)','SMN1 (6606),IGHMBP2 (3508),NAIP (4671),SMN2 (6607),SCO2 (9997),SYP (6855),COX14 (84987),VRK1 (7443),FKTN (2218),ZPR1 (8882)  ',NULL,NULL,'Acetylcholine & abobotulinumtoxinA & Botulinum Toxins & Botulinum Toxins, Type A & Cholinergic Agents',NULL,NULL,'Intrinsic',NULL),('OMIN:253550','Spinal Muscular Atrophy-2','SMN1 (6606),SMN2 (6607),NAIP (4671),NCAM1 (4684)',NULL,NULL,'Hydroxyurea & 4-Aminopyridine & Riluzole & Nucleic Acid Synthesis Inhibitors & Neuroprotective Agents',NULL,NULL,'Intrinsic',NULL),('OMIN:182980','Spinal Muscular Atrophy-4 ','SMN1 (6606),SMN2 (6607) ,COL6A1 (1291),MSTN (2660),VAPB (9217),PLEKHG5 (57449), FST (10468)',NULL,NULL,NULL,NULL,NULL,'Intrinsic',NULL),(NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),('OMIM:130650','BECKWITH-WIEDEMANN SYNDROME','NSD1 (64324),CDKN1C (1028),H19 (283120),KCNQ1OT1 (10984),H19-ICR (105259599),NAP1L4 (4676),PHLDA2 (7262),IGF2(3481)  ','\"ICR1 A maternally inherited point mutation was identified in ICR1 in both IGF2  & H19  which altered binding of OCT transcription factors\",\"616186\"&\"H19\",\"103280\"&\"KCNQ1OT1\",\"604115\"&\"CDKN1C\",\"600856\"','Caused by mutation in the cyclin-dependent kinase inhibitor 1C gene (CDKN1C, 600856.0001)&Caused by mutation in the nuclear receptor binding SET domain protein 1 (NSD1, 606681.0011)& Caused by mutation in the KCNQ1-overlapping transcript 1 gene (KCNQ1OT1, 604115.0001)&Caused by contiguous gene duplication of imprinted region of 11p15.5&Caused by contiguous gene deletion of imprinted region of 11p15.5 ','1. Patients with Beckwith-Wiedemann syndrome (BWS) may require frequent feedings or diazoxide to treat their hypoglycemia. 2. Infants and children must demonstrate the ability to maintain euglycemia during a fast of age-appropriate duration. The normal duration of fasting for an infant or child depends on body mass and the maturity of counterregulatory responses to hypoglycemia, which include gluconeogenesis, glycogenolysis, and ketogenesis.','Image\\BONE & MUSCLE DISEASE\\1.jpg','BONE & MUSCLE DISEASE','Extrinsic',NULL),('OMIM:613812','BILE ACID SYNTHESIS DEFECT,CONGENITAL,3','CYP7B1 (9420)','\"CYP7B1   gene with protein product: Entrez Gene: 9420 C, Ensembl: ENSG00000172817 C Vega: OTTHUMG00000164387 C, UCSC: uc003xvj.3 D, Protein Resource : O75881 D\",\"603711\"&\"Cholesterol degradation to bile acids in the liver can be initiated by either cholesterol 7a-hydroxylase (CYP7A1) of the classic (neutral) pathway, or by mitochondrial sterol 27-hydroxylase (CYP27A1) of the alternative (or acidic) pathway.\" ',NULL,'Diagnosis is based on serum hepatic enzyme and bilirubin profile, and analysis of urine, serum and bile using liquid secondary ionization mass spectrometry (LSIMS) and gas chromatography - mass spectrometry (GC-MS).','Image\\LIVER & KIDENEY DISEASE\\2.jpg','LIVER & KIDENEY DISEASE','Extrinsic',NULL),('OMIM:615085,259700,259710,611490    ','OSTEOPETROSIS,AUTOSOMAL RECESSIVE 8','SNX10 (29887)','\"SNX10\",\"614780\"',NULL,'Patients may require blood transfusions, treatment for infections and management of their developmental and visual problems. Bone marrow transplant can alleviate many features of the disease but needs to be performed early to minimise optic nerve encroachment.','Image\\BONE & MUSCLE DISEASE\\3.jpg','BONE & MUSCLE DISEASE','Extrinsic',NULL),('OMIM:604273','MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY,NUCLEAR TYPE 1; MC5DN1','ATPAF2 (91647),DNAH8 (1769)','\"ATPAF2,ATP12 Homolog,ATP12p,LP3663,MC5DN1\",\"608918\"',' Caused by mutation in the transmembrane protein 70 gene (TMEM70, 612418.0001) - Caused by mutation in the ATP synthase F1 complex assembly factor-2 gene (ATPAF2, 608918.0001)',NULL,'Image\\OTHERS\\4.jpg','OTHERS','Extrinsic',NULL),('OMIM:266150','PYRUVATE CARBOXYLASE DEFICIENCY','PC (5091)','\"PC\",\"608786\"',NULL,'Treatments in patients with pyruvate carboxylase deficiency (PCD) are aimed at stimulating the pyruvate dehydrogenase complex (PDC) and providing alternative fuels. Correction of the biochemical abnormality can reverse some symptoms, but central nervous system damage progresses regardless of treatment.&The PDC can provide an alternative pathway for pyruvate metabolism PDC activity can be optimized by cofactor supplementation with thiamine and lipoic acid and administration of dichloroacetate. Increased pyruvate metabolism through this pathway can help reduce the pyruvate and lactate levels.&Biotin supplementation is given to help optimize the residual enzyme activity but is usually of little use.&Citrate supplementation reduces the acidosis and provides the needed substrate in the citric acid cycle.&Aspartic acid supplementation allows the urea cycle to proceed and reduces the ammonia level.&One patient reportedly was successfully treated with a continuous nocturnal gastric drip feeding of uncooked cornstarch.','Image\\BONE & MUSCLE DISEASE\\5.jpg','BONE & MUSCLE DISEASE','Extrinsic',NULL),('OMIM:222700','LYSINURIC PROTEIN INTOLERANCE','SLC7A7 (9056)','\"SLC7A7\",\"603593\"','Caused by mutation in the solute carrier family 7 (cationic amino acid transporter, y+ system), member 7 gene (SLC7A7, 603593.0001)','Treatment revolves around protein-restricted diet and supplement of lysine, ornithine, and citrulline. The complication of pulmonary alveolar proteinosis has been reported to be successfully treated by whole lung lavage','Image\\LIVER & KIDENEY DISEASE\\6.jpg','LIVER & KIDENEY DISEASE','Extrinsic',NULL),('OMIM:121300','COPROPORPHYRIA,HEREDITARY','CPOX (1371),HMBS (3145),PPOX (5498),ALAD (210),FECH (2235),UROD (7389),UROS (7390),PCBD1 (5092),SPOCK1 (6695)   ','\"CPOX - Harderoporphyria\",\"612732\"&\"CPOX - Coproporphyria\",\"612732\"','Caused by mutation in the coproporphyrinogen oxidase gene (CPO, 612732.0001)','The goals in managing an acute attack of porphyria are to decrease heme synthesis and to reduce the production of porphyrin precursors.&High oral doses of glucose (400 g/d) can inhibit heme synthesis and are useful for the treatment of mild attacks. Intravenous glucose solutions (eg, 5% or 10% dextrose in water) can be used in patients who cannot eat, but may aggravate hyponatremia.&Nausea and vomiting - Prochloperazine, promazine, or ondansetron&Severe agitation and anxiety - Chlorpromazine','Image\\SKIN DISEASE\\7.jpg','SKIN DISEASE','Extrinsic',NULL),('OMIM:251290','BAND-LIKE CALCIFICATION WITH SIMPLIFIED GYRATION AND POLYMICROGYRIA','OCLN (100506658),USP18 (11274),JAM3 (83700),COL4A1 (1282),DKC1 (1736),IFNA1 (3439)  ','\"OCLN\",\"602876\"','Caused by mutation in the occludin gene (OCLN, 602876.0001)',NULL,'Image\\BRAIN DISEASE\\8.jpg','BRAIN DISEASE','Extrinsic',NULL),('OMIM:230900','GAUCHER DISEASE,TYPE II','GBA (2629),PSAP (5660)','\"GBA\",\"606463\"',NULL,'Treating Gaucher disease minimizes symptoms and permanent damage to your body. There are two types of Gaucher disease treatments currently available: enzyme replacement therapy (ERT) and substrate reduction therapy (SRT).','Image\\BRAIN DISEASE\\9.jpg','BRAIN DISEASE','Extrinsic',NULL),('OMIM:201100','ACRODERMATITIS ENTEROPATHICA,ZINC-DEFICIENCY TYPE','SLC39A4 (55630),SLC39A4 (55630),SLC30A4 (7782),ALB (213),PLIN2 (123),OTC (5009),SLC30A2 (7780),SLC39A5 (283375)   ','\"SLC39A4\",\"607059\"',NULL,'Warm compresses to remove the scale crust, followed by application of white petrolatum to eroded skin lesions, may enhance reepithelialization when used concurrently with zinc replacement.&Warm compresses and petrolatum applied 3 times a day to areas of weeping or crusted dermatitis may enhance re-epithelialization when used concurrently with zinc replacement.','Image\\SKIN DISEASE\\10.jpg','SKIN DISEASE','Extrinsic',NULL),('OMIM:233700','GRANULOMATOUS DISEASE,CHRONIC,AUTOSOMAL RECESSIVE,CYTOCHROME B-POSITIVE,TYPE I','NCF1 (653361),NCF4 (4689),CYBB (1536),CYBA (1535),NCF2 (4688),NCF1 (653361),IFNG (3458),MT-CYB (4519),MPO (4353)   ','\"NCF1\",\"608512\"&\"CYBB\",\"300481\"',NULL,'Patients with superficial or deep infections (vs those with obstructing granulomas) should receive aggressive antibiotics; the initial route is parenteral. Treatment usually requires antibiotic coverage for several weeks and should be associated with clear physical signs of resolution and systemic improvement (eg, decreased WBC count and decreased erythrocyte sedimentation rate if elevated at presentation).&Ciprofloxacin with or without additional drug for staphylococcal infection is a common first choice in patients with chronic granulomatous disease. If no response is noted within the first 24-48 hours, coverage should be broadened to include additional antistaphylococcal agents (including coverage for methicillin-resistant Staphylococcus aureus), gram-negative possibilities, and Nocardia species.','Image\\BONE & MUSCLE DISEASE\\11.jpg','BONE & MUSCLE DISEASE','Extrinsic',NULL),('OMIM:276700','TYROSINEMIA,TYPE I','FAH (2184),GSTZ1 (2954),HPD (3242),ALAD (210),AFP (174),CYCS (54205)        ','\"FAH\",\"613871\"','Caused by mutation in the fumarylacetoacetase gene (FAH, 613871.0001)','There is currently no cure for tyrosinemia type 1. Individuals with this condition need to be on a special diet restricted in two amino acids, tyrosine and phenylalanine, throughout life. Affected individuals may also be treated with a medication called nitisinone. Early diagnosis and prompt treatment are essential for an improved prognosis. ','Image\\SKIN DISEASE\\12.jpg','SKIN DISEASE','Extrinsic',NULL),('OMIM:607624','GRISCELLI SYNDROME,TYPE 2','RAB27A (5873),UNC13D (201294),MLPH (79083),MYO5A (4644),CCL5 (6352),AGFG1 (3267)      ','\"RAB27A\",\"603868\"',' Caused by mutations in the Ras-associated protein RAB27A gene (RAB27A, 603868.0001)','Medical treatment of patients with Griscelli syndrome is difficult. The only real treatment for the hemophagocytic lymphohistiocytosis syndromes of which Griscelli syndrome is a part is stem cell transplantation. For patients with defects in RAB27A, antibiotics and antiviral agents are used with mixed effects. Similarly, medications may not control the neurologic symptoms of the disease.','Image\\SKIN DISEASE\\13.jpg','SKIN DISEASE','Extrinsic',NULL),('OMIM:614887','PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)','PEX14 (5195),HSD17B4 (3295),PEX1 (5189),PEX3 (8504),PEX7 (5191),PEX2 (5828),PEX1 (5189)     ','\"PEX14\",\"601791\"',NULL,'The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition.cholic acid (Brand name: Cholbam) - Manufactured by Asklepion Pharmaceuticals, LLC&FDA-approved indication: Treatment of bile acid synthesis disorders due to single enzyme defects and as adjunctive treatment of peroxisomal disorders including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from d','Image\\BONE & MUSCLE DISEASE\\14.jpg','BONE & MUSCLE DISEASE','Extrinsic',NULL),('OMIM:611721','COMBINED SAPOSIN DEFICIENCY','PSAP (5660)','\"PSAP\",\"176801\"','Caused by mutation in the prosaposin gene (PSAP, 176801.0005)','The diagnosis in the present SapB-d patient was complicated by the early finding of a massive infarction of the left arteria cerebri media, presumably coincidental to the leukodystrophy. However, the finding of high urinary sulfatide eventually led to a molecular diagnosis of SapB-d. ','Image\\BRAIN DISEASE\\15.jpg','BRAIN DISEASE','Extrinsic',NULL),('OMIM:611721','COMBINED SAPOSIN DEFICIENCY','PSAP (5660)','\"PSAP\",\"176801\"','Caused by mutation in the prosaposin gene (PSAP, 176801.0005)','The diagnosis in the present SapB-d patient was complicated by the early finding of a massive infarction of the left arteria cerebri media, presumably coincidental to the leukodystrophy. However, the finding of high urinary sulfatide eventually led to a molecular diagnosis of SapB-d. ','Image\\BRAIN DISEASE\\15.jpg','BRAIN DISEASE','Extrinsic',NULL),('OMIM:610678','COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4','TUFM (7284)','\"TUFM\",\"602389\"','caused by defects in the mitochondrial oxidative phosphorylationdue to protein mistranslation, leading to a failure to assemble adequate amounts of three oxidative phosphorylationcomplexes.','No Treatment / medicine available','Image\\BONE & MUSCLE DISEASE\\17.jpg','BONE & MUSCLE DISEASE','Extrinsic',NULL),('OMIM:216360','COACH SYNDROME','CC2D2A (57545),TMEM67 (91147),RPGRIP1L (23322),INPP5E (56623)  ','\"CC2D2A\",\"612013\"&\"TMEM67\",\"609884\"&\"RPGRIP1L\",\"610937\"','Caused by mutation in the transmembrane protein 67 gene (TMEM67, 609884.0013)&Caused by mutation in the coiled-coil and C2 domains-containing protein 2A gene (CC2D2A, 612013.0006)&Caused by mutation in the RPGRIP1-like gene (RPGRIP1L, 610937.0011)','The main clinical problem for patients with COACH syndrome is progressive portal hypertension and liver failure. Treatment aims to reduce symptoms and prevent complications.','Image\\BRAIN DISEASE\\18.jpg','BRAIN DISEASE','Extrinsic',NULL),('OMIM:231005','GAUCHER DISEASE,TYPE IIIC','GBA (2629)','\"GBA\",\"606463\"','Caused by mutation in the acid beta-glucosidase gene (GBA, 606463.0006)','The treatment for patients with GD type 3 exhibiting clinically significant non neurological manifestations is enzyme substitution therapy (imiglucerase with marketing authorization (MA) since 1997). It appears to slow progression of the neurological symptoms and is effective against the systemic manifestations.','Image\\BONE & MUSCLE DISEASE\\19.JPG','BONE & MUSCLE DISEASE','Extrinsic',NULL),('OMIM:232220','GLYCOGEN STORAGE DISEASE IB','SLC37A4 (2542)','\"SLC37A4\",\"602671\"','Caused by mutation in the glucose-6-phosphate transporter 1 gene (G6PT1, 602671.0001)','Treatment varies depending on the type of GSD. For types of GSD that involve the liver, treatment is aimed at keeping the right level of glucose in the blood. This is often enough to maintain the cells fuel needs and prevent long-term complications associated with poorly controlled GSD. Treatment consists of taking regular doses of uncooked cornstarch and/or nutrition supplements. Cornstarch is a complex carbohydrate that is difficult for the body to digest; therefore it maintains normal blood sugar levels  normal while preventing excess glycogen storage in the liver.','Image\\LIVER & KIDENEY DISEASE\\20.jpg','LIVER & KIDENEY DISEASE','Extrinsic',NULL),('OMIM:154800','MAST CELL DISEASE','KIT (3815),IFNA2 (3440),MITF (4286),MPO (4353),ITGB1 (3688),SYT1 (6857),CD44 (960),BMP6 (654)       ','\"KIT\",\"164920\"','Mastocytosis is a disorder that can occur in both children and adults. It is caused by the presence of too many mast cells in your body.','kin and bone marrow biopsies, 1. Measurement of mast cell mediators in blood and urine,2.Blood count, 3.Liver function studies, 4.Genetic tests, Antihistamines are commonly used. Cromolyn sodium, ketotifen and leukotriene-modifying agents are additional medications which may provide benefit. Epinephrine may be required to treat episodes of low blood pressure.','Image\\SKIN DISEASE\\21.jpg','SKIN DISEASE','Extrinsic',NULL),('OMIM:219700','CYSTIC FIBROSIS','CFTR (1080),TGFB1 (7040),FCGR2A (2212),DNASE1 (1773),S100A8 (6279),SLC9A3R1 (9368),CLCA1 (1179),DEFB1 (1672),CLCA4 (22802)     ','\"FCGR2A\",\"146790\"&\"CFTR\",\"602421\"&\"TGFB1\",\"190180\"','Caused by mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR, 602421.0001)','There is no cure for cystic fibrosis, but treatment can ease symptoms and reduce complications.&Antibiotics to treat and prevent lung infections&Anti-inflammatory medications to lessen swelling in the airways in your lungs&Mucus-thinning drugs to help you cough up the mucus, which can improve lung function&Inhaled medications called bronchodilators that can help keep your airways open by relaxing the muscles around your bronchial tubes&Oral pancreatic enzymes to help your digestive tract absorb nutrients','Image\\RESPIRATION DISEASE\\22.jpeg','RESPIRATION DISEASE','Extrinsic',NULL),('OMIN:173900','POLYCYSTIC KIDNEY DISEASE','UMOD (7369),PKD1 (5310),HNF1B (6928),TSC2 (7249),NPHP1 (4867),INVS (27130),MUC1 (4582),NPHP4 (261734) ','\"PKD1\",\"601313\"','Caused by different genetic flaws: Autosomal dominant polycystic kidney disease (ADPKD) and Autosomal recessive polycystic kidney disease (ARPKD).','Some of the treatment options may include: 1.pain medication, except Ibuprofen, which is not recommended as it may worsen kidney disease, 2.blood pressure medication, 3.antibiotics to treat UTIs, 4.a low sodium diet, 5.diuretics to help remove excess fluid from the body, 6.surgery to drain cysts and help relieve discomfort',NULL,NULL,'Extrinsic',NULL),('OMIN:253300','Spinal Muscular Atrophy-1 (SMA1)','SMN1 (6606),IGHMBP2 (3508),NAIP (4671),SMN2 (6607),SCO2 (9997),SYP (6855),COX14 (84987),VRK1 (7443),FKTN (2218),ZPR1 (8882)  ',NULL,NULL,'Acetylcholine & abobotulinumtoxinA & Botulinum Toxins & Botulinum Toxins, Type A & Cholinergic Agents',NULL,NULL,'Extrinsic',NULL),('OMIN:253550','Spinal Muscular Atrophy-2','SMN1 (6606),SMN2 (6607),NAIP (4671),NCAM1 (4684)',NULL,NULL,'Hydroxyurea & 4-Aminopyridine & Riluzole & Nucleic Acid Synthesis Inhibitors & Neuroprotective Agents',NULL,NULL,'Extrinsic',NULL),('OMIN:182980','Spinal Muscular Atrophy-4 ','SMN1 (6606),SMN2 (6607) ,COL6A1 (1291),MSTN (2660),VAPB (9217),PLEKHG5 (57449), FST (10468)',NULL,NULL,NULL,NULL,NULL,'Extrinsic',NULL),(NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL);

UNLOCK TABLES;

/*Table structure for table `mf` */

DROP TABLE IF EXISTS `mf`;

CREATE TABLE `mf` (
  `disease` varchar(10000) DEFAULT NULL,
  `miRNA` varchar(10000) DEFAULT NULL,
  `name` varchar(10000) DEFAULT NULL,
  `goid` varchar(10000) DEFAULT NULL,
  `score` varchar(10000) DEFAULT NULL,
  `affiliating gene` varchar(10000) DEFAULT NULL,
  `did` varchar(2000) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

/*Data for the table `mf` */

LOCK TABLES `mf` WRITE;

insert  into `mf`(`disease`,`miRNA`,`name`,`goid`,`score`,`affiliating gene`,`did`) values ('LYSINURIC PROTEIN INTOLERANCE','SLC7A7 Gene : The protein encoded by this gene is the light subunit of a cationic amino acid transporter. This sodium-independent transporter is formed when the light subunit encoded by this gene dimerizes with the heavy subunit transporter protein SLC3A2. This transporter is found in epithelial cell membranes where it transfers cationic and large neutral amino acids from the cell to the extracellular space. Defects in this gene are a cause of lysinuric protein intolerance (LPI).','catalytic activity','GO:0003824','9.58','ASL(435), SLC3A1(6519), SLC3A2(6520)','OMIM:222700'),('LYSINURIC PROTEIN INTOLERANCE','SLC7A7 Gene : The protein encoded by this gene is the light subunit of a cationic amino acid transporter. This sodium-independent transporter is formed when the light subunit encoded by this gene dimerizes with the heavy subunit transporter protein SLC3A2. This transporter is found in epithelial cell membranes where it transfers cationic and large neutral amino acids from the cell to the extracellular space. Defects in this gene are a cause of lysinuric protein intolerance (LPI).','neutral amino acid transmembrane transporter activity','GO:0015175','9.5','SLC3A2(6520), SLC7A5(8140), SLC7A8(23428)','OMIM:222700'),('LYSINURIC PROTEIN INTOLERANCE','SLC7A7 Gene : The protein encoded by this gene is the light subunit of a cationic amino acid transporter. This sodium-independent transporter is formed when the light subunit encoded by this gene dimerizes with the heavy subunit transporter protein SLC3A2. This transporter is found in epithelial cell membranes where it transfers cationic and large neutral amino acids from the cell to the extracellular space. Defects in this gene are a cause of lysinuric protein intolerance (LPI).','antiporter activity','GO:0015297','9.46','SLC7A5(8140), SLC7A6(9057), SLC7A7(9056), SLC7A8(23428)','OMIM:222700'),('LYSINURIC PROTEIN INTOLERANCE','SLC7A7 Gene : The protein encoded by this gene is the light subunit of a cationic amino acid transporter. This sodium-independent transporter is formed when the light subunit encoded by this gene dimerizes with the heavy subunit transporter protein SLC3A2. This transporter is found in epithelial cell membranes where it transfers cationic and large neutral amino acids from the cell to the extracellular space. Defects in this gene are a cause of lysinuric protein intolerance (LPI).','basic amino acid transmembrane transporter activity','GO:0015174','9.43','SLC3A1(6519), SLC7A2(6542), SLC7A7(9056)','OMIM:222700'),('LYSINURIC PROTEIN INTOLERANCE','SLC7A7 Gene : The protein encoded by this gene is the light subunit of a cationic amino acid transporter. This sodium-independent transporter is formed when the light subunit encoded by this gene dimerizes with the heavy subunit transporter protein SLC3A2. This transporter is found in epithelial cell membranes where it transfers cationic and large neutral amino acids from the cell to the extracellular space. Defects in this gene are a cause of lysinuric protein intolerance (LPI).','peptide antigen binding','GO:0042605','9.37','SLC7A5(8140), SLC7A8(23428)','OMIM:222700'),('COPROPORPHYRIA, HEREDITARY','miR-217 and miR-377 in combination were found to attenuate HMOX1 protein expression, whereas knockdown of miR-217 and miR-377 up-regulates HMOX1 protein, but exhibits no alteration in HMOX1 mRNA levels, suggesting that the regulation occurs at the translational level','lyase activity','GO:0016829','9.02','ALAD(210), FECH(2235), PCBD1(5092), UROD(7389), UROS(7390)','OMIM:121300'),('COPROPORPHYRIA, HEREDITARY','miR-217 and miR-377 in combination were found to attenuate HMOX1 protein expression, whereas knockdown of miR-217 and miR-377 up-regulates HMOX1 protein, but exhibits no alteration in HMOX1 mRNA levels, suggesting that the regulation occurs at the translational level','5-aminolevulinate synthase activity','GO:0003870','8.96','ALAS1(211), ALAS2(212)','OMIM:121300'),('Acrodermatitis Enteropathica',NULL,'cation transmembrane transporter activity','GO:0008324','9.16','SLC30A2(7780), SLC30A4(7782)','OMIM:201100'),('Acrodermatitis Enteropathica',NULL,'metal ion transmembrane transporter activity','GO:0046873','8.96','SLC39A4(7782), SLC39A5(283375)','OMIM:201100'),('Acrodermatitis Enteropathica',NULL,'zinc ion transmembrane transporter activity','GO:0005385','8.92','SLC30A2(7780), SLC30A4(7782), SLC39A4(7782), SLC39A5(283375)','OMIM:201100'),('GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-POSITIVE,TYPE I',NULL,'oxidoreductase activity','GO:0016491','9.87','CAT(847), CYBA(1535), CYBB(1536), DECR1(1666), MPO(4353), MT-CYB(4519)','OMIM:233700'),('GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-POSITIVE,TYPE I',NULL,'cytokine activity','GO:0005125','9.67','CSF2(1437), CSF3(1440), IFNG(3458), IL1B(3553)','OMIM:233700'),('GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-POSITIVE,TYPE I',NULL,'heme binding','GO:0020037','9.65','CAT(847), CYBA(1535), CYBB(1536), HBG2(3048), MPO(4353)','OMIM:233700'),('GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-POSITIVE,TYPE I',NULL,'phosphatidylinositol binding','GO:0035091','9.58','NCF1(653361), NCF1C(654817), NCF4(4689)','OMIM:233700'),('GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME B-POSITIVE,TYPE I',NULL,'electron carrier activity','GO:0009055','9.55','CYBA(1535), CYBB(1536), MT-CYB(4519), NCF1(653361), NCF2(4688)','OMIM:233700'),('Tyrosinemia, Type I',NULL,'metal ion binding','GO:0046872','9.1','AFP(174), ALAD(210), CYCS(54205), FAH(2184), HPD(3242), SLC25A13(1165)','OMIM:276700'),('GRISCELLI SYNDROME, TYPE 2',NULL,'Rab GTPase binding','GO:0017137','8.92','MLPH(79083), MYO5A(4644), UNC13B(10497), UNC13D(201294)','OMIM:607624'),('PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)',NULL,'receptor binding','GO:0005102','9.46','CAT(847), F2R(2149), HSD17B4(3295), PIPOX(51268)','OMIM:614887'),('PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)',NULL,'protein C-terminus binding','GO:0008022','9.43','PEX1(5189), PEX12(5193), PEX6(5190)','OMIM:614887'),('PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)',NULL,'enzyme binding','GO:0019899','9.26','ABCD1(215), CAT(847), PEX5(5830), PEX7(5191)','OMIM:614887'),('PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER)',NULL,'ATPase activity, coupled','GO:0042623','8.62','PEX1(5189), PEX6(5190)','OMIM:614887'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'catalytic activity','GO:0003824','9.81','GAA(2548), PFKM(5213), PYGL(5836), PYGM(5837)','OMIM:232220'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'transferase activity','GO:0016740','9.81','AGL(178), GBE1(2632), GYG1(2992), GYS1(2997), GYS2(2998), PFKM(5213)','OMIM:232220'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'carbohydrate binding','GO:0030246','9.76','AGL(178), GAA(2548), GBE1(2632), PYGL(5836)','OMIM:232220'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'calmodulin binding','GO:0005516','9.73','PHKA1(5255), PHKA2(5256), PHKB(5257), PHKG2(5261)','OMIM:232220'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'hydrolase activity, hydrolyzing O-glycosyl compounds','GO:0004553','9.52','GAA(2548), GBE1(2632)','OMIM:232220'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'transferase activity, transferring glycosyl groups','GO:0016757','9.5','AGL(178), GBE1(2632), GYG1(2992), GYS1(2997), GYS2(2998), PYGL(5836)','OMIM:232220'),('GLYCOGEN STORAGE DISEASE IXC',NULL,'AMP binding','GO:0016208','9.49','PRKAG2(51422), PYGL(5836)','OMIM:232220'),('COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4',NULL,'ATP binding','GO:0005524','9.73','AARS2(57505), EARS2(124454), FARS2(10667), VARS2(57176)','OMIM:610678'),('COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4',NULL,'RNA binding','GO:0003723','9.71','AARS2(57505), EARS2(124454), GFM1(85476), TSFM(10102)','OMIM:610678'),('COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4',NULL,'nucleotide binding','GO:0000166','9.54','AARS2(57505), EARS2(124454), FARS2(10667)','OMIM:610678'),('COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4',NULL,'tRNA binding','GO:0000049','9.33','AARS2(57505), EARS2(124454), FARS2(10667)','OMIM:610678'),('COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4',NULL,'translation elongation factor activity','GO:0003746','9.32','GFM1(85476), TSFM(10102)','OMIM:610678'),('COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4',NULL,'ligase activity, forming aminoacyl-tRNA and related compounds','GO:0016876','9.26','AARS2(57505), EARS2(124454)','OMIM:610678'),('COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4',NULL,'ligase activity','GO:0016874','9.26','AARS2(57505), EARS2(124454), FARS2(10667), VARS2(57176)','OMIM:610678'),('COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4',NULL,'aminoacyl-tRNA ligase activity','GO:0004812','8.92','AARS2(57505), EARS2(124454), FARS2(10667) VARS2(57176)','OMIM:610678'),('OMIM:231005',NULL,'hydrolase activity','GO:0016787','9.91','ACP5(54), ADA(100), ARSA(410), CHIA(27159), CHIT1(1118), GBA(2629)','OMIM:231005'),('GAUCHER DISEASE, TYPE IIIC',NULL,'hydrolase activity, hydrolyzing O-glycosyl compounds','GO:0004553','9.4','CHIA(27159), CHIT1(1118)','OMIM:231005'),('GAUCHER DISEASE, TYPE IIIC',NULL,'chitin binding','GO:0008061','9.32','CHIA(27159), CHIT1(1118)','OMIM:231005'),('GAUCHER DISEASE, TYPE IIIC',NULL,'chitinase activity','GO:0004568','9.26','CHIA(27159), CHIT1(1118)','OMIM:231005'),('GAUCHER DISEASE, TYPE IIIC',NULL,'beta-galactosidase activity','GO:0004565','9.16','GBA3(57733), PSAP(5660)','OMIM:231005'),('GAUCHER DISEASE, TYPE IIIC',NULL,'glucosylceramidase activity','GO:0004348','8.96','GBA(2629), GBA3(57733)','OMIM:231005'),('MAST CELL DISEASE',NULL,'cytokine receptor binding','GO:0005126','9.16','IFNA1(3439), IFNA2(3440)','OMIM:154800'),('MAST CELL DISEASE',NULL,'type I interferon receptor binding','GO:0005132','8.96','IFNA1(3439), IFNA2(3440)','OMIM:154800'),('MAST CELL DISEASE',NULL,'cytokine activity','GO:0005125','8.92','BMP6(654), FGF2(2247), IFNA1(3439), IFNA2(3440)','OMIM:154800'),('CYSTIC FIBROSIS',NULL,'protein N-terminus binding','GO:0047485','9.65','DCTN4(51164), STX1A(6804), TGFB1(7040)','OMIM:219700'),('CYSTIC FIBROSIS',NULL,'chloride channel activity','GO:0005254','9.58','CFTR(1080), CLCA1(1179), CLCA4(22802)','OMIM:219700'),('CYSTIC FIBROSIS',NULL,'intracellular calcium activated chloride channel activity','GO:0005229','9.46','CLCA1(1179), CLCA4(22802)','OMIM:219700'),('CYSTIC FIBROSIS',NULL,'RAGE receptor binding','GO:0050786','9.43','S100A8(6279), S100A9(6280)','OMIM:219700'),('CYSTIC FIBROSIS',NULL,'chloride channel regulator activity','GO:0017081','9.37','CFTR(1080), SLC9A3R1(9368)','OMIM:219700'),('CYSTIC FIBROSIS',NULL,'glycoprotein binding','GO:0001948','9.33','DNAJC5 STX1A TGFB1',NULL),('CYSTIC FIBROSIS',NULL,'chloride channel inhibitor activity','GO:0019869','9.32','CFTR STX1A',NULL);

UNLOCK TABLES;

/*Table structure for table `reg` */

DROP TABLE IF EXISTS `reg`;

CREATE TABLE `reg` (
  `username` varchar(22) NOT NULL,
  `password` varchar(22) DEFAULT NULL,
  `mail` varchar(222) DEFAULT NULL,
  `mobile` varchar(222) DEFAULT NULL,
  `gender` varchar(22) DEFAULT NULL,
  `addr` varchar(222) DEFAULT NULL,
  PRIMARY KEY (`username`)
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

/*Data for the table `reg` */

LOCK TABLES `reg` WRITE;

insert  into `reg`(`username`,`password`,`mail`,`mobile`,`gender`,`addr`) values ('preetha','123','preetha07@gmail.com','14389856625','female','tuticorin'),('ramesh','123','ramesh@gmail.com','1234567890','male','nellai'),('suresh','123','sureshrky07@gmail.com','7708252747','male','tuti');

UNLOCK TABLES;

/*Table structure for table `snconmf` */

DROP TABLE IF EXISTS `snconmf`;

CREATE TABLE `snconmf` (
  `Ave(mi)` varchar(200) DEFAULT NULL,
  `Ave(g)` varchar(200) DEFAULT NULL,
  `Ave(T)` varchar(200) DEFAULT NULL,
  `MiMEC` varchar(200) DEFAULT NULL,
  `TfMEC` varchar(200) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

/*Data for the table `snconmf` */

LOCK TABLES `snconmf` WRITE;

insert  into `snconmf`(`Ave(mi)`,`Ave(g)`,`Ave(T)`,`MiMEC`,`TfMEC`) values ('5.5','28.15','2.5','0.0975','0.2110');

UNLOCK TABLES;

/*!40101 SET SQL_MODE=@OLD_SQL_MODE */;
/*!40014 SET FOREIGN_KEY_CHECKS=@OLD_FOREIGN_KEY_CHECKS */;
